Under a federal law called the Mental Health Parity and Addiction Equity Act (MHPAEA), Aetna Health Insurance Co. must make sure that there is "parity" between mental health and substance use disorder benefits, and medical and surgical benefits. This generally means that financial requirements and treatment limitations applied to mental health or substance use disorder benefits cannot be more restrictive than the financial requirements and treatment limitations applied to medical and surgical benefits. The types of limits covered by parity protections include:

- Financial requirements-such as deductibles, copayments, coinsurance, and out-of-pocket limits; and
- Treatment limitations—such as limits on the number of days or visits covered, or other limits on the scope or duration of treatment (for example, being required to get prior authorization).

Aetna Health Insurance Co. has performed an analysis of mental health parity as required by Maryland law and has submitted the required report to the State of Maryland. Below is a summary of that report.

If you have any questions on this summary, please contact MHPGeneralInquiries@aetna.com .

If you have questions on your specific health plan, please call the member services number on your ID card.

Overview:

We have identified the five health benefit plans with the highest enrollment for each product we offer in the individual, small, and large group markets, as applicable. These plans contain items called Non-Quantitative Treatment Limitations (NQTLs) that put limits on benefits paid. What these NQTLs are and how the health plans achieve parity are discussed below.

1. Definition of Medical Necessity

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

Med/Surg Benefits	MH/SUD Benefits
Medically necessary means healthcare services provided for the	Medically necessary means healthcare services provided for the
purpose of preventing, evaluating, diagnosing or treating a sickness,	purpose of preventing, evaluating, diagnosing or treating a sickness,
injury, mental Illness, substance use disorder, condition, disease or its	injury, mental Illness, substance use disorder, condition, disease or its
symptoms that are all of the following as determined by the Claims	symptoms that are all of the following as determined by the Claims
Administrator or its designee, within the Claims Administrator's sole	Administrator, within the Claims Administrator's sole discretion. The
discretion. The services must be:	services must be:
 in accordance with Generally Accepted Standards of Medical Practice; clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for your sickness, injury, mental illness, substance use disorder disease or its symptoms; not mainly for your convenience or that of your doctor or other health care provider; and not more costly than an alternative drug, service(s) or supply that is at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of your Sickness, Injury, disease or symptoms. 	 in accordance with Generally Accepted Standards of Medical Practice; clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for your sickness, injury, mental illness, substance use disorder disease or its symptoms; not mainly for your convenience or that of your doctor or other health care provider; and not more costly than an alternative drug, service(s) or supply that is at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of your Sickness, Injury, disease or symptoms.
<i>Generally Accepted Standards of Medical Practice</i> are standards that	<i>Generally Accepted Standards of Medical Practice</i> are standards that
are based on credible scientific evidence published in peer-reviewed	are based on credible scientific evidence published in peer-reviewed
medical literature generally recognized by the relevant medical	medical literature generally recognized by the relevant medical
community, relying primarily on controlled clinical trials, or, if not	community, relying primarily on controlled clinical trials, or, if not
available, observational studies from more than one institution that	available, observational studies from more than one institution that
suggest a causal relationship between the service or treatment and	suggest a causal relationship between the service or treatment and
health outcomes.	health outcomes.

If no credible scientific evidence is available, then standards that are based on Physician specialty society recommendations or professional standards of care may be considered. The Claims Administrator reserves the right to consult expert opinion in determining whether health care services are Medically Necessary. The decision to apply Physician specialty society recommendations, the choice of expert and the determination of when to use any such expert opinion, shall be within the Claims Administrator's sole discretion. The Claims Administrator develops and maintains clinical policies that describe the Generally Accepted Standards of Medical Practice scientific evidence, prevailing medical standards and clinical guidelines supporting its determinations regarding specific services. These clinical policies as developed by the Claims Administrator are revised from time to time. Aetna publishes information concerning utilization review and our medical necessity criteria here: https://www.aetna.com/health-care-professionals/utilization- teanset based	If no credible scientific evidence is available, then standards that are based on Physician specialty society recommendations or professional standards of care may be considered. The Claims Administrator reserves the right to consult expert opinion in determining whether health care services are Medically Necessary. The decision to apply Physician specialty society recommendations, the choice of expert and the determination of when to use any such expert opinion, shall be within the Claims Administrator's sole discretion. The Claims Administrator develops and maintains clinical policies that describe the Generally Accepted Standards of Medical Practice scientific evidence, prevailing medical standards and clinical guidelines supporting its determinations regarding specific services. These clinical policies as developed by the Claims Administrator are revised from time to time. Aetna publishes information concerning utilization review and our medical necessity criteria here: https://www.estne.com/health.com.professionals/utilization
management.html Within that site, there is a section dedicated specially to the criteria	https://www.aetna.com/health-care-professionals/utilization- management.html
used for behavioral health conditions, which can be found here: https://www.aetna.com/health-care-professionals/patient-care-	Within that site, there is a section dedicated specially to the criteria used for behavioral health conditions, which can be found here:
programs/locat-aba-guidelines.html We also publish clinical policy	https://www.aetna.com/health-care-professionals/patient-care-
bulletins concerning services we may or may not cover, including behavioral health services that may be excluded on grounds that they	<u>programs/locat-aba-guidelines.html</u> We also publish clinical policy bulletins concerning services we may or may not cover, including
are experimental and investigational, which detail the evidentiary	behavioral health services that may be excluded on grounds that they
bases for our coverage or exclusion determinations: <u>https://www.aetna.com/health-care-</u>	are experimental and investigational, which detail the evidentiary bases for our coverage or exclusion
professionals/clinical-policy-bulletins.html	determinations: <u>https://www.aetna.com/health-care-</u>
	professionals/clinical-policy-bulletins.html
Covered services: All inpatient, outpatient and emergency care services	Covered services, All innotions, outpotions and emergency eero
	Covered services: All inpatient, outpatient and emergency care services
Plan language:	
 Section # 110 / Form # HI COC00110 05 / Page # 4 	Plan language:

Madical paparity (referrel) and presentification	Section # 110 / Form # HI COC00110 05 / Page # 4
Medical necessity[, referral] and precertification	Medical necessity[, referral] and precertification
requirements	
[Note: The second bullet will print when the contract holder's plan doesn't	requirements
require referrals. The third bullet will print when the contract holder's plan requires PCP selection and PCP referral for specialist care.] Your plan pays for its share of the expense for covered services only if	[Note: The second bullet will print when the contract holder's plan doesn't require referrals. The third bullet will print when the contract holder's plan requires PCP selection and PCP referral for specialist care.]
the general requirements are met. They are:	Your plan pays for its share of the expense for covered services only if
• The service is medically necessary	the general requirements are met. They are:
• [You get the service from a network provider]	• The service is medically necessary
• [You get your care from:	• [You get the service from a network provider]
– Your PCP	• [You get your care from:
 Another network provider after you get a referral 	– Your PCP
from your PCP. Referrals are not required for OB,	 Another network provider after you get a referral
GYN and OB/GYN network providers.]	from your PCP. Referrals are not required for OB,
 You or your provider precertifies the service when required 	GYN and OB/GYN network providers.]
na dhadh ann an dhad an an th	• You or your provider precertifies the service when required
Medically necessary, medical necessity	
The medical necessity requirements are in the <i>Glossary</i> section,	
where we define "medically necessary, medical necessity." That is	Medically necessary, medical necessity
where we also explain what our medical directors or a physician they assign consider when determining if a service is medically necessary .	The medical necessity requirements are in the <i>Glossary</i> section, where we define " medically necessary , medical necessity ." That is
	where we also explain what our medical directors or a physician they
Important note:	assign consider when determining if a service is medically necessary .
We cover medically necessary, sex-specific covered services	
regardless of identified gender.	Important note:
	We cover medically necessary , sex-specific covered services
Our clinical policy bulletins explain our policy for specific services and	regardless of identified gender.
supplies. We use these bulletins and other resources to help guide	
individualized coverage decisions under our plans. You can find the	Our clinical policy bulletins explain our policy for specific services and
bulletins and other information at https://www.aetna.com/health-	supplies. We use these bulletins and other resources to help guide

care-professionals/clinical-policy-bulletins.html Section # 170 / Form # HI COC00170 05/ Page # 3 supplies. We use these bulletins and other resources to help guide

individualized coverage decisions under our plans. You can find the

 Medically necessary, medical necessity Health care services that we determine a provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that we determine are: In accordance with generally accepted standards of medical practice Clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for the patient's illness, injury or disease Not primarily for the convenience of the patient, physician, or other health care provider Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease Generally accepted standards of medical practice means: Standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community Following the standards set forth in our clinical policies and applying clinical judgment 	 bulletins and other information at https://www.aetna.com/health- care-professionals/clinical-policy-bulletins.html Section # 170 / Form # HI COC00170 05/ Page # 3 Medically necessary, medical necessity Health care services that we determine a provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that we determine are: In accordance with generally accepted standards of medical practice Clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for the patient's illness, injury or disease Not primarily for the convenience of the patient, physician, or other health care provider Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease Generally accepted standards of medical practice means: Standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community Following the standards set forth in our clinical policies and applying clinical judgment
--	---

B. Identify the factors used in the development of the limitation(s);

Factors: Note: All factors are the same for medical/surgical and MH/SUD

Aetna's Clinical Policy Council (CPC) follows a standard process to develop and/or approve medical necessity criteria for MH/SUD and M/S services. As detailed in the Aetna Clinical Policy Council Charter, the factors the CPC considers are:

- The technology must have final approval from the appropriate governmental regulatory bodies.
- The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
- The technology must improve the net health outcome.
- The technology must be as beneficial as any established alternatives.
- The improvement must be attainable outside the investigational settings.

No formula is used for weighting these factors. CPC members apply their clinical training and expertise in evaluating them.

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

- Factor: The technology must have final approval from the appropriate governmental regulatory bodies
- Source: Evidence-based guidelines from nationally recognized professional healthcare organizations and public health agencies

All other factors share these sources:

- Evidence in the peer-reviewed published medical literature
- Evidence-based consensus statements
- Expert opinions of healthcare providers
- Evidence-based guidelines from nationally recognized professional healthcare organizations and public health agencies
- Technology assessments and structured evidence reviews Clinical training, experience and judgment of Aetna's clinical reviewers

D. Identify the methods and analysis used in the development of the limitation(s); and

Aetna's strategy regarding satisfaction of parity's NQTL requirements includes the utilization of an identical standard/definition of medical necessity.

Medical and BH utilize appropriately applicable and generally accepted standards of practice to guide clinicians with coverage determinations.

Every individual MH/SUD medical necessity determination is afforded independent clinical consideration based on the member's presentation. This point is made clear to Aetna clinicians making medical necessity determinations in both the medical necessity tools utilized and in staff training. Consistent with National Clinical Services (NCS) 503 Medical Review Policy & Procedure (attached), staff considers the individual needs of the member when applying criteria or guidelines, including, but not limited to:

- Age;
- Co-morbidities;
- Complications;
- Progress of treatment;
- Need for skilled care;
- Psychosocial situation;
- Risk related to ethnicity or genetic factors;
- Home environment, when applicable.

The medical necessity criteria are used in distinct circumstances; there is no priority in how they are applied. For inpatient medical stays, Aetna utilizes Milliman Care Guidelines (MCG) as a guideline to determine the medical necessity. For substance use disorder treatments, Aetna utilizes criteria developed by the American Society of Addiction Medicine (or ASAM) as a guideline to determine medical necessity For mental health treatments, Aetna utilizes the Level of Care Utilization System (LOCUS) and the Child and Adolescent Level of Care Utilization System/Child and Adolescent Service Intensity Instrument (CALOCUS/CASII) for its medical necessity reviews. More information about LOCUS, CALOCUS/CASSII and ASAM criteria can be found on Aetna's website at https://www.aetna.com/health-care-professionals/patient-care-programs/locat-aba-guidelines.html. These criteria (MCG, ASAM, LOCUS, and CALOCUS/CASSII) are used to determine the level of care, or the setting in which care is provided. Clinical Policy Bulletins (CPBs) are guidelines for determining the medical necessity of procedures, services and drugs; not the setting in which those are provided.

- Inpatient:
 - M/S: MCG and CPBs
 - MH/SUD: LOCUS, CALOCUS, ASAM and CPBs
- Outpatient (Office and All Other):
 - o M/S: CPBs
 - o MH/SUD: LOCUS, CALOCUS, ASAM and CPBs

- Emergency:
 - o M/S: CPBs
 - MH/SUD: CPBs

All Aetna clinicians are educated and informed of MHPAEA's requirements. The enterprise mandates each year every colleague to complete the compliance training for mental health parity. The course explains mental health parity, how it impacts members and the role the enterprise employees have in supporting it.

The definition of medical necessity for both MH/SUD and medical/surgical share the same definition in our standard Certificates of coverage. Additionally, the Clinical Policy Bulletins (CPB) and evidence-based guidelines used in the medical necessity review process have been found to be aligned to generally accepted practice standards. This validation is completed by our Clinical Policy Council and approval by our chief medical officer or their designee. This process involves annual review of generally accepted national evidence-based guidelines. Upon request, Aetna's Clinical Policy Research and Development Team evaluates and renders an opinion on the experimental and investigational status and medical necessity of medical services or a technology that is considered for coverage under Aetna medical benefit plans.

Requests usually come from Aetna's clinical staff (medical or pharmacy directors or other clinical staff) in the context of preauthorization, precertification, or retrospective claim review. In some instances, an assessment may be conducted at the request of other business areas of Aetna (e.g., Aetna's Special Investigations Unit, Legal Department, Aetna Senior Management), from Aetna's National Quality Advisory Committees (NQAC), from medical technology vendors (e.g. pharmaceutical or medical device manufacturers), or from participating Aetna healthcare providers. In addition, the Clinical Policy Research and Development Team may initiate an assessment at its own initiative, based on new information about a medical technology that is material to its experimental and investigational status and medical necessity.

The Senior Director, Clinical Policy Research & Development and the Chairman of the Clinical Policy Council determine whether a new or revised Clinical Policy Bulletin (CPB) on the medical technology needs to be drafted. The following factors are considered in prioritizing requests for revising or creating new CPBs:

- 1. Whether a new policy or policy revision is necessary to support specific Aetna clinical functions (e.g., precertification, claim reimbursement, special investigations, etc.);
- 2. The potential impact of the medical technology on Aetna and its members;
- 3. The quantity and importance of questions that have arisen regarding the medical technology;
- 4. New evidence, guidelines, consensus statements or other information that is material to the experimental and investigational status and medical necessity of the medical technology;
- 5. Changes in the regulatory status of the medical technology relevant to its experimental and investigational status and medical necessity.

Clinical Policy Bulletins are reviewed annually unless relevant new medical literature, guidelines, regulatory actions, or other relevant new information warrants more frequent review. The CPB development process includes annual assessment of new and emerging evidence-based

information, including clinical information related to health equity, such as that related to race, ethnicity, gender, and underserved populations. Each time a CPB is updated, a comprehensive search of the peer-reviewed, published medical literature is performed to determine if there is a change in the experimental and investigational status or medical necessity of the medical technologies addressed. If the Clinical Policy Research and Development Team determines that new evidence or other information has emerged to warrant a change in Aetna's clinical policy, a revised CPB draft is prepared. If no new evidence has emerged that would warrant a change in Aetna's position, the CPB may be updated with additional supporting background information and references. Each revised CPB is submitted to Aetna's Clinical Policy Council for review and approval. Additional changes to the revised or updated draft CPB may be made upon the recommendations of the Clinical Policy Council.

Approved new, revised, and updated CPBs become effective when they are published on Aetna's CPB websites. A complete index of published CPBs can be found on Aetna's external CPB website. The publication history of each CPB can be found in the Policy History section of the CPB. A summary of recently published new, revised, and updated CPBs is published on Aetna's external CPB What's New website.

The medical necessity criteria, as defined, are applied equally as written. The same definition applies to M/S and MH/SUD services. We do not have different versions of the criteria definitions that apply specifically to M/S versus MH/SUD services.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

Aetna's medical necessity coverage policy development and application process is consistent between mental health/substance use disorder (MH-SUD) and medical/surgical (M/S). Aetna applies comparable evidence-based guidelines to define established standards of effective care in both M/S and MH/SUD benefits. Consistency in policy development, process and application evidences compliance with the NQTL requirement that the definition of medical necessity be applied comparably, and no more stringently, to MH/SUD services than to M/S services.

An "in operation" review of Aetna's application of the medical necessity NQTL, specifically Aetna's clinical policies, medical review journals or peer reviewed research, or the decision to apply Physician specialty society recommendations, the choice of expert and the determination of when to use any such expert opinion revealed no statistically significant discrepancies in medical necessity denial rates as-between MH/SUD and M/S benefits. While operational outcomes are not determinative of NQTL compliance, and a plan may comply with the NQTL requirement notwithstanding a disparate outcome for an NQTL applied to MH/SUD benefits as compared to M/S benefits, comparable outcomes can help evidence compliance with the in-operation component of the NQTL requirement.

A review of the in-operation medical necessity review data shows fewer medical necessity denials for MH/SUD than for M/S overall. A review of claim denials shows the MH/SUD claims identified as denials were not denied as not medically necessary, with the exception of the few that were addressed.

Consequently, Aetna concludes that the medical necessity NQTL was applied comparably and no more stringently to MH/SUD benefits than to M/S benefits.

2. Prior Authorization Review Process

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

Med/Surg Benefits	MH/SUD Benefits
Precertification/Prior Authorization	Precertification/Prior Authorization
Precertification does not apply to any medical surgical or MH/SUD	Precertification does not apply to any medical surgical or MH/SUD
benefits in the Outpatient-Office Visit (In-network and Out of	benefits in the Outpatient-Office Visit (In-network and Out of
Network) Classification. Precertification only applies to the	Network) Classification. Precertification only applies to the
medical/surgical benefit of Fixed-wing Aircraft Transport in the	medical/surgical benefit of Fixed-wing Aircraft Transport in the
Emergency Classification.	Emergency Classification.
Precertification is required for all inpatient admissions for both	Precertification is required for all inpatient admissions for both
MH/SUD and medical/surgical services. (The exceptions for hospice	MH/SUD and medical/surgical services. (The exceptions for hospice
and short maternity/newborn stays are not significant enough to	and short maternity/newborn stays are not significant enough to
suggest a parity concern.) The only factor is whether the services or	suggest a parity concern.) The only factor is whether the services or
items are in the inpatient classification. Because precertification is required for all inpatient admissions for both MH/SUD and	items are in the inpatient classification. Because precertification is required for all inpatient admissions for both MH/SUD and
medical/surgical services, the NQTL is identical as between	medical/surgical services., the NQTL is identical as between
medical/surgical and MH/SUD services, and a comparability analysis	medical/surgical and MH/SUD services, and a comparability analysis
of the in-writing component of factors and evidentiary standards is not	of the in-writing component of factors and evidentiary standards is not
required. The Department of Labor's Self-Compliance Tool for the	required. The Department of Labor's Self-Compliance Tool for the
Mental Health Parity and Addiction Equity Act states on page 23: "If	Mental Health Parity and Addiction Equity Act states on page 23: "If
only certain benefits are subject to an NQTL, such as meeting a fail-	only certain benefits are subject to an NQTL, such as meeting a fail-
first protocol or requiring preauthorization, plans and issuers should	first protocol or requiring preauthorization, plans and issuers should
have information available to substantiate how the applicable factors	have information available to substantiate how the applicable factors
were used to apply the specific NQTL to medical/surgical and	were used to apply the specific NQTL to medical/surgical and
MH/SUD benefits."	MH/SUD benefits."
Precertification applies to four MH/SUD Outpatient All Other	Precertification applies to four MH/SUD Outpatient All Other
benefits: Applied Behavior Analysis, Partial Hospitalization,	benefits: Applied Behavior Analysis, Partial Hospitalization,
Transcranial Magnetic Stimulation and Gender Affirming Surgery.	Transcranial Magnetic Stimulation and Gender Affirming Surgery.
Precertification applies to numerous medical/surgical Outpatient All	Precertification applies to numerous medical/surgical Outpatient All
Other benefits (for example, Outpatient surgery, Private Duty Nursing,	Other benefits (for example, Outpatient surgery, Private Duty Nursing,

Proton beam Radiotherapy, and Electric or Motorized Wheelchairs	Proton beam Radiotherapy, and Electric or Motorized Wheelchairs
and Scooters). Please refer to most up-to date Participating Provider	and Scooters). Please refer to most up-to date Participating Provider
Precertification List for Medical/Surgical services and the Behavioral	Precertification List for Medical/Surgical services and the Behavioral
Health Precertification List for MH/SUD services, which is subject to	Health Precertification List for MH/SUD services, which is subject to
change from time to time. See https://www.aetna.com/health-care-	change from time to time. See https://www.aetna.com/health-care-
professionals/precertification/precertification-lists.html	professionals/precertification/precertification-lists.html
All UM factors, processes, strategies, and evidentiary standards, both MH/SUD and medical/surgical, are singularly developed in unison through the coordination efforts of the Parity Taskforce who leverages both MH/SUD and medical/surgical subject matter experts in factor development and ongoing review, and the National Precertification List (NPL) Committee—a group of clinicians and other subject matter experts representing both MH/SUD and medical/surgical expertise then applies these determinants	All UM factors, processes, strategies, and evidentiary standards, both MH/SUD and medical/surgical, are singularly developed in unison through the coordination efforts of the Parity Taskforce who leverages both MH/SUD and medical/surgical subject matter experts in factor development and ongoing review, and the National Precertification List (NPL) Committee—a group of clinicians and other subject matter experts representing both MH/SUD and medical/surgical expertise then applies these determinants.
Covered services: A detailed analytical framework is not provided for	Covered services: A detailed analytical framework is not provided for
Inpatient because this NQTL applies to all non-palliative procedures,	Inpatient because this NQTL applies to all non-palliative procedures,
services, devices, and therapies for both medical/surgical and	services, devices, and therapies for both medical/surgical and
MH/SUD; as such administration of this NQTL is identical.	MH/SUD; as such administration of this NQTL is identical.
For Medical/Surgical: All outpatient all other non-palliative procedures, services, devices, and therapies on the National Precertification List (NPL) <u>https://www.aetna.com/health-care-professionals/precertification/precertification-lists.html</u>	For Medical/Surgical: All outpatient all other non-palliative procedures, services, devices, and therapies on the National Precertification List (NPL) <u>https://www.aetna.com/health-care-professionals/precertification/precertification-lists.html</u>
For MH/SUD: All outpatient all other non-palliative procedures,	For MH/SUD: All outpatient all other non-palliative procedures,
services, devices, and therapies on the Behavioral Health	services, devices, and therapies on the Behavioral Health
Precertification List (MH/SUDPL)	Precertification List (MH/SUDPL)
<u>https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthc</u>	<u>https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthc</u>
<u>are-professionals/documents-forms/bh_precert_list.pdf</u>	<u>are-professionals/documents-forms/bh_precert_list.pdf</u>
Plan language: ➤ Section # 110 / Form # HI COC00110 05 / Page # 4-7	Plan language: ➤ Section # 110 / Form # HI COC00110 05 / Page # 4-7

 Medical necessity[, referral] and precertification requirements [Note: The second bullet will print when the contract holder's plan doesn't require referrals. The third bullet will print when the contract holder's plan requires PCP selection and PCP referral for specialist care.] Your plan pays for its share of the expense for covered services only if the general requirements are met. They are: The service is medically necessary [You get the service from a network provider] [You get your care from: Your PCP Another network provider after you get a referral from your PCP. Referrals are not required for OB, GYN and OB/GYN network providers.] You or your provider precertifies the service when required 	 Medical necessity[, referral] and precertification requirements [Note: The second bullet will print when the contract holder's plan doesn't require referrals. The third bullet will print when the contract holder's plan requires PCP selection and PCP referral for specialist care.] Your plan pays for its share of the expense for covered services only if the general requirements are met. They are: The service is medically necessary [You get the service from a network provider] [You get your care from: Your PCP Another network provider after you get a referral from your PCP. Referrals are not required for OB, GYN and OB/GYN network providers.] You or your provider precertifies the service when required
 Precertification You need pre-approval from us for some covered services. Pre-approval is also called precertification. We will accept a precertification from a prior carrier for covered services under this plan that require precertification. Contact us for further details. Your network physician or PCP is responsible for obtaining any necessary precertification before you get the care. Network providers cannot bill you if they fail to ask us for precertification. But if your physician or PCP requests precertification and we deny it, and you still choose to get the care, you will have to pay for it yourself. Timeframes for precertification is not required, but you should notify us as shown. 	 Precertification You need pre-approval from us for some covered services. Pre- approval is also called precertification. We will accept a precertification from a prior carrier for covered services under this plan that require precertification. Contact us for further details. Your network physician or PCP is responsible for obtaining any necessary precertification before you get the care. Network providers cannot bill you if they fail to ask us for precertification. But if your physician or PCP requests precertification and we deny it, and you still choose to get the care, you will have to pay for it yourself. Timeframes for precertification is not required, but you should notify us as shown.

To obtain precertification , contact us. You, your physician or the	
facility must call us within these timelines:	

Type of care	Timeframe
Non-emergency admission	Call at least 7 days before the
	date you are scheduled to be
	admitted.
Emergency admission	Call within 48 hours or as soon
	as reasonably possible after
	you have been admitted.
Urgent admission	Call before you are scheduled
	to be admitted.
Outpatient non-emergency	Call at least 7 days before the
medical services	care is provided, or the
	treatment or procedure is
	scheduled.

An urgent admission is a **hospital** admission by a **physician** due to the onset of or change in an illness, the diagnosis of an illness, or injury.

We will tell you and your **physician** in writing of the **precertification** decision, where required by state law. An approval is valid for [30-180 days] as long as you remain enrolled in the plan.

For an inpatient **stay** in a facility, we will tell you, your **physician** and the facility about your **precertified** length of **stay**. If your **physician** recommends that you stay longer, the extra days will need to be **precertified**. You, your **physician**, or the facility will need to call us as soon as reasonably possible, but no later than the final authorized day. We will tell you and your **physician** in writing of an approval or denial of the extra days. If you or your **provider** request **precertification** and we don't approve

If you or your provider request precertification and we don't approve
coverage, we will tell you why and explain how you or your providerIf you or your provider request precertification and we don't approve
coverage, we will tell you why and explain how you or your provider

To obtain **precertification**, contact us. You, your **physician** or the facility must call us within these timelines:

Type of care	Timeframe
Non-emergency admission	Call at least 7 days before the
	date you are scheduled to be
	admitted.
Emergency admission	Call within 48 hours or as soon
	as reasonably possible after
	you have been admitted.
Urgent admission	Call before you are scheduled
	to be admitted.
Outpatient non-emergency	Call at least 7 days before the
medical services	care is provided, or the
	treatment or procedure is
	scheduled.

An urgent admission is a **hospital** admission by a **physician** due to the onset of or change in an illness, the diagnosis of an illness, or injury.

We will tell you and your **physician** in writing of the **precertification** decision, where required by state law. An approval is valid for [30-180 days] as long as you remain enrolled in the plan.

For an inpatient **stay** in a facility, we will tell you, your **physician** and the facility about your **precertified** length of **stay**. If your **physician** recommends that you stay longer, the extra days will need to be **precertified**. You, your **physician**, or the facility will need to call us as soon as reasonably possible, but no later than the final authorized day. We will tell you and your **physician** in writing of an approval or denial of the extra days.

may request review of our decision. See the Complaints, claim	may request review of our decision. See the Complaints, claim
decisions and appeal procedures section.	decisions and appeal procedures section.
<i>Types of services that require precertification</i>	<i>Types of services that require precertification</i>
Precertification is required for inpatient stays and certain outpatient services and supplies.	Precertification is required for inpatient stays and certain outpatient services and supplies.
Contact us to get a list of the services that require precertification .	Contact us to get a list of the services that require precertification .
The list may change from time to time.	The list may change from time to time.
Sometimes you or your provider may want us to review a service that	Sometimes you or your provider may want us to review a service that
doesn't require precertification before you get care. This is called a	doesn't require precertification before you get care. This is called a
predetermination, and it is different from precertification .	predetermination, and it is different from precertification .
Predetermination means that you or your provider requests the pre-	Predetermination means that you or your provider requests the pre-
service clinical review of a service that does not require	service clinical review of a service that does not require
precertification .	precertification .
 Section # 170 / Form # HI COC00170 05 / Page # 4, 7 [Note: References to precertification or precertified may be changed to pre-	 Section # 170 / Form # HI COC00170 05 / Page # 4, 7 [Note: References to precertification or precertified may be changed to pre-
authorization or pre-authorized or pre-approval or pre-approved] [Precertification, precertify Pre-approval that you or your provider receives from us before you	authorization or pre-authorized or pre-approval or pre-approved] [Precertification, precertify Pre-approval that you or your provider receives from us before you
receive certain covered services. This may include a determination by	receive certain covered services. This may include a determination by
us as to whether the service is medically necessary and eligible for	us as to whether the service is medically necessary and eligible for
coverage.]	coverage.]
[Note: Prints if included in the policyholder's plan design.]	[Note: Prints if included in the policyholder's plan design.]

B. Identify the factors used in the development of the limitation(s);

Factors for Adding a Service to the NPL: *Note: All factors are the same for medical/surgical and MH/SUD. All services must meet one or more of the below three criteria to be added to the NPL.*

- Cost: Cost of treatment is satisfied when the average paid Medicare rate is at least \$150 for the service being considered (based on Aetna's national paid Medicare claims experience)
- High-cost growth (projected or actual): Whether, based on internal Aetna claims data, the per member per month expense for the services increased more than 10% in the most recent two-year period compared to an initial year baseline. (For example, if the 2015 per member per month (PMPM)=\$1.00, the 2016 PMPM=\$2.00, and the 2017 PMPM=\$3.00, then that would be a 200% trend increase over the two-year period calculate by subtracting the 2015 PEPM from the 2017 PMPM and then dividing by the 2015 PMPM.)
- Variability in cost and practice: Internal claims data demonstrates that there is greater than three-fold variability in cost per unit, overall length of treatment, or overall number of services per treatment for the procedure, service, device, or therapy in the most recent 12-month period, raising quality of care concerns.

Extenuating Factors for adding a service to the NQTL (precertification). The NPL Committee may add a service that does not meet the above criteria, based on the following Extenuating Factors:

- Patient safety: Considers whether precertification can minimize potential harm to a member, particularly for life changing procedures that are irreversible post-surgery.
- Clinical quality control: Refers to ensuring a provider and proposed treatment are qualified and appropriate so that the possibility of adverse outcomes is reduced.
- Marked variation in provider utilization patterns: Refers to there being a significant range providers' utilization of the service, drug or device, suggesting that some of the utilization may be unnecessary.
- Incorrect utilization: Refers to the potential that a given service, drug or device is not appropriate for the member's condition.
- Application of Clinical Policy Bulletin (CPB) requirements: Refers to the opportunity to make determinations required under Aetna's CPBs and other clinical policies pertaining to the experimental/investigational nature of a service, appropriate use of new/changing technology, step therapy, or site of service.
- Standards of industry practice: Refers to what other health insurers and administrators have decided to be appropriate in terms of precertification.

There are no fixed quantitative standards for the above factors; rather they are evaluated in comparison to other services in the same benefit classification.

Factors for retaining a Service to the NPL:

- ROI 3:1 or greater retain
- ROI 2 to 2.9:1

• ROI </= 1.9:1 and NOT integral to NPL Group/Category (example, breast reduction code may independently have a low ROI, but it is part of a procedure group for which precertification is required) - consider Extenuating Factors

* While ROI may be the primary factor used to determine retention of a service on the NPL, it is not an absolute determinant. The NPL Committee may consider the factors for adding a service to the NPL and/or any Extenuating Factors. There are no fixed quantitative standards for the factors; rather they are evaluated in comparison to other services in the same benefit classification.

No other factors were considered and rejected. No factors were weighted more than another.

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

Sources:

- For Cost: Review of Medicare rates
- For Cost, High-cost growth, and Variability in cost and practice: Internal claims data
- For ROI: Internal admin cost data
- For Extenuating Factors: Clinical resources, clinical training, expertise and judgment
- For Extenuating Factors: Clinical Policy Bulletins
- For Extenuating Factors: Standards of industry practice

No other sources were considered and rejected. No sources were weighted more than another.

Evidentiary Standards:

- Medicare rates
- Internal claims database analysis
- Internal analysis of administrative costs
- Clinical guidelines and standards of practice. (These depend on the service under consideration and would include, by way of example, the most currently available versions of CMS Coverage Determinations and Medicare Benefit Policy Manual, MCG Health guidelines, National Comprehensive Cancer Network (NCCN) guidelines, American Society of Addiction Medicine (ASAM) Criteria, CALOCUS/LOCUS guidelines, and Aetna Clinical Policy Bulletins.)

D. Identify the methods and analysis used in the development of the limitation(s); and

Process for Developing the National Precertification List (NPL):

The NPL is used by participating providers to identify which MH/SUD and M/S services require precertification for INN coverage. The NPL Committee is responsible for determining which services to add, retain or remove from the NPL. It comprises clinicians and other subject matter experts representing both MH/SUD and M/S expertise. Proposed additions or changes to the NPL are submitted to the NPL Committee. The Committee considers the factors listed above and decides whether to add or remove the service. Also, the Committee annually reviews services on the NPL to decide whether to retain or remove them. Any factors and Extenuating Factors relied upon in making the decision must be documented; this allows for validation that they are being applied comparably, and not more stringently, to MH/SUD services.

NPL voting members are Medical Directors, including Behavioral Health Medical Directors; all voting members have comparable clinical expertise. Business partners are clinicians and other subject matter experts who represent a broad range of Aetna programs. The voting members collaborate and solicit input from key business partners to assure delivery of a consistent guideline of high quality.

Process and Standards for Performing Precertification:

Aetna's processes for precertifying services that are on the NPL are designed in accordance with National Committee for Quality Assurance (NCQA) utilization management standards for Health Plan Accreditation and Managed Behavioral Health Organization accreditation, and applicable state and federal law. In brief, precertification requests and supporting documentation are reviewed by clinical support staff who are not licensed health care providers. They can make coverage approvals that do not require clinical review, and administrative denials (due to member's lack of eligibility or benefit plan exclusions, for example). Coverage decisions that require clinical review are performed by licensed clinicians who are RNs, licensed clinical social workers or physicians. If a licensed clinician is unable to approve coverage, the clinician refers the request to a Medical Director who is a physician or to a consulting psychiatrist/ psychologist/ board certified behavior analyst-doctoral (BCBA-D) for further review and action. Consulting psychiatrists/psychologists/BCBA-D use the available clinical information to approve a coverage request or, when unable to approve, make a level of care or service recommendation and forward the recommendation to the Medical Director or the designated psychologist/BCBA-D for issuance of the coverage determination. The licensed clinician or Medical Director draws upon his or her training and expertise in applying the applicable clinical review criteria to the request. (See the Medical Necessity NQTL Comparative Analysis for more information about clinical review criteria.) The precertification determination is made and communicated to the provider/member according to the established timeframes for urgent or non-urgent requests. In some circumstances the treating provider may have a peer-to-peer consultation with a physician.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

The same factors and sources, and the same National Precertification List Policy and Procedure, apply to MH/SUD and M/S benefits in deciding which services to add to, retain or remove from the National Precertification list. The same factors and sources, and the same National Clinical Services Policies and Procedures, apply to handling precertification requests for MH/SUD and M/S benefits. Thus, as written this NQTL is applied comparably, and not more stringently, to MH/SUD benefits.

Operational proportionality data show a lower percentage of MH/SUD services than M/S subject to precertification reviews to total claims in the INN OP-All Other classification. This demonstrates that the NQTL is not more stringently applied to MH/SUD services than M/S services.

Overturn rates for appeals: Precertification review data, from the UR database, for 2021 show zero MH/SUD appeals of precertification decisions. Therefore, there were no peer-to-peer reviews. With no MH/SUD appeals to analyze, it is apparent that the NQTL is not more stringently applied to MH/SUD services than M/S services.

The Internal Quality Reviews and Inter-Rater Reliability process provides a way to evaluate whether precertification and concurrent review of MH/SUD and M/S services is performed comparably, and not more stringently for MH/SUD, in operation. These reports show that both Medical and Behavioral Health Medical Directors and clinicians are performing precertification and concurrent review accurately and consistently.

An "in operation" review of Aetna's application of the precertification NQTL, specifically Denial Rates for INN, OON MH/SUD, M/S retrospective reviews, and overturn rates for appeals show no statistically significant discrepancies between MH/SUD and M/S reviews. While operational outcomes are not determinative of NQTL compliance, and a plan may comply with the NQTL requirement notwithstanding a disparate outcome for an NQTL applied to MH/SUD benefits as compared to M/S benefits, comparable outcomes can help evidence compliance with the in-operation component of the NQTL requirement.

Evaluation of determinations adding to or removing MH/SUD and M/S services from the NPL: Precertification is required for all inpatient admissions for both MH/SUD and M/S services. (The exceptions for hospice and short maternity/newborn stays are not significant enough to suggest a parity concern.) Precertification is not required for any MH/SUD or M/S Outpatient-Office Visits. As for Outpatient-All Other benefits, there are only 5 MH/SUD services in that classification subject to precertification compared to approximately 34 categories of M/S services, and no new MH/SUD services have been added to the NPL in the past 5 years (since the framework for inclusion on the NPL was formalized). In the NPL Committee's 2021 annual retention review, no MH/SUD or M/S services that met the ROI were removed from the NPL. All MH/SUD services met the ROI and were retained on the NPL. From this information it is clear that the factors and sources used to add to, retain or remove a service from the NPL are comparable, and not more stringent, for MH/SUD services.

3. <u>Concurrent Review Process</u>

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

Med/Surg Benefits	MH/SUD Benefits
Concurrent review is performed by licensed healthcare professionals	Concurrent review is performed by licensed healthcare professionals
to review the medical necessity of a patient's care while in the hospital	to review the medical necessity of a patient's care while in the hospital
or while undergoing outpatient treatment, for dates of service beyond	or while undergoing outpatient treatment, for dates of service beyond
the initial precertification authorization. The purpose is to determine	the initial precertification authorization. The purpose is to determine
medical necessity and appropriateness of treatment, assess	medical necessity and appropriateness of treatment, assess appropriateness of level of care and treatment setting, determine
appropriateness of level of care and treatment setting, determine	benefits and eligibility identify the patient's discharge and continuing
benefits and eligibility identify the patient's discharge and continuing	care plan, and identify and refer potential quality of care and patient
care plan, and identify and refer potential quality of care and patient	safety concerns for additional review.
safety concerns for additional review.	
	Concurrent review is performed on all inpatient admissions and
Concurrent review is performed on all inpatient admissions and	outpatient services subject to precertification that entails an ongoing course of treatment.
outpatient services subject to precertification that entails an ongoing course of treatment.	course of treatment.
	Concurrent Review does not apply to any MH/SUD benefit in the
Concurrent Review does not apply to any medical surgical benefit in	Outpatient – Office Visit (INN and OON) Classification.
the Outpatient – Office Visit (INN and OON) Classification.	
	All MH/SUD inpatient admissions are subject to concurrent review.
All medical/surgical inpatient admissions are subject to concurrent	(The exceptions for hospice and short maternity/newborn stays are not
review. (The exceptions for hospice and short maternity/newborn stays	significant enough to suggest a parity concern.) The only factor is whether the services or items are in the inpatient classification.
are not significant enough to suggest a parity concern.) The only factor is whether the services or items are in the inpatient classification.	whether the services of items are in the inpatient classification.
is whether the services of items are in the inpatient classification.	Concurrent review applies to four MH/SUD Outpatient All Other
Concurrent review applies to numerous medical/surgical Outpatient	benefits: Applied Behavior Analysis, Partial Hospitalization,
All Other benefits (for example, Outpatient surgery, Private Duty	Transcranial Magnetic Stimulation and Gender Affirming Surgery.
Nursing, Proton beam Radiotherapy, and Electric or Motorized	Please refer to most up-to date Behavioral Health Precertification List
Wheelchairs and Scooters). Please refer to most up-to date	for MH/SUD services, which is subject to change from time to time.
Participating Provider Precertification List for Medical/Surgical	See

services, which is subject to change from time to time. See https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcarehttps://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcareprofessionals/documents-forms/bh precert list.pdf professionals/2023 Precert List.pdf All UM factors, processes, strategies, and evidentiary standards, both All UM factors, processes, strategies, and evidentiary standards, both MH/SUD and medical/surgical, are singularly developed in unison MH/SUD and medical/surgical, are singularly developed in unison through the coordination efforts of the Parity Taskforce who leverages through the coordination efforts of the Parity Taskforce who leverages both MH/SUD and medical/surgical subject matter experts in factor both MH/SUD and medical/surgical subject matter experts in factor development and ongoing review, and the National Precertification development and ongoing review, and the National Precertification List (NPL) Committee—a group of clinicians and other subject matter List (NPL) Committee—a group of clinicians and other subject matter experts representing both MH/SUD and medical/surgical expertise experts representing both MH/SUD and medical/surgical expertise then applies these determinants. then applies these determinants. Covered services: A detailed analytical framework is not provided for Covered services: A detailed analytical framework is not provided for Inpatient because this NOTL applies to all non-palliative procedures, Inpatient because this NQTL applies to all non-palliative procedures, services, devices, and therapies for both medical/surgical and services, devices, and therapies for both medical/surgical and MH/SUD: as such administration of this NOTL is identical. MH/SUD: as such administration of this NOTL is identical. For MH/SUD: All outpatient all other non-palliative procedures, For Medical/Surgical: All outpatient all other non-palliative services, devices, and therapies on the Behavioral Health procedures, services, devices, and therapies on the National Precertification List (MH/SUDPL) Precertification List (NPL) https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcarehttps://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcareprofessionals/documents-forms/bh precert list.pdf professionals/2023 Precert List.pdf **Plan language:** Section # 110 / Form # HI COC00110 05 / Page # 12 **Plan language: Concurrent care claim extension** Section # 110 / Form # HI COC00110 05 / Page # 12 A concurrent care claim extension occurs when you need us to **Concurrent care claim extension** approve more services than we already have approved. Examples are A concurrent care claim extension occurs when you need us to extending a **hospital stay** or adding a number of visits to a **provider**. approve more services than we already have approved. Examples are For an emergency or urgent request you must let us know you need extending a **hospital stay** or adding a number of visits to a **provider**. this extension 24 hours before the original approval ends. You will For an emergency or urgent request you must let us know you need receive a decision as soon as possible but no later than 24 hours. For this extension 24 hours before the original approval ends. You will all other requests you must let us know you need an extension 1 receive a decision as soon as possible but no later than 24 hours. For working day before the original approval ends. You will receive a all other requests you must let us know you need an extension 1 decision as soon as possible but no later than 1 working day after

 working day before the original approval ends. You will receive a decision as soon as possible but no later than 1 working day after receipt of the information necessary to make the determination. Concurrent care claim reduction or termination A concurrent care claim reduction or termination occur when we decide to reduce or stop payment for an already approved course of treatment. We will notify you of such a determination. You will have enough time to file an appeal. Your coverage for the service or supply will continue until you receive a final appeal decision from us or an external review organization if the situation is eligible for external review. 	receipt of the information necessary to make the determination. Concurrent care claim reduction or termination A concurrent care claim reduction or termination occur when we decide to reduce or stop payment for an already approved course of treatment. We will notify you of such a determination. You will have enough time to file an appeal. Your coverage for the service or supply will continue until you receive a final appeal decision from us or an external review organization if the situation is eligible for external review.
--	--

B. Identify the factors used in the development of the limitation(s);

Factors: Note: All factors are the same for medical/surgical and MH/SUD

The factors used in determining what services are subject to precertification and, by extension, to concurrent review, are described in Aetna's Prior Authorization NQTL Comparative Analysis.

Factors used in determining how concurrent review is performed:

- National Committee for Quality Assurance (NCQA) utilization management standards for Health Plan Accreditation and Managed Behavioral Health Organization Accreditation
- Applicable state and federal law

No other factors were considered and rejected. No factors were weighted more than another.

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above; Sources:

The processes and evidentiary standards used in determining what services are subject to precertification and, therefore, to concurrent review, are described in Aetna's Prior Authorization NQTL Comparative Analysis.

Evidentiary Standards for Performing Concurrent Review:

Aetna's concurrent review processes are designed in accordance with National Committee for Quality Assurance (NCQA) utilization management standards for Health Plan Accreditation and Managed Behavioral Health Organization accreditation, and applicable state and federal law.

Strategy for Performing Concurrent Review:

For both MH/SUD and M/S services, the guiding strategy behind concurrent review relies upon the clinical reviewers' exercise of their clinical judgment, guided by clinical criteria, to determine whether to authorize coverage for additional units of care. They rely upon their training and experience, informed by the member's medical history, clinician progress notes and discharge plans, to assess "severity" and "complexity" (as those terms are used within Aetna's National Clinical Services policies and procedures and clinical guidelines).

D. Identify the methods and analysis used in the development of the limitation(s); and

The processes and evidentiary standards used in determining what services are subject to precertification and, therefore, to concurrent review, are described in Aetna's Prior Authorization NQTL Comparative Analysis.

Process for Developing the National Precertification List (NPL):

The NPL is used by participating providers to identify which MH/SUD and M/S services require precertification for INN coverage. The NPL Committee is responsible for determining which services to add, retain or remove from the NPL. It comprises clinicians and other subject matter experts representing both MH/SUD and M/S expertise. Proposed additions or changes to the NPL are submitted to the NPL Committee. The Committee considers the factors listed above and decides whether to add or remove the service. Also, the Committee annually reviews services on the NPL to decide whether to retain or remove them. Any factors and Extenuating Factors relied upon in making the decision must be documented; this allows for validation that they are being applied comparably, and not more stringently, to MH/SUD services.

NPL voting members are Medical Directors, including Behavioral Health Medical Directors; all voting members have comparable clinical expertise. Business partners are clinicians and other subject matter experts who represent a broad range of Aetna programs. The voting members collaborate and solicit input from key business partners to assure delivery of a consistent guideline of high quality.

Process for Performing Concurrent Review:

Concurrent review is initiated before the authorized coverage period under the initial precertification or previous concurrent review expires. Updated information about the patient's condition, progress and treatment/discharge plan is obtained from the provider. Concurrent reviews are performed by licensed clinicians who are RNs, licensed clinical social workers or physicians. The licensed clinician may approve coverage for

additional units of care or, if unable to approve coverage, will refer the case to a Medical Director who is a physician or to a consultant psychiatrist/ psychologist/ board certified behavior analyst-doctoral (BCBA-D) for further review and action. Consultant psychiatrists/ psychologists/ BCBA-Ds use the available clinical information to approve a coverage request or, when unable to approve, make a level of care or service recommendation and forward the recommendation to the Medical Director or the designated psychologist/BCBA-D for issuance of the coverage determination. The licensed clinician or Medical Director draws upon his or her training and expertise in applying the applicable clinical review criteria to the request. (See Aetna's Medical Necessity NQTL Comparative Analysis for more information about clinical review criteria.) The concurrent review determination is made and communicated to the provider/member according to the established timeframes for urgent or non-urgent requests. In some circumstances the treating provider may have a peer-to-peer consultation with a physician.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

The same factors and sources apply to MH/SUD and M/S benefits in deciding which services are subject to precertification and, by extension, to concurrent review. The same factors and sources, and the same National Clinical Services Policies and Procedures, apply to handling concurrent review requests for MH/SUD and M/S benefits. Thus, as written this NQTL is applied comparably, and not more stringently, to MH/SUD benefits.

Aetna's concurrent review policy development and application process is consistent between MH/SUD and M/S. Aetna applies comparable evidence-based guidelines to define established standards of effective care in both M/S and MH/SUD benefits. Consistency in policy development, process and application evidences compliance with the NQTL requirement that the concurrent review process be applied comparably, and no more stringently, to MH/SUD services than to M/S services.

Aetna's Inter-Rater Reliability and Internal Quality Review processes provide a way to evaluate whether precertification and concurrent review of MH/SUD and M/S services is performed comparably, and not more stringently for MH/SUD, in operation. In that process, Medical Directors and Utilization Management Clinicians are audited for accuracy and consistency in their application of utilization management criteria. These reports show that both Medical and Behavioral Health Medical Directors and clinicians are performing precertification and concurrent review accurately and consistently.

An "in operation" review of Aetna's application of the concurrent review process NQTL, specifically denial rates and turnaround times for INN and OON concurrent reviews, overturn rates for appeals, and Internal Quality Review and Inter-Rater Reliability assessments revealed no statistically significant discrepancies in concurrent review denial rates as-between MH/SUD and M/S benefits. While operational outcomes are not determinative of NQTL compliance, and a plan may comply with the NQTL requirement notwithstanding a disparate outcome for an NQTL applied to MH/SUD benefits as compared to M/S benefits, comparable outcomes can help evidence compliance with the in-operation component of the NQTL requirement.

Consequently, Aetna concludes that the concurrent review process NQTL was applied comparably and no more stringently to MH/SUD benefits than to M/S benefits.

4. <u>Retrospective Review Process</u>

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental	
health and/or substance use disorder benefits to which it applies;	

Med/Surg Benefits	MH/SUD Benefits
Retrospective review is a utilization review service performed by	Retrospective review is a utilization review service performed by
licensed healthcare professionals to determine coverage after treatment	licensed healthcare professionals to determine coverage after treatment
has been given. The intent is to determine medical necessity,	has been given. The intent is to determine medical necessity,
appropriateness of treatment, and determine benefits and eligibility.	appropriateness of treatment, and determine benefits and eligibility.
For OON services, Aetna performs retrospective review on OON	For OON services, Aetna performs retrospective review on OON
Inpatient services that were not pre-certified and OON Outpatient All-	Inpatient services that were not pre-certified and OON Outpatient All-
Other services that are on the member precertification list and were	Other services that are on the member precertification list and were
not precertified. For INN services, Aetna performs retrospective	not precertified. For INN services, Aetna performs retrospective
review in the following limited circumstances: when an INN	review in the following limited circumstances: when an INN
psychiatric hospital or other MH/SUD or M/S facility that is not a	psychiatric hospital or other MH/SUD or M/S facility that is not a
Hospital or Children's Hospital failed to precertify or give timely	Hospital or Children's Hospital failed to precertify or give timely
notice of inpatient admission; when required by state law or Aetna's	notice of inpatient admission; when required by state law or Aetna's
contract with a facility; when provider precertification requirements	contract with a facility; when provider precertification requirements
are waived due to a state or federal disaster declaration; or when there	are waived due to a state or federal disaster declaration; or when there
is a valid reason for failure to precertify or give timely notice (e.g.,	is a valid reason for failure to precertify or give timely notice (e.g.,
member was unable to provide insurance information at the time). For	member was unable to provide insurance information at the time). For
Emergency services, Aetna performs retrospective review on	Emergency services, Aetna performs retrospective review on
"emergency" M/S and MH/SUD services where the diagnosis code	"emergency" M/S and MH/SUD services where the diagnosis code
signifies a non-emergent condition.	signifies a non-emergent condition.
M/S services NQTL applies to:	MH/SUD services NQTL applies to:
All OON M/S inpatient services, and all outpatient-all other services	All OON MH/SUD inpatient services, and outpatient-all other services
on the Member Precertification List, that were not precertified.	on the Member Precertification List, that were not precertified.
INN inpatient services when provided by a facility (other than a hospital or children's hospital) that failed to precertify or give timely notice of admission	INN inpatient services when provided by a psychiatric hospital or facility (other than a hospital or children's hospital) that failed to precertify or give timely notice of admission

"Emergency" M/S services on the NonEmergent ER Diagnosis List	"Emergency" M/S services on the NonEmergent ER Diagnosis List
Plan language:	Plan Language:
Refer to the plan language for precertification.	Refer to the plan language for precertification.
https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-	https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-
professionals/2023 Precert List.pdf	professionals/documents-forms/bh precert list.pdf
Plan language: Section # 40 / Form # HI COC00040 05 / Page # 5	Plan language: Section # 40 / Form # HI COC00040 05 / Page # 5
Emergency services	Emergency services
When you experience an emergency medical condition , you should	When you experience an emergency medical condition , you should
go to the nearest emergency room. You can also dial 911 or your local	go to the nearest emergency room. You can also dial 911 or your local
emergency response service for medical and ambulance help.	emergency response service for medical and ambulance help.
Covered services include only outpatient services to evaluate and	Covered services include only outpatient services to evaluate and
stabilize an emergency medical condition in a hospital emergency room. You can get emergency services from network providers or	stabilize an emergency medical condition in a hospital emergency room. You can get emergency services from network providers or
out-of-network providers.	out-of-network providers.
If your physician decides you need to stay in the hospital (emergency	If your physician decides you need to stay in the hospital (emergency
admission) or receive follow-up care, these are not emergency	admission) or receive follow-up care, these are not emergency
services. Different benefits and requirements apply. You are covered	services. Different benefits and requirements apply. You are covered
for follow-up care only when your physician or primary care physician (PCP) provides or coordinates it. If your emergency medical	for follow-up care only when your physician or primary care physician (PCP) provides or coordinates it. If your emergency medical
condition includes surgery, we will cover follow-up care with the	condition includes surgery, we will cover follow-up care with the
surgeon at network cost sharing if:	surgeon at network cost sharing if:
 It's related to the condition for which the surgery was done 	 It's related to the condition for which the surgery was done
• It is consulted with your physician or primary care physician	• It is consulted with your physician or primary care physician
(PCP)	(PCP)
Please refer to the How your plan works – Medical necessity[,	Please refer to the How your plan works – Medical necessity[,
referral] and precertification requirements section and the Coverage	referral] and precertification requirements section and the Coverage

and exclusions section that fits your situation (for example, Hospital care or Physician services). You can also contact us or your network physician or primary care physician (PCP).	<i>and exclusions</i> section that fits your situation (for example, <i>Hospital care</i> or <i>Physician services</i>). You can also contact us or your network physician or primary care physician (PCP).
Non-emergency services	Non-emergency services
If you go to an emergency room for what is not an emergency	If you go to an emergency room for what is not an emergency
medical condition , the plan may not cover your expenses. See the	medical condition , the plan may not cover your expenses. See the
schedule of benefits for this information.	schedule of benefits for this information.

B. Identify the factors used in the development of the limitation(s);

Factors: Note: All factors are the same for medical/surgical and MH/SUD

The factors used in determining what services are subject to precertification and, by extension, to retrospective review, are described in Aetna's Prior Authorization NQTL Comparative Analysis.

Additional factors used in determining which services are subject to retrospective review are:

- Terms of Aetna's contracts with INN providers
- State and federal laws pertaining to waiver of INN provider precertification requirements
- Federal Law defining "prudent layperson" standard for emergency services
- ICD10 and DSM-V Coding Descriptions

The factors used in determining how retrospective review is performed are:

- National Committee for Quality Assurance (NCQA) utilization management standards for Health Plan Accreditation and Managed Behavioral Health Organization accreditation
- Applicable state and federal law

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

Sources:

Some of the processes and evidentiary standards used in determining what services are subject to retrospective review are described in Aetna's Prior Authorization NQTL Comparative Analysis. Additionally, Aetna reviews its contracts with participating facility providers and monitors state

and federal laws and disaster declarations to determine when the standard obligation for the provider to give timely notice of an admission must be waived; when the obligation to give timely notice of an admission is waived, then Aetna will perform retrospective review instead of imposing a payment penalty on the participating provider. Regarding the list of non-emergent diagnosis codes that trigger a retrospective review of "emergency" services, that list is maintained by Aetna's Payment Policy and Coding Committee. The Medical Directors on the PPDC reviewICD10 and DSM-V coding descriptions and apply their clinical training, experience and judgment to assess whether the symptoms would typically cause a "prudent layperson" (as that term is defined in federal law) to believe emergency care was needed.

Federal law defining "prudent layperson" standard for emergency services:

An emergency medical condition is:

- Manifesting itself by acute symptoms of severity (including severe pain) such that a prudent layperson who has an average knowledge of health and medicine could reasonably expect the absence of immediate medical attention to result in:
- Placing the health of the individual (or, with respect to a pregnant woman, the health of the woman and her unborn child) in serious jeopardy
- Serious impairment to bodily functions, or
- Serious dysfunction of any bodily organ or part.

Evidentiary Standards for Performing Retrospective Review:

The evidentiary standards/sources for Aetna's retrospective review processes are National Committee for Quality Assurance (NCQA) utilization management standards for Health Plan Accreditation and Managed Behavioral Health Organization accreditation, applicable state and federal law.

Strategy for Performing Retrospective Review:

For both MH/SUD and M/S services, the guiding strategy behind retrospective review relies upon the clinical reviewers' exercise of their clinical judgment based on their training and experience, guided by clinical criteria and informed by the member's medical history, to determine whether to approve coverage for care already provided.

D. Identify the methods and analysis used in the development of the limitation(s); and

Process for Developing the National Precertification List (NPL):

The NPL is used by participating providers to identify which MH/SUD and M/S services require precertification for INN coverage. The NPL Committee is responsible for determining which services to add, retain or remove from the NPL. It comprises clinicians and other subject matter experts representing both MH/SUD and M/S expertise. Proposed additions or changes to the NPL are submitted to the NPL Committee. The Committee considers the factors listed above and decides whether to add or remove the service. Also, the Committee annually reviews services on the NPL to decide whether to retain or remove them. Any factors and Extenuating Factors relied upon in making the decision must be documented; this allows for validation that they are being applied comparably, and not more stringently, to MH/SUD services.

The same factors and sources, and the same National Clinical Services Policies and Procedures, apply to handling retrospective review requests for MH/SUD and M/S benefits. Regarding "emergency" services that are subject to retrospective review, of the 1495 diagnosis codes that trigger retrospective review, only 80 (5%) are for MH/SUD conditions. Thus, as written this NQTL is applied comparably, and not more stringently, to MH/SUD benefits.

Process for Performing Retrospective Review:

Retrospective review is performed after services have already been provided. It is done by licensed clinicians who are RNs, licensed clinical social workers or physicians. The licensed clinician may approve coverage or, if unable to approve coverage, will refer the case to a Medical Director who is a physician or to a consultant psychiatrist/ psychologist/ board certified behavior analyst-doctoral (BCBA-D) for further review and action. Consultant psychiatrists/ psychologists/ BCBA-Ds use the available clinical information to approve a coverage request or, when unable to approve, make a level of care or service recommendation and forward the recommendation to the Medical Director or the designated psychologist/BCBA-D for issuance of the coverage determination. The licensed clinician or Medical Director draws upon his or her training and expertise in applying the applicable clinical review criteria to the request. (See Aetna's Medical Necessity NQTL Comparative Analysis for more information about clinical review criteria.) The retrospective review determination is made and communicated to the provider/member according to the established timeframes. In some circumstances the treating provider may have a peer-to-peer consultation with a physician.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

Aetna's retrospective review policy development and application process is consistent between MH-SUD and M/S. Aetna applies comparable evidence-based guidelines to define established standards of effective care in both M/S and MH/SUD benefits. Consistency in policy development, process and application evidence compliance with the NQTL requirement that the retrospective review process be applied comparably, and no more stringently, to MH/SUD services than to M/S services.

Operational proportionality data show a lower percentage of MH/SUD services than M/S subject to retrospective reviews to total claims in the INN OP-All Other classification. This demonstrates that the NQTL is not more stringently applied to MH/SUD services than M/S services.

Overturn rates for appeals: Retrospective review data, from the UR database, for 2021 show zero MH/SUD appeals of retrospective review decisions. Therefore, there were no peer-to-peer reviews. With no MH/SUD appeals to analyze, it is apparent that the NQTL is not more stringently applied to MH/SUD services than M/S services.

The Internal Quality Reviews and Inter-Rater Reliability process provides a way to evaluate whether precertification and concurrent review of MH/SUD and M/S services is performed comparably, and not more stringently for MH/SUD, in operation. These reports show that both Medical and Behavioral Health Medical Directors and clinicians are performing precertification and concurrent review accurately and consistently.

An "in operation" review of Aetna's application of the retrospective review NQTL, specifically Denial Rates for INN, OON MH/SUD, M/S retrospective reviews, and overturn rates for appeals for all but one plan, there were no denials of retrospective reviews. While operational outcomes are not determinative of NQTL compliance, and a plan may comply with the NQTL requirement notwithstanding a disparate outcome for an NQTL applied to MH/SUD benefits as compared to M/S benefits, comparable outcomes can help evidence compliance with the in-operation component of the NQTL requirement.

Consequently, Aetna concludes that the retrospective review NQTL was applied comparably and no more stringently to MH/SUD benefits than to M/S benefits.

5. <u>Emergency Services</u>

NQTLs applicable to emergency services are described in other sections: 1. Medical Necessity; 4. Retrospective Review; 10. Provider Credentialing and Contracting; 14. Reimbursement for Providers and Facilities.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

6. <u>Pharmacy Services</u>

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

NQTL's Applicable to Med/Surg Benefits in Prescription	NQTL's Applicable to MH/SUD Benefits in Prescription
Classification	Classification
Pharmacy Prior Authorization:	Pharmacy Prior Authorization:
Pharmacy prior authorization is typically utilized in drug classes	Pharmacy prior authorization is utilized in drug classes where the
where the potential for use for unapproved indications exists, the	potential for use for unapproved indications exists, the potential for
potential for inappropriate over- or under-utilization exists, or when	inappropriate over- or under-utilization exists, or when safety concerns
safety concerns exist with a drug or drug class. Cost may also be a	exist with a drug or drug class. Cost may also be a consideration in
consideration in determining if prior authorization is appropriate.	determining if prior authorization is appropriate.
Plan Language:	In effect since 1/1/2020 Aetna added coverage state specific benefit
Certain prescription drugs are covered under the medical plan when	code to bypass formulary exclusions, bypass Prior Authorization on
they are given to you by your doctor or health care facility. The	the "Medication Assisted Therapy" list to meet the ASAM criteria.
following precertification information applies to these prescription	Plan Language:
drugs:	Certain prescription drugs are covered under the medical plan when
[Note: This will print when the contract holder's plan requires drug precertification.] [For certain drugs, your provider needs to get approval from us before we will cover the drug. The requirement for getting approval	they are given to you by your doctor or health care facility. The following precertification information applies to these prescription drugs:
in advance guides appropriate use of certain drugs and makes sure	[Note: This will print when the contract holder's plan requires drug precertification.]
they are medically necessary .]	[For certain drugs, your provider needs to get approval from us
The processes and strategies used in the development of CVS Caremark standard Utilization Management (UM) programs are the same for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions.	before we will cover the drug. The requirement for getting approval in advance guides appropriate use of certain drugs and makes sure they are medically necessary .]

The decision to develop prior authorization is based on principles that	The processes and strategies used in the development of CVS
consider the place in therapy for the drug, how the drug might be used	Caremark standard Utilization Management (UM) programs are the
in clinical practice, and the duration or quantity of therapy needed by	same for drugs used in MH/SUD conditions as for drugs used in
	e
most patients, as well as evidence-based reviews of the medical	MED/SURG conditions.
literature and relevant clinical information. UM tools, including PA,	
should not cause delay of care or have an impact on, impede or	The decision to develop prior authorization is based on principles that
prevent emergency or urgent access to medication. UM Criteria are	consider the place in therapy for the drug, how the drug might be used
developed based upon published clinical evidence supporting the	in clinical practice, and the duration or quantity of therapy needed by
different uses of a drug and coverage conditions are not affected or	most patients, as well as evidence-based reviews of the medical
altered by the medication's intended area of utilization. For example,	literature and relevant clinical information. UM tools, including PA,
UM criteria developed for medications used in mental health	should not cause delay of care or have an impact on, impede or
conditions require the same levels of clinical evidence as those that are	prevent emergency or urgent access to medication. UM Criteria are
not used or indicated for mental health conditions.	developed based upon published clinical evidence supporting the
	different uses of a drug and coverage conditions are not affected or
Development of UM Criteria includes a coverage summary and	altered by the medication's intended area of utilization. For example,
algorithm of questions that when completed, renders a coverage	UM criteria developed for medications used in mental health
decision. Criteria include coverage for uses supported by evidence-	conditions require the same levels of clinical evidence as those that are
	not used or indicated for mental health conditions.
based medicine and Standard of Care sources. Coverage conditions are	not used of indicated for mental nearth conditions.
based on safety considerations in black box warnings and/or	
contraindications in the product labeling if these situations can be	Development of UM Criteria includes a coverage summary and
effectively managed through a PA process. Additional safety-related	algorithm of questions that when completed, renders a coverage
concerns may be added at the recommendation of the External Clinical	decision. Criteria include coverage for uses supported by evidence-
Expert(s). Standard UM Criteria are developed based upon published	based medicine and Standard of Care sources. Coverage conditions are
clinical evidence supporting the different uses of a drug, and coverage	based on safety considerations in black box warnings and/or
conditions are not affected or altered by the medication's intended area	contraindications in the product labeling if these situations can be
of utilization. For example, UM Criteria developed for medications	effectively managed through a PA process. Additional safety-related
used in mental health conditions require the same levels of clinical	concerns may be added at the recommendation of the External Clinical
evidence as those that are not used or indicated for mental health	Expert(s). Standard UM Criteria are developed based upon published
conditions.	clinical evidence supporting the different uses of a drug, and coverage
	conditions are not affected or altered by the medication's intended area
MED/SURG drugs with Prior Auth:	of utilization.
(Below are examples of MED/SURG drugs with Prior Auth)	For example, UM Criteria developed for medications used in mental
(Below are examples of WED/SORO drugs with Thoi Auth)	health conditions require the same levels of clinical evidence as those
ADVANCED CONTROL FORMULARY	that are not used or indicated for mental health conditions.
Sovaldi	
Suvalui	

Harvoni	MH/SUD drugs with Prior Auth:
Lenvima	
Xtandi	ADVANCED CONTROL FORMULARY
Sprycel	Loreev XR
Forteo	Sertraline caps
Prolia	Spravato 56mg & 84mg dose
Sunosi	Abilify Mycite tabs
Aubagio	Chlorpromazine
Gilenya	Invega Hafyera
Xtampza ER	Lybalvi
Nucynta	Nuplazid caps, tabs
Enbrel	Rexulti
Humira	Versacloz
Taltz	Vraylar cap/Pack
Skyrizi	Hetlioz caps, oral susp
Targretin	Azstarys
Tacrolimus	
	STANDARD OPT-OUT FORMULARY
STANDARD OPT-OUT FORMULARY	Spravato 56mg & 84mg dose
Sovaldi	Nuplazid caps, tabs
Harvoni	Hetlioz caps, oral susp
Lenvima	Lucemyra
Xtandi	
Sprycel	Pharmacy Step Therapy (ST):
Forteo	Step therapy is a pharmacy UM strategy typically employed in
Prolia	therapeutic classes with broad generic availability. Step Therapy is
Armodafinil	generally used to promote the use of the most cost-effective products
Aubagio	in the therapeutic class, provided efficacy and safety are equivalent,
Gilenya	with the potential for reduced cost from greater utilization of generics
Xtampza ER	and/or lower cost brands.
Nucynta	
Enbrel	Plan Language:
Humira	Step therapy is a type of precertification where we require you to
Taltz	first try certain drugs to treat your medical condition before we will
Skyrizi	cover another drug for that condition.

Targretin Tacrolimus

Pharmacy Step Therapy (ST):

Step therapy is a pharmacy UM strategy typically employed in therapeutic classes with broad generic availability. Step Therapy is generally used to promote the use of the most cost-effective products in the therapeutic class, provided efficacy and safety are equivalent, with the potential for reduced cost from greater utilization of generics and/or lower cost brands.

<u>Plan Language:</u>

Step therapy is a type of **precertification** where we require you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.

We will waive **step therapy** if any of the following conditions is met:

- The **step therapy** drug is not approved by the FDA for your medical condition
- Your **provider** provides supporting medical information showing that a covered **prescription** drug
- Was ordered for you within the past 180 days, and
- In their professional judgement, was effective in treating your disease or condition
 - A **prescription** drug approved by the FDA if:
- The drug is used to treat your stage four advanced metastatic cancer; and
- Use of the drug is:

 Consistent with the FDA approved indication or The National Comprehensive Cancer Network Drugs & Biologics Compendium Indication for the treatment of your cancer, and

 Supported by peer-reviewed medical literature

We will waive **step therapy** if any of the following conditions is met:

- The **step therapy** drug is not approved by the FDA for your medical condition
- Your **provider** provides supporting medical information showing that a covered **prescription** drug
 - Was ordered for you within the past 180 days, and
 - In their professional judgement, was effective in treating your disease or condition
- A **prescription** drug approved by the FDA if:
 - The drug is used to treat your stage four advanced metastatic cancer; and
 - Use of the drug is:
 - Consistent with the FDA approved indication or The National Comprehensive Cancer Network Drugs & Biologics Compendium Indication for the treatment of your cancer, and
 - Supported by peer-reviewed medical literature

[Note: This will print when the contract holder's plan requires drug precertification, step therapy, or both. Appropriate bracketed terms will print based on the contract holder's plan.]

[Contact us or go online to get the most up-to-date [**precertification** requirements] [and] [list of **step therapy** drugs].]

[Note: "or may seek to continue the same cost share. . ." and "If we remove a drug from the drug guide. . ." will print for plans that include a managed prescription drug benefit.]

Sometimes your prescriber or your pharmacist may ask for a medical exception for drugs that are not covered or for which coverage was denied[, or may seek to continue the same cost share when a **prescription** drug or device is moved to a higher cost share tier]. [If we remove a drug from the **drug guide** or move a drug or device to a higher cost share tier, we will give you and your prescriber 30 days

[Note: This will print when the contract holder's plan requires drug precertification, step therapy, or both. Appropriate bracketed terms will	advance notice with the information on how to request a medical exception.].
<pre>print based on the contract holder's plan.] [Contact us or go online to get the most up-to-date [precertification requirements] [and] [list of step therapy drugs].] [Note: "or may seek to continue the same cost share" and "If we remove a drug from the drug guide" will print for plans that include a managed prescription drug benefit.]</pre>	You, someone who represents you or your prescriber can contact us. You will need to provide us with clinical documentation. Any exception granted is based upon an individual and is a case-by-case decision that will not apply to other members.
Sometimes your prescriber or your pharmacist may ask for a medical exception for drugs that are not covered or for which coverage was denied[, or may seek to continue the same cost share when a prescription drug or device is moved to a higher cost share tier]. [If we remove a drug from the drug guide or move a drug or device to a higher cost share tier, we will give you and your prescriber 30 days advance notice with the information on how to request a medical exception.].	 [Note: The text regarding tiers will print for plans that include a managed prescription drug benefit.] We will cover a prescription drug or device not listed in the drug guide[, or cover it at the same cost share when it is moved to a higher tier] if any of the following conditions is met: There is no equivalent prescription drug or device in the drug guide [in a lower tier]; An equivalent prescription drug or device in the drug
You, someone who represents you or your prescriber can contact us. You will need to provide us with clinical documentation. Any exception granted is based upon an individual and is a case-by-case decision that will not apply to other members.	 guide [in a lower tier]: Has been ineffective in treating your disease or condition; or Has caused or is likely to cause an adverse reaction or other harm to you
 [Note: The text regarding tiers will print for plans that include a managed prescription drug benefit.] We will cover a prescription drug or device not listed in the drug guide[, or cover it at the same cost share when it is moved to a higher tier] if any of the following conditions is met: There is no equivalent prescription drug or device in the drug guide [in a lower tier]; An equivalent prescription drug or device in the drug guide [in a lower tier]: Has been ineffective in treating your disease or condition; or 	 [Note: The contraceptive drug bullet will only be removed for religious exemption plans.] [A contraceptive prescription drug or device not in the drug guide is medically necessary for you to adhere to the appropriate use of the prescription drug or device.] Section # 170 / Form # HI COC00170 05 / Page # 4, 7 [Note: References to precertification or precertified may be changed to preauthorization or pre-authorized or pre-approval or pre-approved]

Has caused or is likely to cause an adverse	In effect since 1/1/2020 Aetna added coverage state specific benefit	
reaction or other harm to you	code to bypass Step Therapy drugs on the "Medication Assisted	
[Note: The contraceptive drug bullet will only be removed for religious	Therapy" list to meet the ASAM criteria.	
exemption plans.]		
 [A contraceptive prescription drug or device not in 	Step therapy is a pharmacy UM strategy employed in therapeutic	
the drug guide is medically necessary for you to adhere	classes with broad generic availability. Step Therapy is used to	
to the appropriate use of the prescription drug or	promote the use of the most cost-effective products in the therapeutic	
device.]	class, provided efficacy and safety are equivalent, with the potential	
	for reduced cost from greater utilization of generics and/or lower cost	
• Section # 170 / Form # HI COC00170 05 / Page # 4,	brands.	
7		
[Note: References to precertification or precertified may be changed to pre-	The processes and strategies used in the development of CVS	
authorization or pre-authorized or pre-approval or pre-approved]	Caremark standard Utilization Management (UM) programs are the	
	same for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions.	
The processes and strategies used in the development of CVS	WED/SORO conditions.	
Caremark standard Utilization Management (UM) programs are the	Step Therapy protocols require that alternative drugs be tried first,	
same for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions.	when clinically warranted, and for a certain duration before the	
MED/SURG conditions.	prescribed drug can be covered by a plan. A prior authorization or	
Step Therapy protocols require that alternative drugs be tried first,	exceptions process is available when the protocol is not satisfied, to	
when clinically warranted, and for a certain duration before the	collect information so that coverage consistent with the conditions	
prescribed drug can be covered by a plan. A prior authorization or	included by the ST protocol can be evaluated and coverage determined	
exceptions process is available when the protocol is not satisfied, to	under the benefit. Messaging is provided to the dispensing pharmacy	
collect information so that coverage consistent with the conditions	advising that the plan's ST protocols require alternative drugs first	
included by the ST protocol can be evaluated and coverage determined	before the prescribed drug will be covered.	
under the benefit. Messaging is provided to the dispensing pharmacy		
advising that the plan's ST protocols require alternative drugs first	The decision to implement step therapy is based on principles that	
before the prescribed drug will be covered.	consider the place in therapy for the drug, how the drug might be used in clinical practice, and the duration or quantity of therapy needed by	
	most patients. UM Criteria are developed based upon published	
The decision to implement step therapy is based on principles that	clinical evidence supporting the different uses of a drug and coverage	
consider the place in therapy for the drug, how the drug might be used	conditions are not affected or altered by the medication's intended area	
in clinical practice, and the duration or quantity of therapy needed by	of utilization. For example, UM criteria developed for medications	
most patients. UM Criteria are developed based upon published clinical evidence supporting the different uses of a drug and coverage	used in mental health conditions require the same levels of clinical	
conditions are not affected or altered by the medication's intended area	*	

of utilization. For example, UM criteria developed for medications	evidence as those that are not used or indicated for mental health
used in mental health conditions require the same levels of clinical	conditions.
evidence as those that are not used or indicated for mental health	
conditions.	Development of UM Criteria includes a coverage summary and
	algorithm of questions that when completed, renders a coverage
Development of UM Criteria includes a coverage summary and	decision. Criteria include coverage for uses supported by evidence-
algorithm of questions that when completed, renders a coverage	based medicine and Standard of Care sources. Coverage conditions are
decision. Criteria include coverage for uses supported by evidence-	based on safety considerations in black box warnings and/or
based medicine and Standard of Care sources. Coverage conditions are	contraindications in the product labeling if these situations can be
based on safety considerations in black box warnings and/or	effectively managed through a PA process. Additional safety-related
contraindications in the product labeling if these situations can be	concerns may be added at the recommendation of the External Clinical
effectively managed through a PA process. Additional safety-related	Expert(s). Standard UM Criteria are developed based upon published
concerns may be added at the recommendation of the External Clinical	clinical evidence supporting the different uses of a drug, and coverage
Expert(s). Standard UM Criteria are developed based upon published	conditions are not affected or altered by the medication's intended area
clinical evidence supporting the different uses of a drug, and coverage	of utilization. For example, UM Criteria developed for medications
conditions are not affected or altered by the medication's intended area	used in mental health conditions require the same levels of clinical
of utilization. For example, UM Criteria developed for medications	evidence as those that are not used or indicated for mental health
used in mental health conditions require the same levels of clinical	conditions.
evidence as those that are not used or indicated for mental health	
conditions.	MH/SUD drugs with Step Therapy:
MED/SURG drugs with Step Therapy:	ADVANCED CONTROL FORMULARY
(Below are examples of MED/SURG drugs with ST)	Desvenlafaxine ER
	Trintellix
ADVANCED CONTROL FORMULARY	Zolpidem ER
Januvia	Dyanavel XR
SymlinPen	Quillichew ER
Fosamax Plus D	Quillivant XR
Tekturna HCT	
Myrbetriq	
Cardura XL	STANDARD OPT-OUT FORMULARY
Savella	Fetzima cap/Pack
Aimovig	Pexeva
Emgality	Trintellix
Calcipotriene	Viibryd tab/Pack

	T . 4. 1.
	Latuda
STANDARD OPT-OUT FORMULARY	Rexulti
Fosamax Plus D	Vraylar cap/Pack
Tekturna HCT	Belsomra
Altoprev	Edluar]
Beconase AQ	
Rabeprazole sprinkle caps	Pharmacy Quantity Limits (QL):
Myrbetriq	Quantity Limits establish a maximum quantity of certain medications
Cardura XL	that will be covered over a specified time period. The limit is
Zembrace	expressed in terms of dose or quantity dispensed per prescription, dose
Lumigan	or quantity dispensed per time period, the amount covered for the
Zioptan	drug, or the number of prescription claims for the drug over a period
	of time. Pharmacy QLs are applied to each drug class regardless of
Pharmacy Quantity Limits (QL):	whether the intended use is for a MH/SUD condition or a MED/SURG
Quantity Limits establish a maximum quantity of certain medications	condition. Pharmacy QLs generally apply to both generic and brand
that will be covered over a specified time period. The limit is	drugs.
expressed in terms of dose or quantity dispensed per prescription, dose	
or quantity dispensed per time period, the amount covered for the	Plan Language:
drug, or the number of prescription claims for the drug over a period	Step therapy
of time. Pharmacy QLs are applied to each drug class regardless of	
whether the intended use is for a MH/SUD condition or a MED/SURG	A form of precertification under which certain prescription drugs are
condition. Pharmacy QLs generally apply to both generic and brand	excluded from coverage, unless a first-line therapy drug is used first
drugs.	by you. The list of step-therapy drugs is subject to change by us or an
	affiliate. An updated copy of the list of drugs subject to step therapy
Plan Language:	is available upon request or on our website at
Step therapy	https://www.aetna.com/individuals-families/find-a-medication.html.
A form of precertification under which certain prescription drugs are	
excluded from coverage, unless a first-line therapy drug is used first	Quantity Limits establish a maximum quantity of certain medications
by you. The list of step-therapy drugs is subject to change by us or an	that will be covered over a specified time period. The limit is
	expressed in terms of dose or quantity dispensed per prescription, dose
affiliate. An updated copy of the list of drugs subject to step therapy	or quantity dispensed per time period, the amount covered for the
is available upon request or on our website at	drug, or the number of prescription claims for the drug over a period
https://www.aetna.com/individuals-families/find-a-medication.html.	of time. Pharmacy QLs are applied to each drug class regardless of
	whether the intended use is for a MH/SUD condition or a MED/SURG
The processes and strategies used in the development of CVS	condition. Pharmacy QLs apply to both generic and brand drugs.
Caremark standard Utilization Management (UM) programs are the	

ma tha
re the
in
ications
period.
per
mount
n claims
ceeds
v the
the
has been
of an
of all
es that
t be used
eded by
ed
overage
nded area
tions
nical
ılth
nd
ge
ence-
itions are
n be

utilization and minimize cost associated with uses that are outside the	effectively managed through a PA process. Additional safety-related	
scope of the plan's pharmacy benefit.	concerns may be added at the recommendation of the External Clinical	
	Expert(s). Standard UM Criteria are written to effectively manage	
MED/SURG drugs with Quantity Limits:	utilization and minimize cost associated with uses that are outside the	
(Below are examples of MED/SURG drugs with QL)	scope of the plan's pharmacy benefit.	
ADVANCED CONTROL FORMULARY	MH/SUD drugs with Quantity Limits:	
Descovy	(Below are examples of MED/SURG drugs with QL)	
Lamivudine		
Viread	ADVANCED CONTROL FORMULARY	
Harvoni	Alprazolam tabs, ER tab, ODT	
Sovaldi	Chlordiazepoxide	
Junel	Clonazepam tab, ODT	
Mirena	Diazepam oral conc, oral soln, tabs	
Norditropin	Lorazepam oral conc, tabs	
Omeprazole	Desvenlafaxine ER	
Lansoprazole	Nuplazid caps, tabs	
Ondansetron	Flurazepam	
Granisetron	Hetlioz caps, oral susp	
Aubagio	Ramelteon	
Gilenya	Temazepam	
Lortab	Amphetamine	
Tramadol	Dextroamphetamine	
Aimovig	Vyvanse	
Emgality	Methylphenidate	
Taltz	Buprenorphine/naloxone SL tab, film	
Skyrizi	Bupropion ER	
Cyclosporine	Nicotrol oral inhaler, nasal spray	
Sirolimus	Kloxxado nasal spray	
	Vivitrol injection	
STANDARD OPT-OUT FORMULARY	3	
Descovy	STANDARD OPT-OUT FORMULARY	
Lamivudine	Alprazolam tabs, ER tab, ODT	
Viread	Chlordiazepoxide	
Harvoni	Clonazepam tab, ODT	

Sovaldi	Diazepam oral conc, oral soln, tabs
Lenvima	Lorazepam oral conc, tabs
Xtandi	Nuplazid caps, tabs
Sprycel	Flurazepam
Norditropin	Hetlioz caps, oral susp
Omeprazole	Ramelteon
Lansoprazole	Temazepam
Ondansetron	Amphetamine
Granisetron	Dextroamphetamine
Aubagio	Vyvanse
Gilenya	Methylphenidate
Lortab	Buprenorphine/naloxone SL tab, film
Tramadol	Bupropion ER
Taltz	Nicotrol oral inhaler, nasal spray
Skyrizi	Kloxxado nasal spray
Lidocaine patch	Vivitrol injection
Cyclosporine	
Sirolimus	

B. Identify the factors used in the development of the limitation(s);

Factors: Prior Authorization:

Pharmacy Prior Authorization (PA)			
	Medical/Surgical	Mental Health / Substance Use Disorder	
Factors	 Patient safety concerns exist with a drug or drug class; unknown long-term safety or durability Applicable lab values or other test results required for appropriate treatment Appropriate medication uses for indications or conditions based on national guidelines Use in appropriate patient populations 	 Patient safety concerns exist with a drug or drug class; unknown long-term safety or durability Applicable lab values or other test results required for appropriate treatment Appropriate medication uses for indications or conditions based on national guidelines Use in appropriate patient populations 	

Pharmacy Prior A	Authorization (PA)	
-	Medical/Surgical	Mental Health / Substance Use Disorder
	 Use limited to a specific population based on FDA-approved indications, standard clinical practice, and guidelines Potential for inappropriate or off-label use Opportunity for optimizing patient outcomes, to ensure treatment goals of the drug are being met Requirement for additional treatment supportive therapies, including but not limited to behavioral counseling, diet therapy, case management, and other standard non-drug supportive therapies Reduce waste, unnecessary drug use, fraud, or abuse 	 Use limited to a specific population based on FDA-approved indications, standard clinical practice, and guidelines Potential for inappropriate or off-label use Opportunity for optimizing patient outcomes, to ensure treatment goals of the drug are being met Requirement for additional treatment supportive therapies, including but not limited to behavioral counseling, diet therapy, case management, and other standard non-drug supportive therapies Reduce waste, unnecessary drug use, fraud, or abuse
Definitions of Factors	 Reduce waste, unnecessary drug use, fraud, or abuse Reduce waste, unnecessary drug use, fraud, or abuse Patient safety concerns with a drug or drug class; unknown long-term safety or durability – Imposing prior authorization based on this factor affords an opportunity to ensure that safety protocols are maintained. Evidentiary Standard: Safety concerns noted by the manufacturer in clinical trials or in post-marketing reports Sources: FDA product labeling, published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria Applicable lab values or other test results required for appropriate treatment – Prior authorization may be imposed in order to ensure appropriate monitoring and testing in patient treatment Evidentiary Standard: specific lab values or test results required for proper diagnosis or for determining response to therapy Sources: published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care noted in in clinical literature, appropriate clinical drug information from other sources, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria Applicable lab values or other test results required for proper diagnosis or for determining response to therapy Sources: published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care no	

Pharmacy Prior Authorization (PA)			
N	Iedical/Surgical	Mental Health / Substance Use Disorder	
	 therapy, second line therapy, or concurrent therapy. First line therapy refers to the initial recommended treatment for a disease or illness. • Evidentiary Standard: FDA-approved indications; recommended off-label uses • Sources: published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria 		
•	 Potential for inappropriate or off-label use – National treatment guidelines and the Food and Drug Administration's evaluation of these drugs determine their safety and efficacy for a particular disease or illness and define recommended duration of therapy Evidentiary Standard: controlled substance status; reports of off label use Sources: FDA product labeling, published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria 		
•	 patient is responding to therapy, e.g., A1C Evidentiary Standard: improven cholesterol) Sources: FDA product labeling, p accepted clinical practice guideline information from other sources, con UM criteria, review of any new criteria review of any new criteria authorization coverage criter Requirement for additional treatment s medications, may be recommended in the These therapies include but are not limited standard non-drug supportive therapies. Evidentiary Standard: behaviora Sources: FDA product labeling, p 	hent of symptoms from baseline; reduction of elevated blood levels (e.g., ublished peer-reviewed clinical literature, approved drug compendia, es, standards of care noted in clinical literature, appropriate clinical drug omparison of similar drugs in terms of safety and efficacy, annual review of iteria, updates and annual review of UM criteria, review and approval of ia upportive therapies - Additional supportive therapies, in addition to guidelines as the most effective treatment approach for a given condition. I to behavioral counseling, diet therapy, case management, and other	

Pharmacy Prior Authorization (PA)			
Medical/Surgi	cal	Mental Health / Substance Use Disorder	
UN	information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria		
costs, over ○ Ev ○ So acc inf UN	 Reduce waste, unnecessary drug use, fraud, or abuse: practices that, directly or indirectly, result in unnecessary costs, overusing services. Evidentiary Standard: complex treatment regimens requiring dose titration 		

Factors: Step Therapy:

Pharmacy Step Therapy (ST)		
	Medical/Surgical	Mental Health / Substance Use Disorder
Factors	 Promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands Clinical safety and adverse events based on FDA approved labeling, national clinical guideline recommendations, and other evidentiary standards Clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards Clinical efficacy based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards Multiple dosage forms available for the same or similar chemical entities, or availability of unique dosage forms Availability of therapeutic alternatives, including 	 Promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands Clinical safety and adverse events based on FDA approved labeling, national clinical guideline recommendations, and other evidentiary standards Clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards Clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards Multiple dosage forms available for the same or similar chemical entities, or availability of unique dosage forms Availability of therapeutic alternatives, including
	generics, used to treat the same condition	generics, used to treat the same condition

Pharmacy Step Therapy (ST)			
	Medical/Surgical Mental Health / Substance Use Disorder		
Definitions of Factors	 Promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands; Multiple dosage forms available for the same or similar chemical entities, or availability of unique dosage forms; Availability of therapeutic alternatives, including generics, used to treat the same condition: A drug is considered lower cost when there are other recommended more cost effective alternatives, supported by the resources described below, for the treatment of the disease or illness Evidentiary Standard: generics available to treat a condition; multiple safe and effective dosage forms or therapeutic alternatives available to treat a condition; multiple safe and effective dosage forms or therapeutic alternatives available to treat a condition incal literature, appropriate clinical drug information from other sources, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria Clinical safety and adverse events based on FDA approved labeling, national clinical guideline recommendations, and other evidentiary standards: Applying step therapy based on this factor affords an opportunity to ensure that appropriate dosing and safety protocols based on clinical trials or in post-marketing reports Sources: FDA product labeling, published peer-reviewed clinical literature, approyed drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of UM criteria, review of any new criteria, updates and annual review of UM criteria, review of any new criteria, updates and annual review of uM criteria, review of approved labeling, national clinical guideline recommendations and other evidentiary standards: National treatment guidelines and the FDA's evaluation of these drugs d		

Factors: Pharmacy Quantity Limits:

Pharmacy Quan	Pharmacy Quantity Limits (QL)				
	Medical/Surgical	Mental Health / Substance Use Disorder			
Factors	 Enhance patient safety Potential for a drug to be prescribed in greater quantities and/or at a higher dose than deemed safe and effective by the FDA To promote appropriate drug dosing, including strength and frequency To prevent overutilization When abuse or misuse by the patient is possible For opioids and narcotics, when appropriate dosing and appropriate duration of use is based on treatment for acute or chronic pain Cost and cost effectiveness Prevention of overutilization Discouragement of misuse and waste through dose efficiency QLs, which ensure that the appropriate tablet strength is utilized Lack of documented efficacy/unknown efficacy at higher doses Discourage misuse, waste, and abuse Maximum daily dosing or maximum duration of use limits 	 Enhance patient safety Potential for a drug to be prescribed in greater quantities and/or at a higher dose than deemed safe and effective by the FDA To promote appropriate drug dosing, including strength and frequency To prevent overutilization When abuse or misuse by the patient is possible For opioids and narcotics, when appropriate dosing and appropriate duration of use is based on treatment for acute or chronic pain Cost and cost effectiveness Prevention of overutilization Discouragement of misuse and waste through dose efficiency QLs, which ensure that the appropriate tablet strength is utilized Lack of documented efficacy/unknown efficacy at higher doses Discourage misuse, waste, and abuse Maximum daily dosing or maximum duration of use limits 			
Definitions of Factors	 Enhance patient safety: Applying quantity limits based on this factor affords an opportunity to ensure that safety and treatment goals of the drug are being met: National treatment guidelines and the Food and Drug Administration's evaluation of these drugs determine their safety and efficacy for a particular disease or illness and define recommended duration of therapy Evidentiary Standard: Safety concerns noted by the manufacturer in clinical trials or in post-marketing reports Sources: FDA product labeling, published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of 				

Pharmacy Quantity Limits (QL)		
	 UM criteria, review of any new criteria, updates and annual review of UM criteria, review and approval of prior authorization coverage criteria Cost and cost effectiveness: Excessive quantity is defined as a quantity that exceeds the recommended dosing regimen or the recommended duration of therapy. Quantity limits are based on FDA-approved indications, standard clinical practice, and guidelines: Dosing recommended treatment for a disease or illness. National treatment guidelines and the FDA's evaluation of these drugs determine the appropriate dosing based on safety and efficacy for a particular disease or illness. Evidentiary Standard: lower-cost, safe and effective drugs available to treat a condition Sources: FDA product labeling, published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, appropriate clinical drug information from other sources, comparison of similar drugs in terms of safety and efficacy, annual review of UM criteria, review and approval of prior authorization coverage criteria Discourage misuse, waste, and abuse: practices that, directly or indirectly, result in unnecessary costs, overusing services. Evidentiary Standard: many strengths available for a drug that requires individualized dosing Sources: FDA product labeling, published peer-reviewed clinical literature, approved drug compendia, accepted clinical practice guidelines, standards of care noted in clinical literature, approval of prior authorization coverage criteria 	

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

PA FACTORS and SOURCES

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

PA FACTORS and SOURCES

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

1.

Applicable lab values or other test results required for appropriate treatment

MED/SURG SOURCES

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee MH/SUD SOURCES

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable -e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

2. Appropriate medication uses for indications or conditions based on national guidelines MED/SURG SOURCES

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

3. Use in appropriate patient populations

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

4. Use limited to a specific population based on FDA-approved indications, standard clinical practice, and guidelines

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

5. Potential for inappropriate or off-label use

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

6. Opportunity for optimizing patient outcomes, to ensure treatment goals of the drug are being met

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

7. Requirement for additional treatment supportive therapies, including but not limited to behavioral counseling, diet therapy, case management, and other standard non-drug supportive therapies

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee **MH/SUD SOURCES**

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

8. Reduce waste, unnecessary drug use, fraud, or abuse

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable - e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

Pharmacy Step Therapy:

1. Promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

2. Clinical safety and adverse events based on FDA approved labeling, national clinical guideline recommendations, and other evidentiary standards

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

3. Clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

4. Multiple dosage forms available for the same or similar chemical entities, or availability of unique dosage forms MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

5. Availability of therapeutic alternatives, including generics, used to treat the same condition

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

Pharmacy Quantity Limits:

1. Enhance patient safety

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

2. Cost and cost effectiveness

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

G. Comparison of similar drugs in terms of safety and efficacy

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

3. Discourage misuse, waste, and abuse

MED/SURG SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of the American College of Cardiology

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for treating COPD, American Diabetes Association (ADA) Guidelines for Diabetes Care, American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of Heart Failure

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), US Food and Drug Administration (FDA), National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

MH/SUD SOURCES

A. US Food and Drug Administration (FDA) product labeling

B. Published peer-reviewed clinical literature – e.g., Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), Journal of Clinical Psychiatry

C. Approved drug compendia, including American Hospital Formulary Service Drug Information (AHFS-DI), Lexicomp, Clinical Pharmacology, Micromedex

D. Accepted clinical practice guidelines, consensus statements, or comparable publications – e.g., American Psychiatric Association (APA) Guidelines for treating Depression, Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for treating SUD

E. Standards of care noted in clinical literature, medical or pharmacy societies, standard clinical drug references

F. Appropriate clinical drug information from other sources as applicable – e.g., clinical guidance from agencies such as Centers for Disease Control and Prevention (CDC), The Centers for Medicare & Medicaid Services (CMS), FDA, National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ)

H. Annual review of UM criteria and clinical programs by internal pharmacists in the Clinical Development department and medical directors in the Medical Affairs department

I. Review of any new criteria, updates, and annual review of utilization management criteria, and clinical program content by external clinical experts, who are physicians practicing in the relevant clinical area

J. Review and approval of prior authorization coverage criteria for clinical appropriateness by the CVS Caremark National P&T Committee

- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

In the minutes dated 10/27/2021 a decision was made to add the M/S drug Avonex to the ACF and SOO formularies with PA. The approved criteria included the following requirements: diagnosis; prescriber restrictions; concomitant therapy restrictions. In this case, the criteria reflect the application of the following factors: appropriate medication uses for indications or conditions based on national guidelines, use in appropriate patient populations, and use limited to a specific population based on FDA-approved indications, standard clinical practice, and guidelines. Factors and sources used were not explicit in the minutes, however clinical drug information reviewed by PBM clinicians showed Avonex is approved to treat a certain population of patients diagnosed with multiple sclerosis and has the potential for serious side effects.

During the period of 2021 to 2022, there were no MH/SUD drugs proposed for the addition of prior authorization criteria.

PA Factor	Sources for Avonex – M/S	
Appropriate medication uses for indications	Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple	
or conditions based on national guidelines	Sclerosis (aan.com)	
	https://www.aan.com/Guidelines/home/GuidelineDetail/898	
Use in appropriate patient populations	DailyMed - AVONEX- interferon beta-1a kit AVONEX PEN- interferon beta-1a injection, solution	
	AVONEX- interferon beta-1a injection, solution (nih.gov)	
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-	
	8063b69ea0e1	
Use limited to a specific population based	Drug labeling approved by the U.S. Food and Drug Administration (FDA)	
on FDA-approved indications, standard	US Food and Drug Administration Labeling is accessible via National Library of Medicine.	
clinical practice, and guidelines	The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm	
	Centers for Medicare & Medicaid Services accepted drug compendia	
	Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.	
	https://online.lexi.com/lco/action/login	
	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com	
	Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of	
	care, and government health agencies.	
	Examples:	
	Peer-Reviewed literature and standards of care are accessible via academic databases that	
	enable users to execute searches across multiple journals. National Library of Medicine. Health	
	Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023.	
	Clinical guidelines and standards of care for each disease are accessible via web search or via	
	databases that enable users to execute searches across multiple clinical authors.	
	For example, https://www.guidelinecentral.com/guidelines/	

US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.cdc.gov/index.htm US Food and Drug Administration. https://www.fda.gov/

In the minutes dated 6/1/2022, a decision was made to add the M/S drug Qulipta to the ACF formulary with ST. The approved criteria included requirements for a two-month trial of one generic therapeutic alternative from any of four different drug classes. In this case, the criteria reflect the application of the following factors: promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands and clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards. Factors and sources used were not explicit in the minutes, however clinical drug information reviewed by PBM clinicians showed there are other therapeutic classes of medications with efficacy in migraine prevention that are considered first-line and have generics available.

Similarly, in the minutes dated 2/24/2021, a decision was made to add ST to the MH drug Ambien on the ACF formulary. The approved criteria included requirements for a one-month trial of the generic for Ambien or one other generic alternative. In this case, the criteria reflect the application of the following factors: promote the use of the most cost-effective products in the therapeutic class; promote generics and/or lower cost brands and availability of therapeutic alternatives, including generics, used to treat the same condition. Factors and sources used were not explicit in the minutes, however clinical drug information reviewed by PBM clinicians showed there are generics available for Ambien and other hypnotics in the same therapeutic class.

ST Factor	Sources for Qulipta – M/S	Sources for Ambien – MH
Promote the use of the most cost-	Drug labeling approved by the U.S. Food and	Drug labeling approved by the U.S. Food and
effective products in the therapeutic	Drug Administration (FDA)	Drug Administration (FDA)
class; promote generics and/or lower	US Food and Drug Administration Labeling is	US Food and Drug Administration Labeling is
cost brands	accessible via National Library of Medicine.	accessible via National Library of Medicine.
	The DailyMed database.	The DailyMed database.
	https://dailymed.nlm.nih.gov/dailymed/index.cf	https://dailymed.nlm.nih.gov/dailymed/index.cf
	m	m
	Centers for Medicare & Medicaid Services	Centers for Medicare & Medicaid Services
	accepted drug compendia	accepted drug compendia
	Lexicomp Online, AHFS DI (Adult and	Lexicomp Online, AHFS DI (Adult and
	Pediatric) Online, Hudson, Ohio: UpToDate,	Pediatric) Online, Hudson, Ohio: UpToDate,
	Inc. https://online.lexi.com/lco/action/login	Inc. https://online.lexi.com/lco/action/login

	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies. Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 25, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.fda.gov/	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies. Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 25, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.fda.gov/
Clinical efficacy, based on FDA approved labeling, national clinical guideline recommendations and other evidentiary standards	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cf m	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cf m

searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention.searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention.searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force.	Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies. Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or	Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies. Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or
Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention.Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskfore.org Centers for Disease Control and Prevention.Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force.	care, and government health agencies.	care, and government health agencies.
https://www.cdc.gov/index.htm https://www.cdc.gov/index.htm	Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03- 700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org	 Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org

Pharmacy Quantity Limits:

MHPAEA Summary Form

In the minutes dated 6/2/2021 a decision was made to add the M/S drug Gralise to the ACF and SOO formularies with QL. The approved criteria indicated a quantity that aligns with the recommended daily dose and is specific to each available strength. In this case, applying a quantity limit reflects the application of the following factors: enhance patient safety, discourage misuse, waste and abuse, and cost-effectiveness. Factors and sources used were not explicit in the minutes, however clinical drug information reviewed by PBM clinicians showed the need to titrate the dose of Gralise to the effective level and that the dose should be adjusted in certain patients with comorbid conditions.

Similarly, in the minutes dated 10/27/2021 a decision was made to add the MH drug Qelbree to the ACF formulary with QL. The approved criteria indicated a quantity that is limited to 90 capsules for a one-month supply. In this case, applying a quantity limit reflects the application of the following factors: enhance patient safety, discourage misuse, waste and abuse, and cost-effectiveness. Factors and sources used were not explicit in the minutes, however clinical drug information reviewed by PBM clinicians showed Qelbree is available in multiple strengths, the dose needs to be titrated and it has potential to increase suicidal thoughts and behavior.

QL Factor	Sources for Gralise – M/S	Sources for Qelbree – MH
enhance patient safety	DailyMed - GRALISE- gabapentin tablet, film	DailyMed - QELBREE- viloxazine hydrochloride
	coated GRALISE- gabapentin kit (nih.gov)	capsule, extended release (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.c	https://dailymed.nlm.nih.gov/dailymed/drugInfo.c
	fm?setid=466273b1-c9fc-3930-c94b-	fm?setid=aedf408d-0f84-418d-9416-
	aa11394d5140	7c39ddb0d29a
discourage misuse, waste and abuse	DailyMed - GRALISE- gabapentin tablet, film	DailyMed - QELBREE- viloxazine hydrochloride
	coated GRALISE- gabapentin kit (nih.gov)	capsule, extended release (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.c	https://dailymed.nlm.nih.gov/dailymed/drugInfo.c
	fm?setid=466273b1-c9fc-3930-c94b-	fm?setid=aedf408d-0f84-418d-9416-
	aa11394d5140	7c39ddb0d29a
cost-effectiveness	Drug labeling approved by the U.S. Food and	Drug labeling approved by the U.S. Food and
	Drug Administration (FDA)	Drug Administration (FDA)
	US Food and Drug Administration Labeling is	US Food and Drug Administration Labeling is
	accessible via National Library of Medicine.	accessible via National Library of Medicine.
	The DailyMed database.	The DailyMed database.
	https://dailymed.nlm.nih.gov/dailymed/index.cf	https://dailymed.nlm.nih.gov/dailymed/index.cf
	m	m
	Centers for Medicare & Medicaid Services	Centers for Medicare & Medicaid Services
	accepted drug compendia	accepted drug compendia

 -	-
Lexicomp Online, AHFS DI (Adult and	Lexicomp Online, AHFS DI (Adult and
Pediatric) Online, Hudson, Ohio: UpToDate,	Pediatric) Online, Hudson, Ohio: UpToDate,
Inc. https://online.lexi.com/lco/action/login	Inc. https://online.lexi.com/lco/action/login
Micromedex (electronic version). IBM Watson	Micromedex (electronic version). IBM Watson
Health, Greenwood Village, Colorado, USA.	Health, Greenwood Village, Colorado, USA.
https://www.micromedexsolutions.com	https://www.micromedexsolutions.com
Published peer-reviewed clinical literature,	Published peer-reviewed clinical literature,
accepted clinical practice guidelines, standards of	accepted clinical practice guidelines, standards of
care, and government health agencies.	care, and government health agencies.
Examples:	Examples:
Peer-Reviewed literature and standards of care	Peer-Reviewed literature and standards of care
are accessible via academic databases that	are accessible via academic databases that
enable users to execute searches across	enable users to execute searches across
multiple journals. National Library of	multiple journals. National Library of
Medicine. Health Data Sources.	Medicine. Health Data Sources.
https://www.nlm.nih.gov/oet/ed/stats/03-	https://www.nlm.nih.gov/oet/ed/stats/03-
700.html Accessed October 6, 2023.	700.html Accessed October 6, 2023.
Clinical guidelines and standards of care for	Clinical guidelines and standards of care for
each disease are accessible via web search or	each disease are accessible via web search or
via databases that enable users to execute	via databases that enable users to execute
searches across multiple clinical authors.	searches across multiple clinical authors.
For example,	For example,
https://www.guidelinecentral.com/guidelines/	https://www.guidelinecentral.com/guidelines/
US Preventive Services Task Force.	US Preventive Services Task Force.
http://www.uspreventiveservicestaskforce.org	http://www.uspreventiveservicestaskforce.org
Centers for Disease Control and Prevention.	Centers for Disease Control and Prevention.
https://www.cdc.gov/index.htm	https://www.cdc.gov/index.htm
US Food and Drug Administration.	US Food and Drug Administration.
https://www.fda.gov/	https://www.fda.gov/
https://www.iua.gov/	nups.// w w w.iua.gov/

Advanced Control Formulary 2021 - Aetna

Pharmacy Prior Authorization (PA): Advanced Control Formulary 2021

PRIOR AUTHORIZATION (PA) ANALYSIS							
	Plan: State of MD - AETNA - Advanced Control Formulary - 2021						
Category					Analysi	s	
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	TOTAL Drug Count by Tier	966	206	794	219	188	2,373
Medical /							
Surgical	PA Drug Count by Tier	75	25	350	216	174	840
	% of Total PA Drugs by Tier	8.9%	3.0%	41.7%	25.7%	20.7%	
	% MED/SURG Drugs with PA	7.8%	12.1%	44.1%	98.6%	92.6%	35.4%
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	119	10	38	0	6	173
Mental							
Mental Health	PA Drug Count by Tier	0	2	9	0	6	17
	PA Drug Count by Tier % of Total PA Drugs by Tier	0	2 11.8%	9 52.9%	0	6 35.3%	17
	% of Total PA Drugs by	-		-			17 9.8%
	% of Total PA Drugs by Tier	0.0%	11.8%	52.9%	0.0%	35.3%	
Health	% of Total PA Drugs by Tier % MH Drugs with PA	0.0%	11.8% 20.0%	52.9% 23.7%	0.0%	35.3% 100.0%	9.8%
Health	% of Total PA Drugs by Tier % MH Drugs with PA Substance Use Disorder	0.0% 0.0% Tier 1	11.8% 20.0% Tier 2	52.9% 23.7% Tier 3	0.0% 0.0% Tier 4	35.3% 100.0% Tier 5	9.8% Total Drugs
Health Substance Use	% of Total PA Drugs by Tier % MH Drugs with PA Substance Use Disorder Total Drug Count by Tier PA Drug Count by Tier	0.0% 0.0% Tier 1	11.8% 20.0% Tier 2	52.9% 23.7% Tier 3	0.0% 0.0% Tier 4	35.3% 100.0% Tier 5	9.8% Total Drugs
Health	% of Total PA Drugs by Tier % MH Drugs with PA Substance Use Disorder Total Drug Count by Tier	0.0% 0.0% Tier 1 9	11.8% 20.0% Tier 2 1	52.9% 23.7% Tier 3 7	0.0% 0.0% Tier 4 1	35.3% 100.0% Tier 5 1	9.8% Total Drugs 19

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for pharmacy prior authorization for Advanced Control Formulary – Aetna 2021

When the factors for pharmacy prior authorization are considered consistently across all drugs and drug classes, the outcome shows that prior authorization is applied to a lower percentage of drugs in the MH drug category compared to the MED/SURG drug category, and there is no prior authorization applying to any drugs in the SUD drug category. Pharmacy prior authorization is applied to:

- 35.4% (840 out of 2,373) of the drugs in the Medical/Surgical category
- 9.8% (17 out of 173) of the drugs in the Mental Health category
- None of the drugs in the Substance Use Disorder category

The development of pharmacy prior authorization is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard pharmacy prior authorization UM programs, and a client or health plan chooses which pharmacy prior authorization programs to include in the plan offering. The development of pharmacy prior authorization is based on the factors below.

State of MD-AETNA Advanced Control Formulary					
MH/SUD DRUG CLASSES WITH PA	Prior Authorization Factors	TOTAL Drug Count	Count of Drugs with PA	Percent of Drugs with PA	
ANTIANXIETY Loreev XR	> Use in appropriate patient populations> Potential for inappropriate, off-label use	22	1	5%	
ANTIDEPRESSANTS Sertraline caps Spravato 56mg & 84mg dose	 Patient safety concerns exist/Unknown long-term safety or durability Appropriate medication uses based on national guidelines Use in appropriate patient populations 	47	3	6%	
ANTIPSYCHOTICS Abilify Mycite tabs Chlorpromazine Invega Hafyera Lybalvi Nuplazid caps, tabs Rexulti	 > Appropriate medication uses based on national guidelines > Limited to a specific population based on FDA- approved indications, clinical use, and guidelines documents 	63	10	16%	

The MH/SUD drug classes are listed below, showing the pharmacy prior authorization in each drug class for this plan:

State of MD-AETNA Advanced Control Formulary					
MH/SUD DRUG CLASSES WITH PA	Prior Authorization Factors	TOTAL Drug Count	Count of Drugs with PA	Percent of Drugs with PA	
Versacloz Vraylar cap/Pack					
HYPNOTICS Hetlioz caps, oral susp	 > Use in appropriate patient populations > Limited to a specific population based on FDA- approved indications, clinical use, and guidelines documents > Potential for inappropriate, off-label use 	12	2	17%	
ADHD Azstarys	 Patient safety concerns exist/Unknown long-term safety or durability Appropriate medication uses based on national guidelines Treatment based on obtaining applicable lab values or test results Use in appropriate patient populations 	29	1	3%	
SUD		19	0	0%	

Comparable MED/SURG drug classes are listed below, showing the pharmacy prior authorization in the comparable drug classes for this plan:

State of MD-AETNA Advanced Control Formulary				
MED/SURG DRUG CLASSES WITH PA	Prior Authorization Factors	TOTAL Drug Count	Count of Drugs with PA	Percent of Drugs with PA
ANTIVIRALS - HEPATITIS C	 > Appropriate medication uses based on national guidelines > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	14	11	79%
ANTINEOPLASTIC & ADJUNCTIVE THERAPIES	 > Appropriate medication uses based on national guidelines > Treatment based on obtaining applicable lab values or test results > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	153	116	76%
OSTEOPOROSIS AGENTS	 Patient safety concerns exist/Unknown long-term safety or durability Use in appropriate patient populations Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	16	8	50%
GROWTH HORMONE	 > Appropriate medication uses based on national guidelines > Treatment based on obtaining applicable lab values or test results > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents > Potential for inappropriate, off-label use 	4	4	100%
ANTI- NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS	 Patient safety concerns exist/Unknown long-term safety or durability Treatment based on obtaining applicable lab values or test results Use in appropriate patient populations 	5	4	80%
MULTIPLE SCLEROSIS AGENTS	 > Appropriate medication uses based on national guidelines > Treatment based on obtaining applicable lab values or test results > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	20	20	100%

State of MD-AETNA Advanced Control Formulary				
MED/SURG DRUG CLASSES WITH PA	Prior Authorization Factors	TOTAL Drug Count	Count of Drugs with PA	Percent of Drugs with PA
ANALGESICS - OPIOID	> Use in appropriate patient populations	65	60	92%
	> Potential for inappropriate, off-label use			
	> Reduce waste, unnecessary drug use, fraud or abuse			
ANALGESICS - ANTI-	> Patient safety concerns exist/Unknown long-term safety or durability	56	28	50%
INFLAMMATORY	> Treatment based on obtaining applicable lab values or test results			
	> Use in appropriate patient populations			
	> Limited to a specific population based on FDA-approved indications, clinical			
	use, and guidelines documents			
DERM -	> Patient safety concerns exist/Unknown long-term safety or durability	16	13	81%
ANTIPSORIATICS	> Use in appropriate patient populations			
DERM -	> Patient safety concerns exist/Unknown long-term safety or durability	8	4	50%
ANTINEOPLASTICS	> Appropriate medication uses based on national guidelines			
	> Limited to a specific population based on FDA-approved indications, clinical			
	use, and guidelines documents			
DERM -	> Appropriate medication uses based on national guidelines	2	2	100%
IMMUNOSUPPRESSANTS	> Use in appropriate patient populations			

Note: Drug classes are defined by Generic Product Indicator codes associated with noted classes and drug products shown The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used for counting drugs with UM in a formulary analysis, and there is no requirement to analyze PA data with respect to tier placement. The processes for developing and applying prior authorization to drugs used to treat MH, SUD or MED/SURG conditions is done without regard to a drug's formulary tier placement. The processes of tier placement and UM development are done independently and one does not rely on or relate to the other. Prior authorization is applied to a drug when it is determined to be appropriate based on the attributes of the drug or the condition being treated (as described in Step 1). It is not applied with the goal of staying above or below a threshold within a given tier, that is determined by a comparison of two disparate groups. Please see explanations below.

PRIOR	AUTHORIZATION	Advanced	MIA analysis of data not discussed/explained by Aetna where the data appear to indicate
Control F	ormulary – 2021		that more stringency in application of PAs to MH/SUD medications

 35.4% (840 out of 2,373) of the drugs in the Medical/Surgical category 9.8% (17 out of 173) of the drugs in the Mental Health category None of the drugs in the Substance Use Disorder category 	 Of all medications with PA, there is a greater proportion of MH medications with PA in Tiers 2, 3 and 5 compared to M/S medications with PA. Specifically: 1. Tier 2: 11.8% of all MH medications with PA versus 3% of all M/S medications with PA appears to suggest that fewer preferred branded MH medications are accessible without PA 2. Tier 3: 52.9% of all MH medications with PA versus 41.7% of all M/S medications with PA 3. Tier 5: 35.3% of all MH medications with PA versus 20.7% of all M/S medications with PA
	 The total number of M/S medications on the formulary is 14 times higher than the total number of MH medications, therefore a comparison of their percentages alone does not illustrate the complete picture. 1. Tier 2: There are 10 MH drugs on Tier 2 and 8 of them are available without PA. The 2 drugs with PA are actually 2 dosage forms of the same drug Vraylar (capsule and titration pack)¹. There is a therapeutic alternative for Vraylar available on Tier 1 without PA. The factors that apply to Vraylar are Appropriate medication uses based on national guidelines, and Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents.
	2. Tier 3: There are 38 MH drugs on Tier 3 and 29 of them are available without PA. Of the 9 that require PA, 5 of them have an alternative of the same drug (either in the same or an alternative dosage form) available without PA on Tier 1 (Loreev XR ² , Sertraline caps ³ , Versacloz ⁴ , Chlorpromazine oral conc ⁵ , Ability Mycite ⁶) and one has an alternative available without PA on Tier 3 (Invega Hafyera ⁷). The remaining 3 drugs (Azstarys ⁸ , Lybalvi ⁹ , Rexulti ¹⁰) have therapeutic alternatives available without PA, and have the same factors applying as Vraylar: Appropriate medication uses based on national guidelines, and Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents.
	 Tier 5: There are actually 3 different MH drugs (Spravato¹¹, Nuplazid¹², Hetlioz¹³) that make up the 6 items that require PA on Tier 5, since they are available in different strengths/dosage forms (Spravato 56mg and 84mg, Nuplazid tabs and caps, Hetlioz caps and oral susp).

There are only 17 MH drugs that require PA (less than 10% of all MH drugs on the formulary). These drugs on Tier 5 are specialty drugs that are indicated for use in limited, specific populations, require a screening tool or test results for appropriate diagnosis, require close monitoring to ensure safe use, and Nuplazid and Spravato have black box warnings. These factors make it appropriate for these drugs to require prior authorization.
¹ DailyMed - VRAYLAR- cariprazine capsule, gelatin coated VRAYLAR- cariprazine <u>kit (nih.gov)</u> <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db- bc85c06ff12f</u>
² DailyMed - LOREEV XR- lorazepam capsule, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=227734c1-bf01-9607-73ea- 5a1f38a89bd9
³ DailyMed - SERTRALINE HCL- sertraline hydrochloride capsule (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8bcba9-eaeb-aa44-f9ea- b580de55a439
⁴ DailyMed - VERSACLOZ- clozapine suspension (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2592c9a8-fd74-4e0d-a895- b07b014cf355
⁵ <u>DailyMed - CHLORPROMAZINE HYDROCHLORIDE concentrate (nih.gov)</u> <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9398a0b4-e08b-4eb7-9f31-</u> <u>97d4f384427a</u>
⁶ DailyMed - ABILIFY MYCITE- aripiprazole tablet with sensor (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8787c3f-5e41-42d1-8091- 44b56346620f
⁷ <u>DailyMed-INVEGAHAFYERA-paliperidonepalmitateinjection, suspension, extended</u> release (nih.gov)

	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cd61892-d2cb-434d-83ed- 5c1b2c4e7a0b
	⁸ DailyMed-AZSTARYS-serdexmethylphenidateanddexmethylphenidate capsule (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00b5e716-5564-4bbd-acaf- df2bc45a5663
	⁹ DailyMed - LYBALVI- olanzapine and samidorphan l-malate tablet, film coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32ffddd1-4e2b-45d9-9b36- bb730167ec80
	¹⁰ DailyMed - REXULTI- brexpiprazole tablet REXULTI- brexpiprazole kit (nih.gov) <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850</u>
	¹¹ DailyMed - SPRAVATO- esketamine hydrochloride solution (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c- 0dfa3036eaed
	¹² DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated (nih.gov) <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328- 46e1ee59f83b</u>
	¹³ DailyMed - HETLIOZ- tasimelteon capsule HETLIOZ LQ- tasimelteon suspension (nih.gov) <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4a9b63-708e-49e9-8f9b-010625443b90</u>
Standard Opt-Out Formulary – 2021	MIA Analysis

• 19.9% (490 out of 2,467) of the drugs in the	4. Tier 5: 100% of all MH medications with PA versus 35.1% of all M/S medications with
Medical/Surgical category	PA where NONE of the non-preferred specialty MH medications are available without
	PA where nearly two-thirds of non-preferred MS medications are available without PA
• 3.1% (6 out of 194) of the drugs in the	
Mental Health category	As above in the ACF formulary, the 6 items on Tier 5 are the same specialty drugs that
	are indicated for use in limited, specific populations, require a screening tool or test
• 5.6% (1 out of 18) of the drugs in the	results for appropriate diagnosis, require close monitoring to ensure safe use, and
Substance Use Disorder category	Spravato and Nuplazid have black box warnings. These factors make it appropriate for
	these drugs to require prior authorization.

Step Therapy (ST) for Advanced Control Formulary – Aetna 2021

STEP THERAPY ANALYSIS								
	Plan: State of MD - AE	TNA - A	Advanced	l Contro	l Formul	ary - 202	1	
	Category	Analysis						
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	
	Total Drug Count by Tier	966	206	794	219	188	2,373	
Medical /	ST Drug Count by Tier	1	27	15	0	0	43	
Surgical	% of Total ST Drugs by Tier	2.3%	62.8%	34.9%	0.0%	0.0%		
	% MED/SURG Drugs with ST	0.1%	13.1%	1.9%	0.0%	0.0%	1.8%	
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	
	Total Drug Count by Tier	119	10	38	0	6	173	
Montol								
Mental Health	ST Drug Count by Tier	0	1	5	0	0	6	
	% of Total ST Drugs by Tier	0.0%	16.7%	83.3%	0.0%	0.0%		
	% MH Drugs with ST	0.0%	10.0%	13.2%	0.0%	0.0%	3.5%	

	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	9	1	7	1	1	19
Substance							
Use Disorder	ST Drug Count by Tier	0	0	0	0	0	0
	% of Total ST Drugs by Tier	0.0%	0.0%	0.0%	0.0%	0.0%	
	% SUD Drugs with ST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for step therapy for Advanced Control Formulary – Aetna 2021

When the factors for step therapy are considered consistently across all drugs and drug classes, the outcome shows that step therapy is applied to a comparable and small percentage of drugs in the MH drug category and the MED/SURG drug category, and there is no step therapy applying to any drugs in the SUD drug category. Pharmacy step therapy is applied to:

- 1.8% (43 out of 2,373) of the drugs in the Medical/Surgical category.
- 3.5% (6 out of 173) of the drugs in the Mental Health category.
- None of the drugs in the Substance Use Disorder category.

The development of step therapy is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard step therapy UM programs, and a client or health plan chooses which step therapy programs to include in the plan offering. The development of step therapy is based on the factors below.

The MH/SUD drug classes are listed below, showing the step therapy in each drug class for this plan:

State of MD-AETNA Advanced Control Formulary								
MH/SUD DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST				
ANTIANXIETY		22	0	0%				

	State of MD-AETNA Advanced Control Formulary							
MH/SUD DRUG CLASSES WITH ST	DRUG CLASSES Step Therapy Factors WITH ST		Count of Drugs with ST	Percent of Drugs with ST				
ANTIDEPRESSANTS	> Promote use of most cost-effective products (generics	47	2	4%				
Desvenlafaxine ER	and/or lower cost brands)							
Trintellix	> Alternatives available in the drug class (including							
	generics) used to treat the same condition							
ANTIPSYCHOTICS		63	0	0%				
HYPNOTICS	> Promote use of most cost-effective products (generics	12	1	8%				
Zolpidem ER	and/or lower cost brands)							
	> Alternatives available in the drug class (including							
	generics) used to treat the same condition							
ADHD	> Promote use of most cost-effective products (generics	29	3	10%				
Dyanavel XR	and/or lower cost brands)							
Quillichew ER	> Multiple dosage forms for the same/similar chemical							
Quillivant XR	entity; Availability of unique dosage forms							
	> Alternatives available in the drug class (including							
	generics) used to treat the same condition							
SUD		19	0	0%				

Comparable MED/SURG drug classes are listed below, showing the step therapy in the comparable drug classes for this plan:

State of MD-AETNA Advanced Control Formulary							
MED/SURG DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST			
ANTIDIABETICS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	70	14	20%			

	State of MD-AETNA Advanced Control Formulary			
MED/SURG DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST
OSTEOPOROSIS AGENTS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	16	2	13%
ANTIHYPERTENSI VES	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	57	1	2%
URINARY ANTISPASMODICS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	17	4	24%
GU - BPH	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	7	1	14%
FIBROMYALGIA AGENTS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	2	2	100%
MIGRAINE PRODUCTS	 > Promote use of most cost-effective products (generics and/or lower cost brands) > Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms > Alternatives available in the drug class (including generics) used to treat the same condition 	29	10	34%
DERM - ANTIPSORIATICS	 Promote use of most cost-effective products (generics and/or lower cost brands) Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms Alternatives available in the drug class (including generics) used to treat the same condition 	16	2	13%

MHPAEA Summary Form

The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used for counting drugs with UM in a formulary analysis, and there is no requirement to analyze ST data with respect to tier placement. The processes for developing and applying step therapy to drugs used to treat MH, SUD or MED/SURG conditions is done without regard to a drug's formulary tier placement. The processes of tier placement and UM development are done independently and one does not rely on or relate to the other. Step therapy is applied to a drug when it is determined to be appropriate based on the attributes of the drug or the condition being treated (as described in Step 1). It is not applied with the goal of staying above or below a threshold within a given tier, that is determined by a comparison of two disparate groups. Two results that are both less than 4% or 7%, respectively, are considered comparable when other NQTL totals are much higher. Also, 3.5% represents only 6 MH drugs in the ACF formulary, and 6.2% represents 12 MH drugs in the SOO formulary, compared to 43 and 36 drugs, respectively, for M/S. Please see explanations below.

STEP THERAPY	MIA analysis of data not discussed/explained by Aetna where the data appear to indicate
Advanced Control Formulary – 2021	that more stringency in application of ST to MH/SUD medications
 1.8% (43 out of 2,373) of the drugs in the Medical/Surgical category. 3.5% (6 out of 173) of the drugs in the Mental Health category. 	1. Tier 3: 83.3% of all MH medications with ST versus 34.9% of all M/S medications with step therapy appears to suggest that fewer non-preferred branded MH medications are available without ST
• None of the drugs in the Substance Use Disorder category.	There are 38 MH drugs on Tier 3 and 33 of them are available without ST. The 5 drugs with ST on Tier 3 (Desvenlafaxine ER ¹ , Zolpidem ER ² , Dyanavel XR ³ , Quillivant XR ⁴ and Quillichew ER ⁵) are different dosage forms or therapeutic alternatives of generic drugs that are available on Tier 1 without ST. These 5 drugs display the factors of: Promote use of most cost-effective products (generics and/or lower cost brands); Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms; and Alternatives available in the drug class (including generics) used to treat the same condition, which indicates that it is appropriate to apply ST.
	¹ DailyMed - DESVENLAFAXINE ER tablet, film coated, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a834c66-846e-38a8-e053- 2a95a90a4035
	² DailyMed - ZOLPIDEM TARTRATE EXTENDED-RELEASE- zolpidem tartrate tablet, film coated, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2977f646-8a5a-4e7b-94e1- 0b0c0c5478ba

Standard Opt-Out Formulary – 2021	 ³DailyMed - DYANAVEL XR- amphetamine suspension, extended release DYANAVEL XR- amphetamine tablet, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae304b29-0b40-40ec-ad0d- 76b742d4a9b9 ⁴DailyMed-QUILLIVANTXR-methylphenidatehydrochloride suspension, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2dc2109-44a6-4797-b04e- 18761dd9d45a ⁵DailyMed - QUILLICHEW ER- methylphenidate hydrochloride tablet, chewable, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=defc1205-8e90-4b1e-b862- 05e4c35c7364 MIA Analysis
 1.5% (36 out of 2,467) of the drugs in the Medical/Surgical category. 6.2% (12 out of 194) of the drugs in the Mental Health category. None of the drugs in the Substance Use Disorder category. 	 Tier 2: 75% of all MH medications with ST versus 25% of all M/S medications with ST appears to suggest that fewer preferred branded MH medications are accessible without ST The 9 drugs with ST on Tier 2 (Viibryd tabs and starter pack⁶, Trintellix⁷, Fetzima caps and titration pack⁸, Vraylar caps and pack⁹, Latuda¹⁰ and Belsomra¹¹) are therapeutic alternatives of generic drugs that are available on Tier 1 without ST. These 9 drugs display the factors of: Promote use of most cost-effective products (generics and/or lower cost brands); Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms; and Alternatives available in the drug class (including generics) used to treat the same condition, which indicates that it is appropriate to apply ST. ⁶DailyMed - VIIBRYD- vilazodone hydrochloride tablet VIIBRYD- vilazodone hydrochloride kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66 ⁷DailyMed - TRINTELLIX- vortioxetine tablet, film coated (nih.gov)

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6- 1ca97145e838
⁸ DailyMed - FETZIMA- levomilnacipran hydrochloride capsule, extended release FETZIMA- levomilnacipran hydrochloride kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f371258d-91b3-4b6a-ac99- 434a1964c3af
⁹ <u>DailyMed - VRAYLAR- cariprazine capsule, gelatin coated VRAYLAR- cariprazine kit</u> (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db- bc85c06ff12f
¹⁰ DailyMed - LATUDA- lurasidone hydrochloride tablet, film coated (nih.gov) <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684- e8262a133af8</u>
¹¹ DailyMed - BELSOMRA- suvorexant tablet, film coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13- 290ad12d3951

Quantity Limits (QL) for Advanced Control Formulary – Aetna 2021

	QUANTITY LIMITS (QL) ANALYSIS							
	Plan: State of MD - AET	NA - Ac	lvanced (Control F	ormular	y - 2021		
	Category Analysis							
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	
Medical /	Total Drug Count by Tier	966	206	794	219	188	2,373	
Surgical								
Surgical	QL Drug Count by Tier	219	62	121	209	172	783	
	% of Total QL Drugs by Tier	28.0%	7.9%	15.5%	26.7%	22.0%		

	% MED/SURG Drugs with QL	22.7%	30.1%	15.2%	95.4%	91.5%	33.0%
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	119	10	38	0	6	173
Mental							
Health	QL Drug Count by Tier	38	3	12	0	4	57
IIcalth	% of Total QL Drugs by Tier	66.7%	5.3%	21.1%	0.0%	7.0%	
	% MH Drugs with QL	31.9%	30.0%	31.6%	0.0%	66.7%	32.9%
	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	9	1	7	1	1	19
Substance							
Use	QL Drug Count by Tier	4	1	5	0	1	11
Disorder	% of Total QL Drugs by Tier	36.4%	9.1%	45.5%	0.0%	9.1%	
	% SUD Drugs with QL	44.4%	100.0%	71.4%	0.0%	100.0%	57.9%

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for Quantity Limits for Advanced Control Formulary – Aetna 2021

When the factors for quantity limits are considered consistently across all drugs and drug classes, the outcome shows that quantity limits are applied to a varying percentage of drugs across the MH, SUD, and MED/SURG drug categories. Quantity limits are applied to:

- 33.0% (783 out of 2,373) of the drugs in the Medical/Surgical category.
- 32.9% (57 out of 173) of the drugs in the Mental Health category.
- 57.9% (11 out of 19) of the drugs in the Substance Use Disorder category.

The development of quantity limits is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard quantity limit UM programs, and a client or health plan chooses which quantity limit programs to include in the plan offering. The development of quantity limits is based on the factors below.

The MH/SUD drug classes are listed below, showing the quantity limits in each drug class for this plan:

State of MD-AETNA Advanced Control Formulary				
MH/SUD DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ANTIANXIETY Alprazolam tabs, ER tab, Intensol oral conc, oral susp, ODT Chlordiazepoxide Clonazepam tab, ODT Clorazepate Diazepam oral conc, oral soln, tabs Lorazepam oral conc, tabs Oxazepam	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	22	16	73%
ANTIDEPRESSANTS Desvenlafaxine ER	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	47	1	2%
ANTIPSYCHOTICS Nuplazid caps, tabs	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	63	2	3%

State of MD-AETNA Advanced Control Formulary				
MH/SUD DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
HYPNOTICS Estazolam Eszopiclone Flurazepam Hetlioz caps, oral susp Ramelteon Temazepam Triazolam Zaleplon Zolpidem tab, ER tab	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	12	11	92%
ADHD Includes the controlled substance drugs used to treat ADHD.	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST-EFFECTIVENESS) Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	29	27	93%

	State of MD-AETNA Advanced Control Formulary			
MH/SUD DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
SUD	> Potential to be prescribed in greater qty and/or higher dose than safe and	19	11	58%
Apo-Varenicline	effective per FDA (PT SAFETY)			
Varenicline	> Promote appropriate dosing, including strength/frequency (PT SAFETY)			
Bupropion ER	> Prevent overutilization (PT SAFETY)			
Nicotrol Oral Inhaler	> Possible abuse or misuse by the patient (PT SAFETY)			
Nicotrol Nasal Spray	> Prevent overutilization (COST-EFFECTIVENESS)			
Buprenorphine Film, SL	> Discourage misuse/waste through dose efficiency QLs (ensure appropriate			
Buprenorphine/Naloxone SL	strength is utilized) (COST-EFFECTIVENESS)			
Zubsolv	> Lack of documented efficacy at higher doses (COST-EFFECTIVENESS)			
Kloxxado nasal	> Maximum daily dose/duration of use limits (DISCOURAGE			
Vivitrol inj	MISUSE/ABUSE)			

Comparable MED/SURG drug classes are	listed below, showing the quantit	v limits in the comparable drug	class for this plan:

State of MD-AETNA Advanced Control Formulary				
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ANTIVIRALS - HIV	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) 	60	60	100%
ANTIVIRALS - HEPATITIS C	 > Prevent overutilization (PT SAFETY) > Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) > Promote appropriate dosing, including strength/frequency (PT SAFETY) > Prevent overutilization (PT SAFETY) 	14	14	100%

	State of MD-AETNA Advanced Control Formulary			
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
CONTRACEPTIVES	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) 	55	55	100%
GROWTH HORMONE	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) 	4	4	100%
GI AGENTS - PPIs	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST-EFFECTIVENESS) 	11	11	100%
ANTIEMETICS - 5-HT3	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) 	9	9	100%
MULTIPLE SCLEROSIS AGENTS	 Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	20	20	100%

	State of MD-AETNA Advanced Control Formulary			
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ANALGESICS - OPIOID	 > Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) > Promote appropriate dosing, including strength/frequency (PT SAFETY) > Prevent overutilization (PT SAFETY) > Possible abuse or misuse by the patient (PT SAFETY) > Prevent overutilization (COST-EFFECTIVENESS) > Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) > Lack of documented efficacy at higher doses (COST-EFFECTIVENESS) > Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	65	60	92%
MIGRAINE AGENTS	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST-EFFECTIVENESS) 	29	25	86%
DERM - ANTIPSORIATICS	 > Promote appropriate dosing, including strength/frequency (PT SAFETY) > Prevent overutilization (PT SAFETY) > Possible abuse or misuse by the patient (PT SAFETY) 	16	13	81%

State of MD-AETNA Advanced Control Formulary				
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTA L Drug Count	Count of Drugs with QL	Percent of Drugs with QL
IMMUNOSUPPRESSANTS	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Discourage misuse and waste through dose efficiency QLs (ensure appropriate strength is utilized) Lack of documented efficacy at higher doses 	22	19	86%

The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used for counting drugs with UM in a formulary analysis, and there is no requirement to analyze QL data with respect to tier placement. The processes for developing and applying quantity limits to drugs used to treat MH, SUD or MED/SURG conditions is done without regard to a drug's formulary tier placement. The processes of tier placement and UM development are done independently, and one does not rely on or relate to the other. Quantity limits are applied to a drug when it is determined to be appropriate based on the attributes of the drug or the condition being treated (as described in Step 1). It is not applied with the goal of staying above or below a threshold within a given tier, that is determined by a comparison of two disparate groups. Please see explanations below.

QUANTITY LIMITS Advanced Control Formulary – 2021	MIA analysis of data not discussed/explained by Aetna where the data appear to indicate that more stringency in application of QLs to MH/SUD medications
• 33.0% (783 out of 2,373) of the drugs in the Medical/Surgical category.	1. Tier 1 : 66.7% of all MH medications and 36.4% of all SUD medications with QL versus 28% of all M/S medications with QL
• 32.9% (57 out of 173) of the drugs in the	
Mental Health category. • 57.9% (11 out of 19) of the drugs in the	M/S medication with QL
Substance Use Disorder category.	The SUD category represents a very small number of drugs, most of which are used to treat tobacco use and
	opioid use disorders. Three of the 4 SUD drugs with QL on Tier 1 (buprenorphine sl tab ¹ ,
	buprenorphine/naloxone sl tab and film ²) are also opioids themselves, and have a significant potential for
	abuse or misuse, indicating the need for close monitoring. Four of the 5 SUD drugs with QL on Tier 3

(Nicotrol nasal spray ³ , Nicotrol inhaler ⁴ , Apo-varenicline ⁵ and Varenicline ⁶) are used to treat tobacco use disorder, and one is used in the treatment of opioid use disorder. Quantity limits have been placed on these drugs to align with treatment guidelines, as well as FDA dosing recommendations. These limits reflect the factors of enhance patient safety, discourage misuse, waste and abuse, and cost-effectiveness, making it appropriate to apply QL.
In the MH category, the antianxiety class also contains controlled substances with potential for misuse and abuse (Antianxiety agents with QL on Tier 1: alprazolam (3 dosage forms) ⁷ , chlordiazepoxide ⁸ , clonazepam tabs and ODT ⁹ , clorazepate ¹⁰ , diazepam (3 dosage forms) ¹¹ , lorazepam tabs and oral concentrate ¹² , oxazepam ¹³ . Antianxiety agents with QL on Tier 1: alprazolam (2 dosage forms) ⁷ Hypnotics is another class that contains controlled substances and chronic use of these agents for sleep disorders may actually be a sign of underlying physical or psychiatric disorders, it is important to monitor their use in order to assess the need for further evaluation of the condition. Hypnotics with QL on Tier 1: estazolam ¹⁴ , eszopiclone ¹⁵ , flurazepam ¹⁶ , ramelteon ¹⁸ , temazepam ¹⁹ , triazolam ²⁰ , zaleplon ²¹ , zolpidem tabs ²² . Hypnotics with QL on Tier 3: zolpidem ER tabs ²²). Most of the drugs used to treat ADHD are schedule II controlled substances, which have the highest potential for abuse among FDA approved prescription drugs. (ADHD agents with QL on Tier 1: dextroampletamine ²⁶ , amphetamine ²⁶ , amphetamine ²⁷ , atomoxetine ²⁹ , dexmethylphenidate (4 dosage forms) ³⁰ , methylphenidate (5 dosage forms) ³¹ , (ADHD agents with QL on Tier 3: amphetamine ³² , Dyanavel XR ³³ , Qelbree ³⁴ , methylphenidate CR tabs, chew tabs ³⁵ , Quillivant XR ³⁶ , Quillichew ER ³⁷ , Azstarys ³⁸).
Quantity limits have been placed on these drugs to align with treatment guidelines, as well as FDA dosing recommendations. These limits also reflect the factors of enhance patient safety, discourage misuse, waste and abuse, and cost-effectiveness, making it appropriate to apply QL.
¹ DailyMed - BUPRENORPHINE HCL SL- buprenorphine hcl tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77d3c308-58b8-2ab0-e053-2991aa0a4918
² DailyMed - BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM- buprenorphine and naloxone film (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4210afeb-474c-d842-d68e-af7e0021851a
³ DailyMed - NICOTROL- nicotine spray, metered (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acb7d02d-249b-4645-ac1b-8ff9a56dd244

⁴ DailyMed - NICOTROL- nicotine inhalant (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f32f9c92-cbb4-483b-9e70-0b6e4567824f
⁵ DailyMed - APO-VARENICLINE- varenicline kit APO-VARENICLINE- varenicline tablet, film coated (<u>nih.gov</u>) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e295f42-88f3-5dda-2358-f57b5d71735c
⁶ DailyMed - VARENICLINE tablet, film coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78d1857f-8708-5410-792f-4a3e5e7971a5
⁷ DailyMed - ALPRAZOLAM tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9b0e228-17cf-40d7-b62e-5050311c571c DailyMed - ALPRAZOLAM EXTENDED RELEASE- alprazolam tablet, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a64496be-bf43-4ba9-a4b1-bd632965c1a0
DailyMed - ALPRAZOLAM solution, concentrate (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b945ac6f-796e-41ef-85e9-61007e4a4e9a DailyMed - ALPRAZOLAM tablet, orally disintegrating (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ceed721-2e65-4c81-bd84-f110b1ac9d2e
⁸ DailyMed - CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE- chlordiazepoxide hcl and clidinium bromide capsule (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd820fcb-b6a8-43f4-a6d9-f94546d380c8
⁹ DailyMed - CLONAZEPAM tablet, orally disintegrating (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb2e209e-e69b-422b-8abb-34df2bc92caa DailyMed - CLONAZEPAM tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebc11109-e7bf-452d-b675-4b3236d54164 ¹⁰ DailyMed - CLORAZEPATE DIPOTASSIUM tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4b80e69-b7c7-471a-8ce8-4e992808c669 ¹¹ DailyMed - DIAZEPAM tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c397a9da-862f-4f3f-8109-7d21691de53a

DailyMed - DIAZEPAM- diazepam oral solution DIAZEPAM (diazepam oral solution- concentrate solution
(nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdb839fb-27e5-4a11-aed6-da0a7ab6e996
DailyMed - DIAZEPAM INTENSOL solution, concentrate (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1aaf9375-ae3d-4fed-9cd1-24102e00be1a
¹² DailyMed - LORAZEPAM concentrate (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73bfaeab-94db-48c2-a194-8b173025de78
DailyMed - LORAZEPAM tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fae1607-69d7-47ce-9b78-7474af50036d
¹³ DailyMed - OXAZEPAM capsule, gelatin coated (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43
¹⁴ DailyMed - ESTAZOLAM tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e
¹⁵ DailyMed - ESZOPICLONE tablet, coated (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b363b90-93dc-1fc1-0501-d140dfc762c7
https://dairymed.min.min.gov/dairymed/drugmio.emi:sedd=00505070=75de=11e1=0501=d140d1e702e7
¹⁶ DailyMed - FLURAZEPAM HYDROCHLORIDE capsule (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f476891-1346-4e8c-ac1b-f8cbdc64f5a1
¹⁸ DailyMed - RAMELTEON tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b71cd925-1bae-5a6a-072b-941ad6d3ce65
¹⁹ DailyMed - TEMAZEPAM capsule (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4370eb4-b00d-4247-af8d-980e59fbbec6
²⁰ DailyMed - TRIAZOLAM tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5add318e-11b9-42f8-b052-0d8cebb32fcf
https://dutymed.html.html.gov/dutymed/drughtto.etht.settu = 5udd5166-1165-4216-0052-00600052161
²¹ DailyMed - ZALEPLON capsule (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f44db39-e1d9-451e-ba31-e4b10366a430

²² DailyMed - ZOLPIDEM TARTRATE capsule (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916
DailyMed - ZOLPIDEM TARTRATE EXTENDED-RELEASE- zolpidem tartrate tablet, film coated,
extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2977f646-8a5a-4e7b-94e1-0b0c0c5478ba
²³ DailyMed - DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE,
DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c922de13-7ae0-a09c-e053-2995a90a4411
DailyMed - DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE,
DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE capsule, extended release
(nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34726042-2386-4c19-abec-440769fff99a
DailyMed - DEXTROAMPHETAMINE solution (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7658071e-ee2c-4d23-94ce-1906959ec036
²⁴ DailyMed - ZENZEDI- dextroamphetamine sulfate tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84
²⁶ DailyMed - METHAMPHETAMINE HYDROCHLORIDE tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90c02ac6-e5e2-4c97-8c68-81e4e389a195
$\frac{1000}{1000}$
²⁷ DailyMed - DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE,
DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c922de13-7ae0-a09c-e053-2995a90a4411
²⁹ DailyMed - ATOMOXETINE- atomoxetine capsule (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f266ab7b-5a68-42b5-b204-e3249bea0aed
³⁰ DailyMed-DEXMETHYLPHENIDATEHYDROCHLORIDEcapsule, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5312f2c3-bd73-4d29-b8d1-e989282be750

DailyMed - DEXMETHYLPHENIDATE HYDROCHLORIDE tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=830df993-db01-40df-beef-90af6b86f561
³¹ DailyMed - METHYLPHENIDATE capsule, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f8983ce-71b8-4c62-830d-e4692ddededa
DailyMed - METHYLPHENIDATE HCL solution (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d66dbf9-3966-4949-b7c9-d2ca8c7f3278
$\frac{1}{1000001} = \frac{1}{1000001} = \frac{1}{10000001} = \frac{1}{10000000000000000000000000000000000$
DailyMed - METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE- methylphenidate
hydrochloride tablet, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b0f2ff-d9df-42ab-b471-226ecf97e075
<u>https://ddityfiled.html.html.gov/ddityfiled/drugfilio.effil.setid_01801211/dydi_12d8_01/11/220001/10/15</u>
DailyMed - METHYLPHENIDATE HYDROCHLORIDE tablet, chewable (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb73cd3e-aa7c-4f7e-826d-75e71fb6d1e0
DailyMed - METHYLPHENIDATE HYDROCHLORIDE tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f04e8194-7077-42cf-99ee-b61e42a76cf0
1000000000000000000000000000000000000
³² DailyMed - AMPHETAMINE SULFATE- amphetamine sulfate tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26dbad66-13c4-4906-88b3-ab7ee191466c
³³ DailyMed - DYANAVEL XR- amphetamine suspension, extended release DYANAVEL XR- amphetamine
tablet, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae304b29-0b40-40ec-ad0d-76b742d4a9b9
³⁴ DailyMed - QELBREE- viloxazine hydrochloride capsule, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a
<u>https://dditymed.html.html.gov/dditymed/drughtto.etml:settd_dedi400d=0104=410d=9410=7659dd00d29d</u>
³⁵ DailyMed-METHYLPHENIDATE HYDROCHLORIDE CD- methylphenidate hydrochloride capsule,
extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e45c75dc-d381-475b-b649-a871c8a36e60
³⁶ DailyMed-QUILLIVANTXR-methylphenidatehydrochloride suspension, extended release (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2dc2109-44a6-4797-b04e-18761dd9d45a

Standard Opt-Out Formulary – 2021	MIA Analysis
	³⁸ DailyMed-AZSTARYS-serdexmethylphenidateand dexmethylphenidate capsule (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00b5e716-5564-4bbd-acaf-df2bc45a5663
	³⁷ DailyMed - QUILLICHEW ER- methylphenidate hydrochloride tablet, chewable, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=defc1205-8e90-4b1e-b862-05e4c35c7364

 28.3% (697 out of 2,467) of the drugs in the Medical/Surgical category. 33.5% (65 out of 194) of the drugs in the Mental Health category. 	 Tier 1: 66.2% of all MH medications with QL versus 32% of all M/S medications with QL Tier 3: 23.1% of all MH medications and 45.5% of all SUD medications with QL versus 8.8% of all M/S medications with QL
• 61.1% (11 out of 18) of the drugs in the Substance Use Disorder category.	As above in the ACF formulary, the SUD category represents a very small number of drugs, most of which are used to treat tobacco use and opioid use disorders. Three of the 4 SUD drugs with QL on Tier 1 (buprenorphine sl tab ¹ , buprenorphine/naloxone sl tab and film ²) are also opioids themselves, and have a significant potential for abuse or misuse, indicating the need for close monitoring. Three of the 5 SUD drugs with QL on Tier 3 (Nicotrol nasal spray ³ , Nicotrol inhaler ⁴ and Apo-varenicline ⁵) are used to treat tobacco use disorder, and two are used in the treatment of opioid use disorder (Lucemyra ³⁹ and Kloxxado ⁴⁰). Quantity limits have been placed on these drugs to align with treatment guidelines, as well as FDA dosing recommendations. These limits reflect the factors of enhance patient safety, discourage misuse, waste and abuse, and cost-effectiveness, making it appropriate to apply QL.
	In the MH category, the antianxiety class also contains controlled substances with potential for misuse and abuse (Antianxiety agents with QL on Tier 1: alprazolam (3 dosage forms) ⁷ , chlordiazepoxide ⁸ , clonazepam tabs and ODT ⁹ , clorazepate ¹⁰ , diazepam (3 dosage forms) ¹¹ , lorazepam tabs and oral concentrate ¹² , oxazepam ¹³ . Antianxiety agents with QL on Tier 1: alprazolam (2 dosage forms) ⁷ Hypnotics is another class that contains controlled substances and chronic use of these agents for sleep disorders may actually be a sign of underlying physical or psychiatric disorders, it is important to monitor their use in order to assess the need for further evaluation of the condition. Hypnotics with QL on Tier 1: estazolam ¹⁴ , eszopiclone ¹⁵ , flurazepam ¹⁶ , ramelteon ¹⁸ , temazepam ¹⁹ , triazolam ²⁰ , zaleplon ²¹ , zolpidem tabs ²² . Hypnotics with QL on Tier 3: zolpidem ER tabs ²²). Most of the drugs used to treat ADHD are schedule II-controlled substances, which have the highest potential for abuse among FDA approved prescription drugs. (ADHD agents with QL on Tier 1: dextroamphetamine (3 dosage forms) ²³ , Zenzedi ²⁴ , methamphetamine ²⁶ , amphetamine/dextroamphetamine ²⁷ , atomoxetine ²⁹ , dexmethylphenidate (4 dosage forms) ³⁰ , methylphenidate (5 dosage forms) ³¹ , (ADHD agents with QL on Tier 3: amphetamine ³² , Dyanavel XR ³³ , Qelbree ³⁴ , methylphenidate CR tabs, chew tabs ³⁵ , Quillivant XR ³⁶ , Quillichew ER ³⁷ , Azstarys ³⁸). Quantity limits have been placed on these drugs to align with treatment guidelines, as well as FDA dosing recommendations. These limits also reflect the factors of enhance patient safety, discourage misuse, waste
	and abuse, and cost-effectiveness, making it appropriate to apply QL. ³⁹ DailyMed - LUCEMYRA- lofexidine hydrochloride tablet, film coated (nih.gov) <u>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b748f308-ba71-4fd9-84ec-ec7e0f210885</u>



<u>Standard Opt-Out Formulary 2021 Plan – Aetna</u>

Pharmacy Prior Authorization (PA) for Standard Opt-Out Formulary 2021 Plan – Aetna

PRIOR AUTHORIZATION (PA) ANALYSIS								
	Plan: State of MD - AETNA	- Stand	ard Opt-	Out Forn	nulary wi	th ACSF	- 2021	
	Category		Analysis					
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	
	TOTAL Drug Count by Tier	1,162	269	636	212	188	2,467	
Medical /								
Surgical	PA Drug Count by Tier	74	16	21	207	172	490	
	% of Total PA Drugs by Tier	15.1%	3.3%	4.3%	42.2%	35.1%		
	% MED/SURG Drugs with PA	6.4%	5.9%	3.3%	97.6%	91.5%	19.9%	
	Montal Hoalth	Tior 1	Tion 2	Tion 3	Tior 4	Tior 5	Total Drugs	
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	
	Mental Health Total Drug Count by Tier	Tier 1 135	Tier 2 17	Tier 3 36	Tier 4 0	Tier 5 6	Total Drugs 194	
Mental	Total Drug Count by Tier		-		-			
Mental Health		135	17	36	0	6	194	
	Total Drug Count by Tier PA Drug Count by Tier % of Total PA Drugs by	135 0	17 0	36 0	0	6 6	194	
Health	Total Drug Count by Tier PA Drug Count by Tier % of Total PA Drugs by Tier	135 0 0.0%	17 0 0.0%	36 0 0.0%	0 0 0.0%	6 6 100.0%	194 6	
	Total Drug Count by Tier PA Drug Count by Tier % of Total PA Drugs by Tier % MH Drugs with PA	135 0 0.0% 0.0%	17 0 0.0% 0.0%	36 0 0.0% 0.0%	0 0 0.0% 0.0%	6 6 100.0% 100.0%	194 6 3.1%	
Health Substance	Total Drug Count by Tier PA Drug Count by Tier % of Total PA Drugs by Tier % MH Drugs with PA Substance Use Disorder	135 0 0.0% 0.0% Tier 1	17 0 0.0% 0.0% Tier 2	36 0 0.0% 0.0% Tier 3	0 0 0.0% 0.0% Tier 4	6 6 100.0% 100.0% Tier 5	194 6 3.1% Total Drugs	

% of Total PA Drugs by Tier	0.0%	0.0%	100.0%	0.0%	0.0%	
% SUD Drugs with PA	0.0%	0.0%	20.0%	0.0%	0.0%	5.6%

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of administration

Comparative Analysis for pharmacy prior authorization Standard Opt-Out Formulary with ACSF - 2021

When the factors for pharmacy prior authorization are considered consistently across all drugs and drug classes, the outcome shows that pharmacy prior authorization is applied to a lower percentage of drugs in the MH and SUD drug categories compared to the MED/SURG drug category. Pharmacy prior authorization is applied to:

- 19.9% (490 out of 2,467) of the drugs in the Medical/Surgical category
- 3.1% (6 out of 194) of the drugs in the Mental Health category
- 5.6% (1 out of 18) of the drugs in the Substance Use Disorder category

The development of pharmacy prior authorization is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard pharmacy prior authorization programs, and a client or health plan chooses which pharmacy prior authorization programs to include in the plan offering. The development of pharmacy prior authorization is based on the factors below.

The MH/SUD drug classes are listed below, showing the pharmacy prior authorization in each drug class for this plan:

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021						
MH/SUD DRUG CLASSES WITH PA	Prior Authorization Factors		Count of Drugs with PA	Percent of Drugs with PA		
ANTIANXIETY		22	0	0%		
ANTIDEPRESSANTS Spravato 56mg & 84mg dose	 Patient safety concerns exist/Unknown long-term safety or durability Appropriate medication uses based on national guidelines Use in appropriate patient populations 	55	2	4%		
ANTIPSYCHOTICS Nuplazid caps, tabs	 > Appropriate medication uses based on national guidelines > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	65	2	3%		

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021				
MH/SUD DRUG CLASSES WITH PA	Prior Authorization Factors		Count of Drugs with PA	Percent of Drugs with PA
HYPNOTICS	> Use in appropriate patient populations	15	2	13%
Hetlioz caps, oral susp	> Limited to a specific population based on FDA-approved indications,			
	clinical use, and guidelines documents			
	> Potential for inappropriate, off-label use			
ADHD		37	0	0%
SUD	> Use in appropriate patient populations	18	1	6%
Lucemyra	> Limited to a specific population based on FDA-approved indications,			
	clinical use, and guidelines documents			
	> Potential for inappropriate, off-label use			
	> Requirement for additional treatment supportive therapies			

Comparable MED/SURG drug cla	asses are listed below, showing	g the pharmacy price	or authorization in the compar	able drug classes for this plan:
		S me promine j pric	i annielizanieli ili ale eeliipai	mere and enables rer and prairie

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021						
MED/SURG DRUG CLASSES WITH PA	Prior Authorization Factors		Count of Drugs with PA	Percent of Drugs with PA		
ANTIVIRALS - HEPATITIS C	> Appropriate medication uses based on national guidelines	14	11	79%		
	> Use in appropriate patient populations					
	> Limited to a specific population based on FDA-approved					
	indications, clinical use, and guidelines documents					
ANTINEOPLASTIC &	> Appropriate medication uses based on national guidelines	144	107	74%		
ADJUNCTIVE THERAPIES	> Treatment based on obtaining applicable lab values or test results					
	> Use in appropriate patient populations					
	> Limited to a specific population based on FDA-approved					
	indications, clinical use, and guidelines documents					

St	ate of MD - AETNA - Standard Opt-Out Formulary with ACSF - 202	21			
MED/SURG DRUG CLASSES WITH PA	DRUG CLASSES Prior Authorization Factors WITH PA				
OSTEOPOROSIS AGENTS	 Patient safety concerns exist/Unknown long-term safety or durability Use in appropriate patient populations Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	16	8	with PA 50%	
GROWTH HORMONE	 > Appropriate medication uses based on national guidelines > Treatment based on obtaining applicable lab values or test results > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents > Potential for inappropriate, off-label use 	3	3	100%	
ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS	 Patient safety concerns exist/Unknown long-term safety or durability Treatment based on obtaining applicable lab values or test results Use in appropriate patient populations 	4	2	50%	
MULTIPLE SCLEROSIS AGENTS	 > Appropriate medication uses based on national guidelines > Treatment based on obtaining applicable lab values or test results > Use in appropriate patient populations > Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	20	20	100%	
ANALGESICS - OPIOID	 > Use in appropriate patient populations > Potential for inappropriate, off-label use > Reduce waste, unnecessary drug use, fraud or abuse 	66	61	92%	
ANALGESICS - ANTI- INFLAMMATORY	 Patient safety concerns exist/Unknown long-term safety or durability Treatment based on obtaining applicable lab values or test results Use in appropriate patient populations Limited to a specific population based on FDA-approved indications, clinical use, and guidelines documents 	58	25	43%	

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021									
MED/SURG DRUG CLASSES WITH PA	TOTAL Drug Count	Count of Drugs with PA	Percent of Drugs with PA						
DERM - ANTIPSORIATICS	> Patient safety concerns exist/Unknown long-term safety or	20	12	60%					
	durability								
	> Use in appropriate patient populations								
DERM -	> Appropriate medication uses based on national guidelines	2	2	100%					
IMMUNOSUPPRESSANTS	> Use in appropriate patient populations								

Step Therapy (ST) for Standard Opt-Out Formulary 2021 Plan – Aetna

	STEP THERAPY ANALYSIS									
Plan: State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021										
	Category			Α	nalysis					
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs			
	Total Drug Count by Tier	1,162	269	636	212	188	2,467			
Medical /										
Surgical	ST Drug Count by Tier	0	9	27	0	0	36			
Surgicui	% of Total ST Drugs by Tier	0.0%	25.0%	75.0%	0.0%	0.0%				
	% MED/SURG Drugs with ST	0.0%	3.3%	4.2%	0.0%	0.0%	1.5%			
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs			
Mandal	Total Drug Count by Tier	135	17	36	0	6	194			
Mental Health										
пеани	ST Drug Count by Tier	0	9	3	0	0	12			
	% of Total ST Drugs by Tier	0.0%	75.0%	25.0%	0.0%	0.0%				

	% MH Drugs with ST	0.0%	52.9%	8.3%	0.0%	0.0%	6.2%
	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	10	1	5	1	1	18
Substance							
Use Disorder	ST Drug Count by Tier	0	0	0	0	0	0
Disorder	% of Total ST Drugs by Tier	0.0%	0.0%	0.0%	0.0%	0.0%	
	% SUD Drugs with ST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for step therapy Standard Opt-Out Formulary with ACSF - 2021

When the factors for step therapy are considered consistently across all drugs and drug classes, the outcome shows that step therapy is applied to a comparable and small percentage of drugs in the MH drug category and the MED/SURG drug category, and there is no step therapy applying to any drugs in the SUD drug category. Pharmacy step therapy is applied to:

- 1.5% (36 out of 2,467) of the drugs in the Medical/Surgical category.
- 6.2% (12 out of 194) of the drugs in the Mental Health category.
- None of the drugs in the Substance Use Disorder category.

The development of step therapy is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard step therapy UM programs, and a client or health plan chooses which step therapy programs to include in the plan offering. The development of step therapy is based on the factors below.

The MH/SUD drug classes are listed below, showing the step therapy in each drug class for this plan:

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021									
MH/SUD DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST					
ANTIANXIETY		22	0	0%					

	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021							
MH/SUD DRUG CLASSES WITH ST	RUG CLASSES Step Therapy Factors WITH ST							
ANTIDEPRESSANTS Fetzima cap/Pack Pexeva Trintellix Viibryd tab/Pack	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	55	6	11%				
ANTIPSYCHOTICS Latuda Rexulti Vraylar cap/Pack	 Promote use of most cost-effective products (generics and/or lower cost brands) Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms Alternatives available in the drug class (including generics) used to treat the same condition 	65	4	6%				
HYPNOTICS Belsomra Edluar	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	15	2	13%				
ADHD		37	0	0%				
SUD		18	0	0%				

Comparable MED/SURG drug classes are listed below, showing the step therapy in the comparable drug classes for this plan:

	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021								
MED/SURG DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST					
OSTEOPOROSIS AGENTS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	16	2	13%					

	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021			
MED/SURG DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST
ANTIHYPERTENSIVES	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	60	3	5%
ANTIHYPERLIPIDEMI CS - STATINS	 > Promote use of most cost-effective products (generics and/or lower cost brands) > Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms > Alternatives available in the drug class (including generics) used to treat the same condition 	12	5	42%
NASAL AGENTS	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	13	5	38%
GI AGENTS - PPIs	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	12	1	8%
URINARY ANTISPASMODICS	 > Promote use of most cost-effective products (generics and/or lower cost brands) > Alternatives available in the drug class (including generics) used to treat the same condition 	18	5	28%
GU - BPH	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	7	1	14%
MIGRAINE PRODUCTS	 > Promote use of most cost-effective products (generics and/or lower cost brands) > Multiple dosage forms for the same/similar chemical entity; Availability of unique dosage forms > Alternatives available in the drug class (including generics) used to treat the same condition 	31	3	10%

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021									
MED/SURG DRUG CLASSES WITH ST	Step Therapy Factors	TOTAL Drug Count	Count of Drugs with ST	Percent of Drugs with ST					
OPHTHALMIC AGENTS - GLAUCOMA	 Promote use of most cost-effective products (generics and/or lower cost brands) Alternatives available in the drug class (including generics) used to treat the same condition 	25	5	20%					

Quantity Limits (QL) Standard Opt-Out Formulary with ACSF - 2021

QUANTITY LIMITS (QL) ANALYSIS									
Plan: State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021									
	Category			I	Analysis				
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs		
	Total Drug Count by Tier	1,162	269	636	212	188	2,467		
Medical /	QL Drug Count by Tier	223	40	61	202	171	697		
Surgical	% of Total QL Drugs by Tier	32.0%	5.7%	8.8%	29.0%	24.5%			
	% MED/SURG Drugs with QL	19.2%	14.9%	9.6%	95.3%	91.0%	28.3%		
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs		
	Total Drug Count by Tier	135	17	36	0	6	194		
Mandal									
Mental Health	QL Drug Count by Tier	43	3	15	0	4	65		
incartin	% of Total QL Drugs by Tier	66.2%	4.6%	23.1%	0.0%	6.2%			
	% MH Drugs with QL	31.9%	17.6%	41.7%	0.0%	66.7%	33.5%		

	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs
	Total Drug Count by Tier	10	1	5	1	1	18
Substance							
Use	QL Drug Count by Tier	4	1	5	0	1	11
Disorder	% of Total QL Drugs by Tier	36.4%	9.1%	45.5%	0.0%	9.1%	
	% SUD Drugs with QL	40.0%	100.0%	100.0%	0.0%	100.0%	61.1%

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for Quantity Limits Standard Opt-Out Formulary with ACSF - 2021

When the factors for quantity limits are considered consistently across all drugs and drug classes, the outcome shows that quantity limits are applied to a varying percentage of drugs across in the MH, SUD, and MED/SURG drug categories. Quantity limits are applied to:

- 28.3% (697 out of 2,467) of the drugs in the Medical/Surgical category.
- 33.5% (65 out of 194) of the drugs in the Mental Health category.
- 61.1% (11 out of 18) of the drugs in the Substance Use Disorder category.

The development of quantity limits is based on comparable processes, strategies, evidentiary standards, and factors, for therapeutic drug classes used to treat MH, SUD, and MED/SURG conditions. CVS Caremark develops standard quantity limit UM programs, and a client or health plan chooses which quantity limits programs to include in the plan offering. The development of quantity limits is based on the factors below.

The MH/SUD drug classes are listed below, showing the quantity limits in each drug class for this plan:

Sta	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021								
MH/SUD DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL					
ANTIANXIETY Alprazolam tabs, ER tabs, Intensol oral conc, oral susp, ODT Chlordiazepoxide Clonazepam tab, ODT Clorazepate Diazepam oral conc, oral soln, tabs Lorazepam oral conc, tabs Oxazepam	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	22	17	77%					
ANTIDEPRESSANTS		55	0	0%					
ANTIPSYCHOTICS Nuplazid caps, tabs	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	65	2	3%					
HYPNOTICS Estazolam Eszopiclone Flurazepam Hetlioz caps, oral susp Ramelteon Temazepam Triazolam Zaleplon Zolpidem tab, ER tab	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	15	11	73%					

St	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021			
MH/SUD DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ADHD Includes substance controlled drugs used to treat ADHD.	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST- EFFECTIVENESS) Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	37	35	95%
SUD Apo-Varenicline Bupropion ER Nicotrol Oral Inhaler Nicotrol Nasal Spray Buprenorphine SL, Film Buprenorphine/Naloxone Zubsolv Kloxxado nasal Lucemyra Vivitrol inj	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST- EFFECTIVENESS) Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	18	11	61%

Comparable MED/SURG drug classes are listed below, showing the quantity limits in the comparable drug classes for this plan:

Sta	State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021			
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ANTIVIRALS - HIV	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) 	60	60	100%
ANTIVIRALS - HEPATITIS C	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) 	14	14	100%
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Discourage misuse and waste through dose efficiency QLs (ensure appropriate strength is utilized) Lack of documented efficacy at higher doses 	144	107	74%
GROWTH HORMONE	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) 	3	3	100%

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021				
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL
GI AGENTS - PPIs	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST- EFFECTIVENESS) 	12	12	100%
ANTIEMETICS - 5-HT3	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) 	9	9	100%
MULTIPLE SCLEROSIS AGENTS	 Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	20	20	100%

St	ate of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2	021		
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL
ANALGESICS - OPIOID	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Discourage misuse/waste through dose efficiency QLs (ensure appropriate strength is utilized) (COST-EFFECTIVENESS) Lack of documented efficacy at higher doses (COST- EFFECTIVENESS) Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	66	61	92%
DERM - ANTIPSORIATICS	 Promote appropriate dosing, including strength/frequency (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) 	20	13	65%
DERM - POST-HERPETIC NEURALGIA	 Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY) Prevent overutilization (PT SAFETY) Possible abuse or misuse by the patient (PT SAFETY) Prevent overutilization (COST-EFFECTIVENESS) Maximum daily dose/duration of use limits (DISCOURAGE MISUSE/ABUSE) 	10	8	80%

State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021				
MED/SURG DRUG CLASSES WITH QL	Quantity Limit Factors	TOTAL Drug Count	Count of Drugs with QL	Percent of Drugs with QL
IMMUNOSUPPRESSANTS	> Potential to be prescribed in greater qty and/or higher dose than safe and effective per FDA (PT SAFETY)	18	16	89%
	> Promote appropriate dosing, including strength/frequency (PT			
	SAFETY) > Prevent overutilization (PT SAFETY)			
	 Discourage misuse and waste through dose efficiency QLs 			
	(ensure appropriate strength is utilized)			
	> Lack of documented efficacy at higher doses			

It is important to note, the MH and SUD categories include a limited number of drugs that are used to treat specific conditions considered as MH/SUD conditions. However, the M/S drug category encompasses drugs used to treat specific medical or surgical conditions, as well as all other products included in the pharmacy benefit formulary that are not classified as MH or SUD. The products classified in the M/S drug category, therefore, may also include items such as vaccines, vitamins, insulin syringes and needles, and antibiotics, which are not appropriate comparisons to the drugs that are used to treat anxiety, ADHD, opioid use disorder or tobacco use disorder, for example. The inclusion of these types of drugs in the calculation of the rate of quantity limits in the MED/SURG category may result in a total that appears lower than it would be if it only included comparable drugs used to treat chronic conditions like HIV, hepatitis-C, and multiple sclerosis, for example.

The methodology used in the analysis included comparing the percent of PA, ST, QL at the drug class level in order to achieve a more focused and appropriate comparison. The results include of ALL of the MH/SUD classes since they are the focus of the analysis, and it is important to see how each NQTL affects all of those classes. Comparable MED/SURG classes, as defined by clinical pharmacists doing the analysis, are those that treat conditions that require long-term therapy and have a similar or greater magnitude of the NQTL as seen in the MH/SUD classes, as opposed to classes that are categorized as M/S but are actually made up of other items as described above.

As described above, comparable M/S classes, are those that treat conditions that require long-term therapy and have a similar or greater magnitude of the NQTL as seen in the MH/SUD classes. MH/SUD classes remain the same for each NQTL because they are the only classes in that category. It would not be practical to include each and every M/S drug class in the results (as is done in the MH/SUD classes) due to the volume of drugs and classes in that category, so only a sample of classes are shown. The comparable M/S classes are not the same in each NQTL because the classes that are listed for PA, for example, may not be appropriate for ST due to the make-up of drugs that are available in the class, the conditions

they treat, and the factors. For example, on the ACF formulary, 16% of the Antipsychotics class has PA but there is no ST in the class. The drugs requiring PA are brands that did not have a generic available in 2021 and are indicated for use in specific populations or as adjunct therapy. Prior authorization is appropriate for these drugs to ensure they are being used for the right patients in the right situations but requiring a trial of previous therapy is less applicable in this class. Similarly, the M/S class of Antineoplastics has PA on 76% of the drugs, since it is important to ensure the right drug for the right patient and situation, but there is no ST in the class since that approach is not appropriate in cancer treatment.

Findings and Conclusion for Pharmacy Services: The analysis reveals that decisions about applying Prior Authorization, Step Therapy and Quantity Limit NQTLs follow the same process when rendered for MH/SUD drugs or M/S drugs. The conclusion that the processes, strategies, evidentiary standards, and factors used to apply PA, ST and QL to MH/SUD drugs are comparable to, and applied no more stringently than, the processes, strategies, evidentiary standards, and factors used to apply PA, ST and QL to MH/SUD drugs is based on the results shown.

The written materials analysis revealed that <u>as written</u> factors and standards used for applying PA to drugs are the same and are not used differently or more restrictively based on a drug being for M/S or MH/SUD treatment. The review of the P&T Committee minutes showing the decisions made for the period of 2021-2022 revealed that no decisions were made regarding PA for MH or SUD drugs during that timeframe.

An analysis of the formulary data showed that the M/S category had a higher percentage of drugs requiring PA than MH or SUD for both ACF and SOO formularies, as below:

Drugs requiring PA – Advanced Control Formulary – 2021

- 35.4% (840 out of 2,373) of the drugs in the M/S category
- 9.8% (17 out of 173) of the drugs in the MH category
- None of the drugs in the SUD category

Drugs requiring PA – Standard Opt Out Formulary – 2021

- 19.9% (490 out of 2,467) of the drugs in the M/S category
- 3.1% (6 out of 194) of the drugs in the MH category
- 5.6% (1 out of 18) of the drugs in the SUD category

The analysis by the PBM clinician noted that processes of tier placement and UM development are done independently, and one does not rely on or relate to the other. PA is not applied to drugs with the goal of staying above or below a threshold within a given tier. The drugs that have PA were reviewed and the PBM clinician found that it is appropriate for those drugs to require PA based on the factors noted

The written materials analysis revealed that <u>as written</u> factors and standards used for applying ST to drugs are the same and are not used differently or more restrictively based on a drug being for M/S or MH/SUD treatment. The review of the minutes showing the decisions made for the period of 2021-2022 revealed that the decision to apply ST to the M/S drug Qulipta and the MH drug Ambien followed a consistent process.

Also, the analysis of the factors and the level of evidence for the sources used to inform the factors, as written in the policies show a consistent process. The sources of information are not explicit in the minutes but the PBM clinician analyzing the decisions can find the sources and standards as described in the process and assess that the process was followed consistently.

An analysis of the formulary data showed that step therapy is applied to a small percentage of drugs in the MH drug category and the MED/SURG drug category, and there is no step therapy applying to any drugs in the SUD drug category, as below:

Drugs requiring ST – Advanced Control Formulary – 2021

- 1.8% (43 out of 2,373) of the drugs in the M/S category
- 3.5% (6 out of 173) of the drugs in the MH category
- None of the drugs in the SUD category

Drugs requiring ST – Standard Opt Out Formulary – 2021

- 1.5% (36 out of 2,467) of the drugs in the M/S category
- 6.2% (12 out of 194) of the drugs in the MH category
- None of the drugs in the SUD category

While the rate of ST in MH drugs is two times and four times the rate of ST in M/S drugs, in ACF and SOO formularies respectively, these values also represent a *number* of **M/S** drugs with ST that is seven times and three times the number of MH drugs with ST, illustrating that a comparison of percentages alone does not provide a complete view. As noted above, the analysis of the minutes revealed that decisions made to apply ST to M/S and MH/SUD drugs showed a consistent process of applying the factors and utilizing sources with comparable levels of evidence. Also, the analysis by the PBM clinician noted that processes of tier placement and UM development are done independently, and one does not rely on or relate to the other. ST is not applied to drugs with the goal of staying above or below a threshold within a given tier. The drugs that have ST on both formularies were reviewed and the PBM clinician found that it is appropriate for those drugs to require ST based on the factors noted.

The written materials analysis revealed that <u>as written</u> factors and standards used for applying QL to drugs are the same and are not used differently or more restrictively based on a drug being for M/S or MH/SUD treatment. The review of the minutes showing the decisions made for the period of 2021-2022 revealed that the decision to apply QL to the M/S drug Gralise and the MH drug Qelbree followed a consistent process. Also, the analysis of the factors and the level of evidence for the sources used to inform the factors, as written in the policies show a consistent process. The sources of information are not explicit in the minutes but the PBM clinician analyzing the decisions can find the sources and standards as described in the process and assess that the process was followed consistently.

An analysis of the formulary data showed that quantity limits are applied to the ACF and SOO formularies, as below:

Drugs requiring QL – Advanced Control Formulary – 2021

- 33.0% (783 out of 2,373) of the drugs in the M/S category
- 32.9% (57 out of 173) of the drugs in the MH category
- 57.9% (11 out of 19) of the drugs in the SUD category

Drugs requiring QL – Standard Opt Out Formulary – 2021

- 28.3% (697 out of 2,467) of the drugs in the M/S category
- 33.5% (65 out of 194) of the drugs in the MH category
- 61.1% (11 out of 18) of the drugs in the SUD category
- •

The M/S drug category encompasses drugs used to treat specific medical or surgical conditions, as well as **all** other products included in the pharmacy benefit formulary that are not classified as MH or SUD, which may include items such as vaccines, vitamins, insulin syringes and needles, and antibiotics. Since these items are not appropriate comparisons to the drugs that are used to treat anxiety, ADHD, opioid use disorder or tobacco use disorder, for example, but they are still included in the denominator for the M/S category, the rate of QL applying to this category is not a direct reflection of comparable drugs.

Nonetheless, as noted above, the analysis of the minutes revealed that decisions made to apply QL to M/S and MH/SUD drugs showed a consistent process of applying the factors and utilizing sources with comparable levels of evidence. It is important to note that 4 of the 6 MH/SUD classes contain controlled substances (Antianxiety, Hypnotics, ADHD, SUD; ranging from 26%-86% of the class) therefore, a higher percentage of these drugs have QL. In the SUD class, 9 of the 11 drugs with QL are indicated for tobacco use disorder or opioid use disorder where dosing is titrated often, so it is important to monitor the amount used by the patient.

The drugs that have QL on both formularies were reviewed and the PBM clinician found that it is appropriate for those drugs to require QL based on the factors noted. Also, the analysis of the factors and the level of evidence used for the sources used to inform the factors, in operations show a consistent process. No unique process exists that is different in any way to apply the factors; sources used are different and drug/disease-specific. This analysis was done by PBM Clinicians, they are pharmacists, and they made no recommendations regarding NQTLs applied to MH/SUD and M/S drugs. No variation in the use of PBM Clinicians for MH/SUD compared to M/S NQTL analyses.

7. Prescription Drug Formulary Design

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

NQTL's Applicable to Med/Surg Benefits in Prescription	NQTL's Applicable to MH/SUD Benefits in Prescription
Classification	Classification
Formulary Tiering and Design:	Formulary Tiering and Design:
	In effect since 1/1/2020 Aetna added coverage state specific
Aetna delegates the formulary tiering and design to CVS Caremark.	benefit code to bypass formulary exclusions for drugs on the
The formulary, also called drug guide, is developed and managed	"Medication Assisted Therapy" list to meet the ASAM criteria.
through the activities of CVS Caremark National Pharmacy and	
Therapeutics (P&T) Committee (P&T Committee) and the Formulary	Aetna delegates the formulary tiering and design to CVS Caremark.
Review Committee (FRC). Formulary decisions are made first as	The formulary, also called drug guide, is developed and managed
recommendations for additions and deletions voted on by FRC and	through the activities of CVS Caremark National Pharmacy and
then these recommendations are forwarded to the P&T Committee for	Therapeutics (P&T) Committee (P&T Committee) and the Formulary
final review and approval. Disciplines, involved in the formulary	Review Committee (FRC). Formulary decisions are made first as
decision for medications to treat medical, mental health, substance use	recommendations for additions and deletions voted on by FRC and
disorder and medical/surgical conditions included in these committees	then these recommendations are forwarded to the P&T Committee for
are pharmacists, physicians, and specialty physicians (allergists,	final review and approval. Disciplines, involved in the formulary
cardiology, endocrinology, family practice, neurology, infectious	decision for medications to treat medical, mental health, substance
disease, gerontology, gastroenterology, medical ethics, neurology,	use disorder and medical/surgical conditions included in these
psychiatrists, hematology/oncology, pharmacology, and	committees are pharmacists, physicians, and specialty physicians
rheumatology). There is no separate formulary for medications to treat	(allergists, cardiology, endocrinology, family practice, neurology,
medical, mental health, and substance use disorder conditions, and	infectious disease, gerontology, gastroenterology, medical ethics,
there is no separate process of formulary design for medications to	neurology, psychiatrists, hematology/oncology, pharmacology, and
treat medical, mental health, and substance use disorder conditions.	rheumatology). There is no separate formulary for medications to
Accordingly, there is no mention of a separate formulary for	treat medical, mental health, and substance use disorder conditions,
medications to treat medical, mental health, and substance use disorder	and there is no separate process of formulary design for medications
conditions in the Aetna Health Rider prescription drug plan member	to treat medical, mental health, and substance use disorder conditions.
information documents. There is no separate committee making	Accordingly, there is no mention of a separate formulary for
decisions only for medications to treat medical, mental health,	medications to treat medical, mental health, and substance use
substance use disorder and medical/surgical conditions. The P&T	disorder conditions in the Aetna Health Rider prescription drug plan
Committee reviews medications from a purely clinical perspective and	member information documents. There is no separate committee
does not have access to nor does it consider any information on	making decisions only for medications to treat medical, mental
rebates, negotiated discounts or net costs. FRC makes business	health, substance use disorder and medical/surgical conditions. The
recommendations evaluating factors such as utilization trends, impact	P&T Committee reviews medications from a purely clinical
of generic drugs or drugs designated to become available over the	perspective and does not have access to nor does it consider any
counter, brand sand generic pipeline, line of business, plan sponsor	information on rebates, negotiated discounts or net costs. FRC makes
cost, applicable manufacturer agreement, potential impact on	business recommendations evaluating factors such as utilization

members. CVS Caremark works to include the most cost-effective drugs on the drug list. The above processes are used when making formulary decisions for all drug classes including drugs used for MH/SUD and MED/SURG conditions.

Cost-control measures: When drug classes have multiple generic and low-cost brand-name options that cover the same indications as more costly brand-name options in the same class, and the generic and low-cost brand-name options offer similar efficacy and safety. **Therapeutic alternatives** in formulary design: since many brand-name drugs do not provide clear clinical and/or financial advantages when compared to available drug options within the therapeutic class, several strategies are available to promote cost-effective use of medications ranging from tiered copays, excluding products from coverage or having a closed plan design.

- Tiered copays encourage members to use preferred formulary drugs.
- Products not included in the formulary have therapeutic alternatives available that deliver cost savings and are covered in the formulary.

Plan Language

- Coverage and exclusions
- Providing covered services
- Your prescription drug plan provides covered services. Your provider can give you a prescription in different ways including:
- A written prescription that you take to a network pharmacy
- Calling or e-mailing a prescription to a network pharmacy
- Submitting the prescription to a network pharmacy electronically

For covered pharmacy services:

• You need a prescription from the prescribing provider

trends, impact of generic drugs or drugs designated to become available over the counter, brand sand generic pipeline, line of business, plan sponsor cost, applicable manufacturer agreement, potential impact on members. CVS Caremark works to include the most cost-effective drugs on the drug list. The above processes are used when making formulary decisions for all drug classes including drugs used for MH/SUD and MED/SURG conditions.

Cost-control measures: When drug classes have multiple generic and low-cost brand-name options that cover the same indications as more costly brand-name options in the same class, and the generic and low-cost brand-name options offer similar efficacy and safety. **Therapeutic alternatives** in formulary design: since many brandname drugs do not provide clear clinical and/or financial advantages when compared to available drug options within the therapeutic class, several strategies are available to promote cost-effective use of medications ranging from tiered copays, excluding products from coverage or having a closed plan design.

- Tiered copays encourage members to use preferred formulary drugs.
- Products not included in the formulary have therapeutic alternatives available that deliver cost savings and are covered in the formulary.

Plan Language

Coverage and exclusions

Providing covered services

- Your prescription drug plan provides covered services. Your provider can give you a prescription in different ways including:
- A written prescription that you take to a network pharmacy
- Calling or e-mailing a prescription to a network pharmacy
- Submitting the prescription to a network pharmacy electronically

• You need to show your ID card to the network pharmacy when you get a prescription filled

Off-label use

Off-label drug use unless recognized for treatment in any of the standard reference compendia or for indications recognized through peer-reviewed medical literature, and includes medically necessary services associated with the administration of the recognized drug

Prescription drugs:

- That are ordered by a dentist or prescribed by an oral surgeon in relation to the removal of teeth or prescription drugs for the treatment to a dental condition

- That are considered oral dental preparations and fluoride rinses except pediatric fluoride tablets or drops as specified on the plan's drug guide

- That are being used or abused in a manner that is determined to be furthering an addiction to a habit-forming substance, the use of or intended use of which is illegal, unethical, imprudent, abusive, not medically necessary or otherwise improper and drugs obtained for use by anyone other than the member as identified on the ID card

- Replacement of lost or stolen prescriptions
- Test agents except diabetic test agents

• Treatment, drug, service or supply to stop or reduce smoking or the use of tobacco products or to treat or reduce nicotine addition, dependence or craving including medications, nicotine patches and gum unless approved by the FDA as an aid to stop the use of tobacco products

• [We reserve the right to exclude:

A manufacturer's product when the same or similar drug (one with the same active ingredient or same therapeutic effect), supply or equipment is on the plan's drug guide
 [We same active ingredient or same therapeutic effect]

For covered pharmacy services:

- You need a prescription from the prescribing provider
- You need to show your ID card to the network pharmacy when you get a prescription filled

Off-label use

Off-label drug use unless recognized for treatment in any of the standard reference compendia or for indications recognized through peer-reviewed medical literature, and includes medically necessary services associated with the administration of the recognized drug

Prescription drugs:

- That are ordered by a dentist or prescribed by an oral surgeon in relation to the removal of teeth or prescription drugs for the treatment to a dental condition

- That are considered oral dental preparations and fluoride rinses except pediatric fluoride tablets or drops as specified on the plan's drug guide

- That are being used or abused in a manner that is determined to be furthering an addiction to a habit-forming substance, the use of or intended use of which is illegal, unethical, imprudent, abusive, not medically necessary or otherwise improper and drugs obtained for use by anyone other than the member as identified on the ID card

• Replacement of lost or stolen prescriptions

• Test agents except diabetic test agents

• Treatment, drug, service or supply to stop or reduce smoking or the use of tobacco products or to treat or reduce nicotine addition, dependence or craving including medications, nicotine patches and gum unless approved by the FDA as an aid to stop the use of tobacco products

[We reserve the right to exclude:

- Any dosage or form of a drug when the same drug is available	 A manufacturer's product when the same or similar drug 	
in a different dosage or form on the plan's drug guide]	(one with the same active ingredient or same therapeutic effect),	
	supply or equipment is on the plan's drug guide	
There is no separate specialty pharmacy formulary and "non-specialty"	- Any dosage or form of a drug when the same drug is	
formulary. There are not four formularies. This information is about	available in a different dosage or form on the plan's drug guide]	
two formularies, Advanced Control Formulary and Standard Opt Out.	There is no separate specialty pharmacy formulary and "non-	
Both formularies have drugs that are specialty and drugs that are not	specialty" formulary. There are not four formularies. This information	
specialty.	is about two formularies, Advanced Control Formulary and Standard	
On page 9 of the Aetna Health Rider prescription drug plan, there is	Opt Out. Both formularies have drugs that are specialty and drugs that	
member information about what is needed to know about the	are not specialty.	
prescription drug plan such as:	On page 9 of the Aetna Health Rider prescription drug plan,	
· How to access network pharmacies	there is member information about what is needed to know	
· How to get an emergency prescription filled	about the prescription drug plan such as:	
· Coverage and exclusions	 How to access network pharmacies 	
· How to access their benefit	• How to get an emergency prescription filled	
· Where their schedule of benefits fits in	· Coverage and exclusions	
• Precertification requirements that apply	· How to access their benefit	
· Utilization review	• Where their schedule of benefits fits in	
· Requesting a medical exception	• Precertification requirements that apply	
· General provisions – other things you should know	· Utilization review	
· How to read your schedule of benefits	 Requesting a medical exception 	
It also states: "This plan doesn't cover all prescription drugs and some	· General provisions – other things you should know	
coverage may be limited. This doesn't mean you can't get	• How to read your schedule of benefits	
prescription drugs that aren't covered; you can, but you have to pay	It also states: "This plan doesn't cover all	
for them yourself."	prescription drugs and some coverage may be	
	limited. This doesn't mean you can't get prescription	
On page 9 of the Aetna Health Rider prescription drug plan, there is	drugs that aren't covered; you can, but you have to	
information on how members or their provider can ask for a medical	pay for them yourself."	
exception for drugs that are not covered in the drug guide if it is	On page 9 of the Aetna Health Rider prescription drug plan, there is	
medically necessary for a member to use a prescription drug that is not	information on how members or their provider can ask for a medical	
on this drug guide; members or their provider must request a medical	exception for drugs that are not covered in the drug guide if it is	
exception. The plan will make a coverage decision within 24 hours	medically necessary for a member to use a prescription drug that is not	
after an urgent request is received.	on this drug guide; members or their provider must request a medical	
	exception. The plan will make a coverage decision within 24 hours	
	after an urgent request is received.	

All formularies include generic drugs, which are in the lowest copay tier for members. Brand-name products may be considered preferred or non-preferred in the common three-tier plan design. Preferred brandname drugs are encouraged with a lower copay than non-preferred brand-name products. Tiered benefit design encourages generic utilization and lower pharmacy cost through copay differentials. The goal is to include in the formulary the lowest net cost drug within each therapeutic class while ensuring that options available on the formularies are consistent with current standards of practice and clinical guidelines.

Formulary Review Committee (FRC) is an internal CVS Caremark committee that evaluates factors that may affect the formulary. The FRC makes business recommendations based on such factors to the P&T Committee. It is important to note that any drug product must first be deemed safe and effective by the P&T Committee before it is considered eligible for inclusion on a CVS Caremark Formulary or Drug List, and that any recommendations made by the FRC must be approved by the P&T Committee before implementation.

The P&T Committee reviews all standard formularies annually. The review is conducted by drug class to assure that the formulary recommendations previously established are maintained and to recommend additional changes for clinical appropriateness if advisable based on newly available pharmaceutical information.

Formulary benefit design and copay tiering are applied consistently across all drugs and drug classes and do not discriminate based on whether the drug is for a medical or surgical condition, mental health or substance use disorder diagnosis, or other health conditions. Any pharmacy coverage factors, sources or evidentiary standards, processes and development or implementation strategies applied to drugs used to treat mental health or substance use disorders are comparable to, and are applied no more stringently than the coverage factors, source or evidentiary standards, processes and development or implementation All formularies include generic drugs, which are in the lowest copay tier for members. Brand-name products may be considered preferred or non-preferred in the common three-tier plan design. Preferred brand-name drugs are encouraged with a lower copay than nonpreferred brand-name products. Tiered benefit design encourages generic utilization and lower pharmacy cost through copay differentials. The goal is to include in the formulary the lowest net cost drug within each therapeutic class while ensuring that options available on the formularies are consistent with current standards of practice and clinical guidelines.

Formulary Review Committee (FRC) is an internal CVS Caremark committee that evaluates factors that may affect the formulary. The FRC makes business recommendations based on such factors to the P&T Committee. It is important to note that any drug product must first be deemed safe and effective by the P&T Committee before it is considered eligible for inclusion on a CVS Caremark Formulary or Drug List, and that any recommendations made by the FRC must be approved by the P&T Committee before implementation.

The P&T Committee reviews all standard formularies annually. The review is conducted by drug class to assure that the formulary recommendations previously established are maintained and to recommend additional changes for clinical appropriateness if advisable based on newly available pharmaceutical information.

Formulary benefit design and copay tiering are applied consistently across all drugs and drug classes and do not discriminate based on whether the drug is for a medical or surgical condition, mental health or substance use disorder diagnosis, or other health conditions. Any pharmacy coverage factors, sources or evidentiary standards, processes and development or implementation strategies applied to drugs used to treat mental health or substance use disorders are comparable to, and are applied no more stringently than the coverage strategies used in applying the limitations to drugs used to treat medical or surgical conditions. The formulary tiers are based on whether the drug is available as a generic or a brand product, and whether the brand or generic drug product is considered preferred or non-preferred.

Plan Language

Brand-name prescription drug

An FDA approved **prescription drug** marketed with a specific brand name by the company that manufactures it, usually by the company which develops and patents it.

Generic prescription drug, generic drug

A **prescription drug** with the same dosage, safety, strength, quality, performance and intended use as the brand name product. It is defined as therapeutically equivalent by the U.S. Food and Drug Administration (FDA) and is considered to be as effective as the brand name product.

Non-preferred drug

A **prescription drug** or device that may have a higher out-of-pocket cost than a **preferred drug**.

Preferred drug

A **prescription drug** or device that may have a lower out-of-pocket cost than a **non-preferred drug**.

On page 7 of the Aetna Health Rider prescription drug plan explains this formulary design for members using the words "drug guide" and explains how to access this pharmacy benefit, including retail, mail factors, source or evidentiary standards, processes and development or implementation strategies used in applying the limitations to drugs used to treat medical or surgical conditions. The formulary tiers are based on whether the drug is available as a generic or a brand product, and whether the brand or generic drug product is considered preferred or non-preferred. Plan Language

Brand-name prescription drug

An FDA approved **prescription drug** marketed with a specific brand name by the company that manufactures it, usually by the company which develops and patents it.

Generic prescription drug, generic drug

A **prescription drug** with the same dosage, safety, strength, quality, performance and intended use as the brand name product. It is defined as therapeutically equivalent by the U.S. Food and Drug Administration (FDA) and is considered to be as effective as the brand name product.

Non-preferred drug

A **prescription drug** or device that may have a higher out-of-pocket cost than a **preferred drug**.

Preferred drug

A **prescription drug** or device that may have a lower out-of-pocket cost than a **non-preferred drug**.

On page 7 of the Aetna Health Rider prescription drug plan explains this formulary design for members using the words "drug guide" and explains how to access this pharmacy benefit, including retail, mail

order, and specialty pharmacies, including 90 day supply for	order, and specialty pharmacies, including 90 day supply for
maintenance drugs.	maintenance drugs.
On page 9 of the Aetna Health Rider prescription drug plan, there is	On page 9 of the Aetna Health Rider prescription drug plan, there is
information on how members or their provider can ask for a medical	information on how members or their provider can ask for a medical
exception for drugs that are not covered in the drug guide if it is	exception for drugs that are not covered in the drug guide if it is
medically necessary for a member to use a prescription drug that is not	medically necessary for a member to use a prescription drug that is not
on this drug guide, members or their provider must request a medical	on this drug guide, members or their provider must request a medical
exception. The plan will make a coverage decision within 24 hours	exception. The plan will make a coverage decision within 24 hours
after an urgent request is received.	after an urgent request is received.
On page 13 of the Aetna Health Rider prescription drug plan COPAY information states: Preferred generic prescription drugs 30 day supply at a retail pharmacy \$15 after deductible 31-90 day supply at a retail pharmacy or mail order \$30 after deductible Value prescription drugs 30 day supply at retail pharmacy \$3 after deductible 31-90 day supply at retail or mail order pharmacy \$6 after deductible Preferred brand name prescription drugs 30 day supply at retail pharmacy \$35 after deductible 31-90 day supply at retail or mail order pharmacy \$70 after deductible Non-preferred generic prescription drugs 30 day supply at retail pharmacy \$85 after deductible 31-90 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible 31-90 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible 31-90 day supply at retail or mail order pharmacy \$170 after deductible 31-90 day supply at retail or mail order pharmacy \$170 after deductible 31-90 day supply at specialty pharmacy or retail pharmacy \$150 after deductible 31-90 day supply at specialty pharmacy or retail pharmacy \$300 after deductible 31-90 day supply at specialty pharmacy or retail pharmacy \$300 after deductible Non-preferred specialty prescription drugs	On page 13 of the Aetna Health Rider prescription drug plan COPAY information states: Preferred generic prescription drugs 30 day supply at a retail pharmacy \$15 after deductible 31-90 day supply at a retail pharmacy or mail order \$30 after deductible Value prescription drugs 30 day supply at retail pharmacy \$3 after deductible 31-90 day supply at retail or mail order pharmacy \$6 after deductible Preferred brand name prescription drugs 30 day supply at retail pharmacy \$35 after deductible 31-90 day supply at retail or mail order pharmacy \$70 after deductible Non-preferred generic prescription drugs 30 day supply at retail pharmacy \$85 after deductible 31-90 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible Non-preferred brand name prescription drugs 30 day supply at retail or mail order pharmacy \$170 after deductible Preferred specialty prescription drugs 30 day supply at a specialty pharmacy or retail pharmacy \$150 after deductible 31-90 day supply at specialty pharmacy or retail pharmacy \$300 after

30 day supply at a specialty pharmacy or retail pharmacy \$150 after	Non-preferred specialty prescription drugs
deductible	30 day supply at a specialty pharmacy or retail pharmacy \$150 after
31-90 day supply at specialty pharmacy or retail pharmacy \$300 after	deductible
deductible	31-90 day supply at specialty pharmacy or retail pharmacy \$300 after
 Maximum copay is capped at \$150 	deductible
	Maximum copay is capped at \$150
On page 11 of the Aetna Health Rider prescription drug plan,	
information on deductible and cost share waiver for tobacco cessation	On page 11 of the Aetna Health Rider prescription drug plan,
prescription and OTC drugs. The prescription drug and the per	information on deductible and cost share waiver for tobacco cessation
prescription cost share will not apply to the first two 90-day	prescription and OTC drugs. The prescription drug and the per
treatment programs for tobacco cessation prescription and OTC drugs	prescription cost share will not apply to the first two 90-day
when obtained at a network retail pharmacy. This means they will be	treatment programs for tobacco cessation prescription and OTC drugs
paid at 100%. Member's per prescription cost share will apply after	when obtained at a network retail pharmacy. This means they will be
those two programs have been exhausted.	paid at 100%. Member's per prescription cost share will apply after
Deductible waiver provisions for preventive prescription drugs and	those two programs have been exhausted.
supplements information indicate that the deductible is waived for all	Deductible waiver provisions for preventive prescription drugs and
preferred and non-preferred generic, value and brand name prescription	supplements information indicate that the deductible is waived for all
drugs.	preferred and non-preferred generic, value and brand name
No deductible apply to preventive covered prescription drug expenses	prescription drugs.
for those prescription drugs used to treat:	No deductible apply to preventive covered prescription drug expenses
The prevention of conditions relating to:	for those prescription drugs used to treat:
Hypertension	The prevention of conditions relating to:
Heart disease	• Hypertension
Diabetic complications	Heart disease
Asthmatic episodes	Diabetic complications
Conditions resulting from osteoporosis	Asthmatic episodes
• Stroke	 Conditions resulting from osteoporosis
• Various pediatric conditions including maternal and fetal	• Stroke
problems during pregnancy	• Various pediatric conditions including maternal and fetal
Plan Language	problems during pregnancy
Tobacco cessation prescription and OTC drugs	Plan Language
Covered services include FDA approved prescription and OTC drugs	Tobacco cessation prescription and OTC drugs
to help stop the use of tobacco products. You must receive a	Covered services include FDA approved prescription and OTC drugs
prescription from your provider and submit the prescription to the	to help stop the use of tobacco products. You must receive a
pharmacy for processing. It also includes two 90-day courses of	prescription from your provider and submit the prescription to the

nicotine replacement therapy during each [contract] year. See the	pharmacy for processing. It also includes two 90-day courses of
Deductible and cost share waiver for tobacco cessation prescription	nicotine replacement therapy during each [contract] year. See the
and OTC drugs provision for more information.	Deductible and cost share waiver for tobacco cessation prescription
and o re drugs provision for more mornation.	and OTC drugs provision for more information.
Over-the-counter drugs	and one drugs provision for more information.
Covered services include certain OTC medications, as determined by	Over-the-counter drugs
the plan. Coverage of these medications may require a prescription. You can access a list of these OTC medications. See the Contact us	Covered services include certain OTC medications, as determined by
	the plan. Coverage of these medications may require a prescription.
section for how.	You can access a list of these OTC medications. See the Contact us
	section for how.
[Note: This will print for plans subject to ACA and plans not subject to	
ACA but elect to include this benefit.]	[Note: This will print for plans subject to ACA and plans not subject
[Preventive care drugs and supplements	to ACA but elect to include this benefit.]
Covered services include preventive care drugs and supplements,	[Preventive care drugs and supplements
including OTC drugs and supplements, as required by the ACA.]	Covered services include preventive care drugs and supplements,
	including OTC drugs and supplements, as required by the ACA.]
Specialty Drug designation:	
Specialty pharmacy member information indicates that members can	Specialty Drug designation:
get many commonly prescribed specialty medicines from a specialty	
pharmacy, or based on their plan, they can use a retail pharmacy.	Specialty pharmacy member information indicates that members can
Specialty drugs treat complex, chronic conditions. A nurse or	get many commonly prescribed specialty medicines from a specialty
pharmacist will often support their use during treatment. These drugs	pharmacy, or based on their plan, they can use a retail pharmacy.
may be injected, infused or taken by mouth. A member may need to	Specialty drugs treat complex, chronic conditions. A nurse or
refrigerate them. They are often expensive and may not be available at	pharmacist will often support their use during treatment. These drugs
retail pharmacies. Contact information is provided for members to get	may be injected, infused or taken by mouth. A member may need to
access to specialty medications. Document is found at:	refrigerate them. They are often expensive and may not be available at
https://www.aetna.com/docfind/cms/assets/pdf/specialty_pharmacy.pdf	retail pharmacies. Contact information is provided for members to get
	access to specialty medications. Document is found at:
Aetna delegates the Specialty Drug designation to CVS Caremark,	https://www.aetna.com/docfind/cms/assets/pdf/specialty_pharmacy.pd
except for the purpose of applying a copay or restricting distribution at	f
a specialty pharmacy. The CVS Caremark specialty drug designation	
decision making process details include the specialty drug designation	Aetna delegates the Specialty Drug designation to CVS Caremark,
decisions are made by CVS Caremark Pharmaceutical Technology	except for the purpose of applying a copay or restricting distribution at
Evaluation Committee (PTEC). The personnel involved in PTEC is	a specialty pharmacy. The CVS Caremark specialty drug designation
multidisciplinary are voting members making decisions, and is	decision making process details include the specialty drug designation
manual of the stand memory making decisions, and is	decision making process decans metude the speciarty drug designation

comprised of internal employees' representatives from various business areas including Medical Affairs, Specialty Product Safety, Professional Practice and others. Details of the composition of PTEC personnel include pharmacists, physicians, other businesspersons knowledgeable about the PBM business and pharmacy distribution channels. None of the personnel are MH/SUD specialists. The PTEC committee meets quarterly to evaluate pharmaceuticals, biologics, medical devices and emerging technologies to determine specialty drug designation using an established decision model. CVS Specialty designation and removal decisions are made without regard to whether the drugs are used to treat MH/SUD conditions or MED/SURG conditions and is applied to drugs or drug classes using factors such as risk profile of a drug, safety and effectiveness of drug (e.g., close clinical monitoring), a drug's indication for use and cost, a drug's route of administration or delivery systems, a drug's dispensing requirements (i.e., special handling, special storage). Due to the special handling of the drug or the drug's limited distribution imposed by a manufacturer, the prescription may or may not need to be dispensed from a Specialty Pharmacy.

On page 9 of the Aetna Health Rider prescription drug plan, there is information on how members or their provider can ask for a medical exception for drugs that are not covered in the drug guide if it is medically necessary for a member to use a prescription drug that is not on this drug guide; members or their provider must request a medical exception. The plan will make a coverage decision within 24 hours after an urgent request is received. Coverage requests data for 2021 matched by drug GPI to the drug list was reviewed. Quality control of the data by a PBM pharmacist found that not all requests processed did not match GPI. These non-matching GPIs were also reviewed and are here reported, and are considered to be in-scope since they did not match due to the drug not being present in the drug list. A second PBM pharmacist inspected the data for accuracy. Findings: ACF

ACF

Totals

decisions are made by CVS Caremark Pharmaceutical Technology Evaluation Committee (PTEC). The personnel involved in PTEC is multidisciplinary are voting members making decisions, and is comprised of internal employees' representatives from various business areas including Medical Affairs, Specialty Product Safety, Professional Practice and others. Details of the composition of PTEC personnel include pharmacists, physicians, other businesspersons knowledgeable about the PBM business and pharmacy distribution channels. None of the personnel are MH/SUD specialists. The PTEC committee meets quarterly to evaluate pharmaceuticals, biologics, medical devices and emerging technologies to determine specialty drug designation using an established decision model. CVS Specialty designation and removal decisions are made without regard to whether the drugs are used to treat MH/SUD conditions or MED/SURG conditions and is applied to drugs or drug classes using factors such as risk profile of a drug, safety and effectiveness of drug (e.g., close clinical monitoring), a drug's indication for use and cost, a drug's route of administration or delivery systems, a drug's dispensing requirements (i.e., special handling, special storage). Due to the special handling of the drug or the drug's limited distribution imposed by a manufacturer, the prescription may or may not need to be dispensed from a Specialty Pharmacy.

On page 9 of the Aetna Health Rider prescription drug plan, there is information on how members or their provider can ask for a medical exception for drugs that are not covered in the drug guide if it is medically necessary for a member to use a prescription drug that is not on this drug guide; members or their provider must request a medical exception. The plan will make a coverage decision within 24 hours after an urgent request is received. Coverage requests data for 2021 matched by drug GPI to the drug list was reviewed. Quality control of the data by a PBM pharmacist found that not all requests processed did not match GPI. These non-matching GPIs were also reviewed and are here reported, and are considered to be in-scope since they did not match due to the drug not being present in the drug

Totals

		Med/Sur	MH/SU
		g	D
	Number of requests pursuant		
	to \S 15-831(c)(1) for coverage		
	of a drug that is not on the		
1	formulary	67	10
	Number of requests in line 1		
	that were denied as adverse		
a	decisions	51	7
	Number of requests in line 1		
b	that were approved	16	3

 MH/SUD drugs being denied ACF list is: Invega Trinza (paliperidone palmitate ER) (MH) Suboxone 8-2MG SL FILM (SUD) Viibryd (vilazodone) (MH)

The SUD has a generic alternative covered in a preferred tier. The MH drugs have multiple therapeutic alternatives available in preferred tiers.

	-	SOO Totals	SOO Totals
		Med/Surg	MH/SU D
1	Number of requests pursuant to § 15-831(c)(1) for coverage of a drug that is not on the formulary	10	0
а	Number of requests in line 1 that were denied as adverse decisions	5	0
b	Number of requests in line 1 that were approved	5	0

	list. A second PBM pharmacist inspected the data for accuracy. Findings:						
1	,51		ACF	ACF			
		_	Totals	Totals			
			Med/Su	MH/SU			
			rg	D			
		Number of requests pursuant					
		to § 15-831(c)(1) for coverage					
		of a drug that is not on the					
	1	formulary	67	10			
		Number of requests in line 1					
		that were denied as adverse					
	а	decisions	51	7			
		Number of requests in line 1					
	b	that were approved	16	3			

MH/SUD drugs being denied ACF list is:

 Invega Trinza (paliperidone palmitate ER) (MH)
 Suboxone 8-2MG SL FILM (SUD)
 Viibryd (vilazodone) (MH)

The SUD has a generic alternative covered in a preferred tier. The MH drugs have multiple therapeutic alternatives available in preferred tiers.

	SOO	SOO
_	Totals	Totals
		MH/SU
	Med/Surg	D

• There were no MH/SUD drugs denied.	15-831(c)(1	requests pursuant to § L) for coverage of a s not on the formulary	10	0
Examination of the same 2021 requests for coverage data by a PBM pharmacist (both matched GPI and non-matched), revealed that no		requests in line 1 that ed as adverse decisions	5	0
prescription request had been denied due to experimental/investigational determinations.	Number of b were appro	requests in line 1 that	5	0
	• There were no MH/SUD drugs denied.			
	Examination of the same 2021 requests for coverage data by a PB pharmacist (both matched GPI and non-matched), revealed that no prescription request had been denied due to experimental/investigational determinations.			

B. Identify the factors used in the development of the limitation(s);

The same factors are considered when establishing formulary tier designation for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions, all factors are considered.

The factors used are:

Factors	Sources
Brand or generic status of the drug	Drug labeling approved by the U.S. Food and Drug Administration (FDA)
	US Food and Drug Administration Labeling is accessible via National Library of Medicine. The
	DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm
	Centers for Medicare & Medicaid Services accepted drug compendia
	Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.
	https://online.lexi.com/lco/action/login
	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA.
	https://www.micromedexsolutions.com

Impact of generic drugs or drugs designated to become available over- the-counter	 Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com OTC - Over The Counter (fda.gov) https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm
Brand and generic pipeline	CVS Caremark pipeline reports based on manufacturer information, or manufacturer pipeline information For example: CVS Health Payor Solutions. Drugs to Watch. Drug Pipeline <u>https://payorsolutions.cvshealth.com/tags/drug-pipeline</u> Bristol Myers Squibb Pipeline website <u>https://www.bms.com/researchers-and-partners/in-the-pipeline.html</u> Note: there are thousands of manufacturers, these are just examples.
Line of business	Per regulatory requirement state or federal as applicable
Availability of therapeutic alternatives	Advanced Control Formulary and Standard Opt Out Formulary. Formulary, or drug list drugs used for the disease or condition in question.
Indication for use and cost (cost- effectiveness) Potential impact on members	Utilization trends reports Plan sponsor cost reports Applicable manufacturer agreement Advance Control Formulary and Standard Opt Out Formulary. Formulary, or drug list drugs used for the disease or condition in question.

Specialty Drug designation:

The same factors are considered when applying specialty drug designation for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions:

Factors	Sources
Risk profile	Drug labeling approved by the U.S. Food and Drug Administration (FDA)
1	US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia
	Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login
	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com
	Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies.
	 Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.fda.gov/
Safety and effectiveness	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia
	Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login
	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com
	Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies.

	Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.fda.gov/
Indication for use and cost	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm Cost information from internal database
Route of administration or delivery systems	 Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/action/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolutions.com Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and government health agencies. Examples: Peer-Reviewed literature and standards of care are accessible via academic databases that enable users to execute searches across multiple journals. National Library of Medicine. Health Data Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example, https://www.guidelinecentral.com/guidelines/ US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org Centers for Disease Control and Prevention. https://www.fda.gov/

D ¹ · · · · ·	Drug labeling approved by the U.S. Food and Drug Administration (FDA)
Dispensing requirements	US Food and Drug Administration Labeling is accessible via National Library of Medicine. The
	DailyMed database. https://dailymed.nlm.nih.gov/dailymed/index.cfm
	Centers for Medicare & Medicaid Services accepted drug compendia
	Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.
	https://online.lexi.com/lco/action/login
	Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA.
	https://www.micromedexsolutions.com
	Published peer-reviewed clinical literature, accepted clinical practice guidelines, standards of care, and
	government health agencies.
	Examples:
	Peer-Reviewed literature and standards of care are accessible via academic databases that enable
	users to execute searches across multiple journals. National Library of Medicine. Health Data
	Sources. https://www.nlm.nih.gov/oet/ed/stats/03-700.html Accessed October 6, 2023.
	Clinical guidelines and standards of care for each disease are accessible via web search or via
	databases that enable users to execute searches across multiple clinical authors.
	For example, https://www.guidelinecentral.com/guidelines/
	US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org
	Centers for Disease Control and Prevention. https://www.cdc.gov/index.htm
	US Food and Drug Administration. https://www.fda.gov/

C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

The same factors and standards are considered when establishing formulary tier and design for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions:

Factors	Definitions	Sources	Standard
Brand or generic	The FDA definition of a brand drug,	Drug labeling approved by the U.S.	FDA definition of a brand drug, and
status of the drug	and a generic drug.	Food and Drug Administration (FDA)	a generic drug.
		US Food and Drug	
		Administration Labeling is	
		accessible via National	

		Library of Medicine. The	
		DailyMed database.	
		https://dailymed.nlm.nih.gov	
		/dailymed/index.cfm	
		Centers for Medicare & Medicaid	
		Services accepted drug compendia	
		Lexicomp Online, AHFS DI	
		(Adult and Pediatric) Online,	
		Hudson, Ohio: UpToDate,	
		Inc.	
		https://online.lexi.com/lco/act	
		ion/login	
		Micromedex (electronic	
		version). IBM Watson	
		Health, Greenwood Village,	
		Colorado, USA.	
		https://www.micromedexsolu	
		tions.com	
Impact of generic	The FDA definition of a brand drug,	1. Drug labeling approved by	FDA definition of a over-the-
drugs or drugs	and a generic drug.	the U.S. Food and Drug	counter drug, and/or a generic drug.
designated to become		Administration (FDA)	
available over-the-		US Food and Drug	
counter		Administration Labeling is	
		accessible via National	
		Library of Medicine. The	
		DailyMed database.	
		https://dailymed.nlm.nih.gov	
		/dailymed/index.cfm	
		2. Centers for Medicare &	
		Medicaid Services accepted	
		drug compendia	
		Lexicomp Online, AHFS DI	
		(Adult and Pediatric) Online,	
		Hudson, Ohio: UpToDate,	
		Inc.	

		 https://online.lexi.com/lco/act ion/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsol utions.com OTC - Over The Counter (fda.gov) https://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfivd /search.cfm 	
Brand and generic pipeline	Drugs that are in late stage development as defined by the pharmaceutical industry	CVS Caremark pipeline reports based on manufacturer information, or manufacturer pipeline information. For Example: CVS Health Payor Solutions. Drugs to Watch. Drug Pipeline https://payorsolutions.cvshealth.com /tags/drug-pipeline Examples of manufacturer's pipeline: https://www.abbvie.com/science/pip eline.html https://www.regeneron.com/pipelin e-medicines Note: there are thousands of manufacturers, these are examples	As communicated by drug manufacturers

Line of business	Category of insurance, such as Commercial, Medicare,	Per regulatory requirement state or federal as applicable	Per regulatory requirement state or federal as applicable
	Health Insurance Marketplace, etc.		
Availability of therapeutic alternatives	Alternative drugs available to treat the same condition.	 Other drugs used for the same disease or condition already in the formularies Advanced Control Formulary and Standard Opt Out. Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example: https://www.guidelinecentral.co m/guidelines/ 	Disease/ condition-dependent
Indication for use and cost (cost- effectiveness)	This factor is not considered by the P&T Committee. Cost effectiveness is when multiple drugs exist to treat a given condition, the drugs that are less costly provide more cost-effective therapy. The plan sponsor cost is the net cost option for generic, biosimilar, and brand-name drugs being considered.	Utilization trends reports Plan sponsor cost reports Applicable manufacturer agreement	There is no set threshold, since this is a qualitative comparison. Drug dependent qualitative measure: The cost is a relative measure looking at price of a drug measured in comparison to the price of another drug or group of drugs that are used for the same indication. A cost can be higher than, similar to, or lower than other drugs that are used for the same indication
Potential impact on members	If the decision to remove of a drug will impact patients negatively because there are no comparable therapeutic alternatives left in the formulary to treat the disease or condition.	Advance Control Formulary and Standard Opt Out Formulary. Formulary, or drug list drugs used for the disease or condition in question.	Drug-dependent qualitative measure: Large impact occurs when the formulary in question does not have enough drugs choices to treat the disease or condition. Low impact occurs when the formulary in question has multiple drugs

	choices to treat the disease or
	condition.

Specialty Drug designation: The same factors and standards are considered when establishing specialty designation for drugs used in MH/SUD conditions as for drugs used in MED/SURG conditions:

Factors	Definitions	Sources	Standards
Risk profile	The risk characteristics associated with the drug such as box warnings, REMS, adverse drug reactions and patient monitoring requirements.	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/ dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/act ion/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA.	 As assigned by the FDA. For further information, please see: 1. FDA's Application of Statutory Factors in Determining When a REMS is Necessary: Guidance for Industry. 2. Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk https://www.jacionline.org/article/S 0091-6749(05)02325-0/fulltext

		https://www.micromedexsolu tions.com	
Safety and effectiveness	The level of patient proficiency needed for self-management and maintaining adherence, as well as any required therapeutic response monitoring and dose adjustments.	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/ dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/act ion/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolu tions.com	As assigned by the FDA and described in the FDA labeling. For further information, please see: FDA's Labeling Resources for Human Prescription Drugs. https://www.fda.gov/drugs/laws-acts- and-rules/fdas-labeling-resources- human-prescription-drugs
Indication for use and cost	The indication is what the drug is used for.	Drug labeling approved by the U.S. Food and Drug Administration (FDA)	There is no set threshold, since this is a qualitative comparison.

	The cost is a relative price measured in comparison to other drugs for the same indication. The complexity of the condition where the drug is intended for use (e.g., rare, chronic) and its actual or anticipated cost.	US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/ dailymed/index.cfm	The indication is as assigned in the drug labeling by the FDA. The cost is a relative measure looking at price of a drug measured in comparison to the price of another drug or group of drugs that are used for the same indication. A cost can be higher than, similar to, or lower than other drugs that are used for the same indication.
Route of administration or delivery systems	The level of complexity to administer the drug, such as via infusion, injection or inhalation and whether the administration of the drug requires ancillary supplies and/or a device.	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/ dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/act ion/login Micromedex (electronic version). IBM Watson Health, Greenwood Village,	A route is required by the FDA labeling. Standard routes of administration are known by clinicians making decisions to be easier or more difficult to execute by a patient or may require administration by a health care provider.

		Colorado, USA. https://www.micromedexsolu tions.com	
Dispensing requirements	The storage and handling requirements for the drug and any necessary coordination of care with a provider.	Drug labeling approved by the U.S. Food and Drug Administration (FDA) US Food and Drug Administration Labeling is accessible via National Library of Medicine. The DailyMed database. https://dailymed.nlm.nih.gov/ dailymed/index.cfm Centers for Medicare & Medicaid Services accepted drug compendia Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc. https://online.lexi.com/lco/act ion/login Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. https://www.micromedexsolu tions.com	A storage and handling requirements are required by the FDA labeling and as required by the manufacturer. This is a qualitative measure known to clinicians and communicated by drug manufacturers. For example, the handling and storage of a complex drug that is susceptible to thermal stress, and its transport and delivery must be coordinated with the health care provider to avoid spoilage.

D. Identify the methods and analysis used in the development of the limitation(s); and

Comparative analyses demonstrating comparability and no more stringency in application of factors <u>as written</u> was performed by PBM Clinicians via a review of the policies and procedures detailing the PBM formulary management, P&T Committee process, and sample of committee minutes. The policies and procedures and the minutes <u>as written</u> used do not show a different process for MH/SUD drugs from M/S drugs, and no separate policies as procedures exist for MH/SUD drugs. The meeting minutes reveal that no separate meetings occur to vote on decision about MH/SUD drugs. All drugs are voted on using the same process for MH/SUD and M/S drugs. Factors and sources used were <u>not explicit</u> in all policies and procedures and minutes reviewed, however no deviations from factors used were noted in the minute meetings or policies and procedures, and examples of decisions did not show evidence that more restrictive decisions are being made.

Formulary Review Committee (FRC) is an internal CVS Caremark committee that makes business recommendations to the P&T Committee, as written in the formulary management policy based on factors utilization trends and/or drug spend, client cost, applicable manufacturer agreements, impact of generic drugs and drugs designated to become OTC, brand and generic pipeline, client mix (line of business), plan member disruption. Any drug product must first be deemed safe and effective by the P&T Committee before it is considered eligible for inclusion on a CVS Caremark Formulary, and that any recommendations made by the FRC must be approved by the P&T Committee before implementation. The National P&T Committee reviews and approves all inclusions or exclusions to the formulary. The FRC meets a minimum of 10 times per year and on an ad hoc basis to meet emergent business needs. The FRC meeting agenda is set in advance based on previous open action items and/or requests received since the prior meeting and are electronically distributed to the committee members. Recommendations for additions and deletions are voted on by FRC and then forwarded to the National P&T Committee for final review and approval. All CVS Caremark formularies are submitted to and approved by the National P&T Committee. The P&T Committee reviews all standard formularies annually. The FRC votes on bringing forth business formulary recommendations to the P&T Committee.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

This internal review determined that the Committee members were comprised of comparable experts for MH/SUD conditions and medical/surgical conditions, and that such experts evaluated and applied the factors in a comparable manner for tiering, specialty designation.

The meeting minutes reveal that no separate meetings occur to vote on decision about MH/SUD drugs vs. M/S drugs. Examination of the past two years FRC Meeting minutes revealed that no different committee members were used in decisions for MH/SUD drugs from M/S drugs, and factors used brand/generic status, pipeline new to market information, line of business (commercial, Medicare part D, etc.), information found in FDA approved drug labeling (drug class, category, brand name, dosage form, etc.) are explicit in the minutes, and are not different for MH/SUD drugs than for M/S drugs. The factors availability of therapeutic alternatives and cost effectiveness and potential impact on members, are not explicit in

the FRC minutes. Nevertheless, decisions about MH/SUD drugs do not have a different process from M/S drugs or reached more restrictive decisions. For example, on minutes dated 01/06/2022 an FRC decision was made to bring forth a business formulary recommendation to P&T Committee about adding new SUD naloxone spray generic launch to tier 1 for ACF and SOO formularies, the same decision was made for the M/S drug adapalene-benzoyl peroxide gel due to a generic launch. Additionally, on minutes dated 04/06/2022 an FRC decision was made to bring forth a business formulary recommendation to P&T Committee about adding new MH drug LOREEV XR cap to tier 3, and the same decision was made for new M/S drug orphenadrine, aspirin, and caffeine combination tab to tier 3.

Factors	SUD Drug	M/S Drug
		Sources for adapalene-benzoyl peroxide gel launch add to Tier 1
Brand or generic status of the drug	naloxone hydrochloride nasal spray inhalant (nih.gov)	DailyMed - ADAPALENE AND BENZOYL PEROXIDE gel (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?seti d=05babd5f-18ab-4646-8962-cb000ed0f9a8
Impact of generic drugs or drugs designated to become available over-the-counter	naloxone hydrochloride nasal spray inhalant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?seti d=05babd5f-18ab-4646-8962-cb000ed0f9a8
Brand and generic pipeline	Pipeline website generic launch announced: https://www.us.sandoz.com/news/media-releases/sandoz- launches-authorized-generic-narcan-naloxone-	Note this drug was not OTC in 2021. Pipeline website generic launch announced: https://www.businesswire.com/news/home/20211201005 573/en/
Line of business	Commercial	Commercial
Availability of therapeutic alternatives		Available therapeutic drugs information is found at: Journal of the American Academy of Dermatology - Guidelines of care for the management of acne vulgaris

		https://www.jaad.org/article/S0190-9622(15)02614- 6/fulltext
Indication for use and cost (cost-effectiveness)	Generic relative cost is lower than brand	Generic relative cost is lower than brand
		This is a new drug. The decision was to add to formulary as preferred, the impact is not negative since this offers another therapeutic option to many existing ones.

The meeting minutes reveal that no separate meetings occur to vote on decision about MH/SUD drugs vs. M/S drugs. Examination of the past two years P&T Committee minutes revealed no different committee members were used in decisions for MH/SUD drugs from M/S drugs, and factors used brand/generic status, pipeline new to market information, line of business (commercial, Medicare part D, etc.), information found in FDA approved drug labeling (drug class, category, brand name, dosage form, etc.) are explicit in the minutes, and are not different for MH/SUD drugs than for M/S drugs. For example, in P&T Committee minutes dated 6/2/2021 a decision was made to add MH drug Qelbree (viloxazine ER) oral capsules to the formularies with a non-preferred status. There was a note about the rationale for a decision about this drug stating the generic atomoxetine and/or guanfacine ER. On the same minutes, a decision was made to add the M/S drug Zegalogue (dasiglucagon) SC injection at the non-preferred Brand Specialty tier. The minutes indicate that the same clinical pharmacist with a Pharm D provided an overview of the drugs to the committee including FDA Approved indications, efficacy and safety information, clinical trials and clinical rationale in supporting materials. Comments about the MH drug was made by an MD Psychiatry Specialist and a MD Pediatrics Specialist; a comparable MD -PhD in Endocrinology Specialist provided comments about the M/S drug. The factors considered were that both these drugs are brand and do not have a generic or OTC version available, there is no pipeline information available from the manufacturers, the line of business is the same (commercial) for both drugs, clinical comments from the comparable credentialled physicians considered alternative therapies in the a comparable manner, and not comment was more stringent because a drug was used for mental health, cost related factors were not considered by P&T Committee and the impact on members was similar, since the decision was the same, to add to a

The sources of information are not explicit in the minutes but the PBM clinician analyzing the decision can find the following information consistent with the sources and standards as described in the process:

Factors	_ ()	Sources for Zegalogue (dasiglucagon) SC injection Medical/Surgical Drug
Brand or generic status of the drug	capsule, extended release (nih.gov)	DailyMed - ZEGALOGUE- dasiglucagon injection, solution (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set id=14704879-872c-4967-8779-04a3bbdfb4e6
Impact of generic drugs or drugs designated to become available over-the-counter	 DailyMed - QELBREE- viloxazine hydrochloride capsule, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set id=aedf408d-0f84-418d-9416-7c39ddb0d29a 	 DailyMed - ZEGALOGUE- dasiglucagon injection, solution (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.c fm?setid=14704879-872c-4967-8779- 04a3bbdfb4e6
	 OTC - Over The Counter (fda.gov) https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfivd/search.cfm 	 OTC - Over The Counter (fda.gov) https://www.accessdata.fda.gov/scripts/cdrh/cfdoc s/cfivd/search.cfm
Brand and generic pipeline	*	Pipeline website: https://www.novonordisk.com/science-and- technology/r-d-pipeline.html
Line of business	Commercial	Commercial
Availability of therapeutic alternatives	ç ,	The comment in minutes considered the availability of other brand and generics stating that this drug is a positive ready-to-use product rather than products that must be reconstituted, and having the benefit of long shelf live, and patients needed less frequent refills advantages.
Indication for use and cost (cost-effectiveness)	This factor is not considered by the P&T Committee.	This factor is not considered by the P&T Committee.

Potential impact on members	e	This is a new drug. The decision was to add to
i otentiai impaet on memoers	formulary as non-preferred, the impact is not negative	formulary as non-preferred, the impact is not negative
	since this offers another therapeutic option to many	since this offers another therapeutic option to many
	existing ones.	existing ones.

According to their policy, the National Pharmacy and Therapeutics Committee (P&T Committee) is an independent group of clinical experts that objectively appraises and evaluates drugs to be considered for the CVS Caremark National Formulary and the CVS Caremark formularies. According to the Formulary Development and Management at CVS Caremark white paper, the voting members on the P&T committee are not employees of CVS Caremark. According to the P&T Committee policy, the P&T Committee meets on a regular basis and not less frequently than on a quarterly basis; if an emergent issue exists that needs to be reviewed between regularly scheduled meetings, an ad hoc meeting may be convened or an email vote taken; all P&T Committee decisions are documented in writing; excluded from attendance are any product sponsor representative. The P&T Committee votes on adopting formulary recommendations.

Specialty Designation: Comparative analyses demonstrating comparability and no more stringency in application of factors as written was performed by PBM Clinicians via a review of written materials, power point presentation about the PTEC process, past two years committee minutes.

This internal review determined that the Committee members were comprised of comparable experts for MH/SUD conditions and medical/surgical conditions, and that such experts evaluated and applied the factors in a comparable manner for specialty designation. The written materials and the minutes as written used do not show a different process for MH/SUD drugs from M/S drugs, and no separate policies as procedures exist for MH/SUD drugs.

The meeting minutes reveal that no separate meetings occur to vote on decision about MH/SUD drugs vs. M/S drugs. All drugs are voted on using the same process for MH/SUD and M/S drugs. Factors and sources used were not explicit in all policies and procedures and minutes reviewed, however there are no deviations from factors used noted in the minute meetings or written material. Examples of decisions did not show evidence that more restrictive decisions are being made. PBM clinician doing the analysis can find the drug-specific sources by searching the same databases indicated as sources.

Examples of decisions made by PTEC include, per Q2-2021 minutes, the designation of the MH drug Zyprexa Relprevv (olanzapine) as not specialty. The factors used were: the risk profile having serious adverse effects if not used properly; the safety and effectiveness drug information source showing a high risk of complications with nonadherence and monitoring required; the restricted distribution based upon REMS and box warning; the dispensing requirements present for mail and retail to not dispense if pharmacy is unable to meet REMS requirements; indication for use the maintenance treatment of schizophrenia in adults. This decision was compared to the decision made by PTEC per Q2-2021 minutes about the designation of the M/S drug Ozurdex (dexamethasone intravitreal implant) as specialty. The factors used were risk profile as the drug having the risk of post-operative complications; safety and effectiveness of the drug having high risk of complications needing coordination of care;

distribution deemed as limited; dispensing requirements needing coordination of care; indication for use as non-infectious uveitis affecting the posterior segment of the eye and for diabetic macular edema.

The sources of information are not explicit in the minutes but the PBM clinician analyzing the decision can find the following information consistent with the sources and standards as described in the process:

Factors	Sources for Zyprexa Relprevv	Sources for Ozurdex
Risk profile	 DailyMed - ZYPREXA RELPREVV- olanzapine pamoate kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm ?setid=f9a73185-88de-4d7b-b3c0-bbf231483241 Zyprexa Relprevv (fda.gov) https://www.fda.gov/drugs/drug-safety-and- availability/risk-evaluation-and-mitigation- strategies-rems 	 DailyMed - OZURDEX- dexamethasone implant (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm ?setid=4b204f44-6e8a-4d17-803c-268f0b04679f No REMS found searching the Approved Risk Evaluation and Mitigation Strategies (REMS) (fda.gov) https://www.accessdata.fda.gov/scripts/cder/rems/in dex.cfm
Safety and effectiveness	Zyprexa Relprevv - olanzapine pamoate kit medication guide https://pi.lilly.com/us/zyprexa_relprevv_medguide.pdf	See patient education found at OZURDEX® Resources for Your Practice OZURDEX® for HCPs https://hcp.ozurdex.com/resources
Indication for use and cost	 DailyMed - ZYPREXA RELPREVV- olanzapine pamoate kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm ?setid=f9a73185-88de-4d7b-b3c0-bbf231483241 Cost is found in internal database to be greater than olanzapine generic tablets and to other drugs for schizophrenia. 	?setid=4b204f44-6e8a-4d17-803c-268f0b04679f
Route of administration or delivery systems	DailyMed - ZYPREXA RELPREVV- olanzapine pamoate kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set id=f9a73185-88de-4d7b-b3c0-bbf231483241	DailyMed - OZURDEX- dexamethasone implant (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set id=4b204f44-6e8a-4d17-803c-268f0b04679f

	DailyMed - ZYPREXA RELPREVV- olanzapine	DailyMed - OZURDEX- dexamethasone implant
Dispensing requirements	pamoate kit (nih.gov)	(nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?set
	id=f9a73185-88de-4d7b-b3c0-bbf231483241	id=4b204f44-6e8a-4d17-803c-268f0b04679f

Methodology used for in operations analysis Formulary Tiering and Design:

A PBM analyst using a drug coverage extract followed these steps:

- Drugs were grouped into MH, SUD and MED/SURG categories.
- Drugs were organized into formulary tier groups.
- Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration.
- Counts of drugs and percentages on each formulary tier were summarized.
- Percentages of drugs with preferred status were summarized.

Qualitative assessment was done to identify if less percent of MH/SUD drugs were available <u>overall</u> in preferred tiers (not by tier). Only if such result was present, further analysis was done of how the decisions were made, aiming to identify any possible more stringent use of the factors in the decision-making process.

Quality assurance was performed by another PBM clinician looking at formulary data after the analysis tables were generated, and spot checking the tables to make sure the counting of drugs was done accurately and correlate with the original drug coverage extract.

Methodology used for in operations analysis Specialty Drug designation:

A PBM analyst using a drug coverage extract followed these steps:

- Drugs were grouped into MH, SUD and MED/SURG categories.
- Drugs were organized into formulary tier groups.
- Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration
- Counts of drugs with Specialty drug designation and percentages with Specialty drug designation compared to total drug count on each formulary tier were summarized.
- Percentage of drugs with Specialty drug designation in the category was summarized.

Qualitative assessment was done to identify if more percent of MH/SUD drugs were designated <u>overall</u> as Specialty (not by tier). Only if such result was present, further analysis was done of how the decisions were made, aiming to identify any possible more stringent use of the factors in the decision-making process.

Quality assurance was performed by another PBM clinician looking at formulary data after the analysis tables were generated, and spot checking the tables to make sure the counting of drugs was done accurately and correlate with the original drug coverage extract. MD-Instructions for MHPAEA NQTL Analysis Report and Data Report (8-6-21).pdf (adobe.com)

Methodology data for 2021 requests matched by drug GPI to the drug list was reviewed. Quality control of the data by a PBM pharmacist found that 15% of the prior authorizations processed did not match GPI. These non-matching GPIs were also reviewed and are here reported, since they did not match due to the drug not being present in the drug list.

There are no SUD drugs being denied.

Only one drug in MH was found to be denied for non-covered: Viibryd (vilazodone)

Formulary Tiering and Design and Specialty Drug designation:

FORMULARY TIERING FOR: Advanced Control Formulary 2021 Plan - Aetna

- Tier 1 = Preferred Generics
- Tier 2 = Preferred Brands
- Tier 3 = Non-Preferred Brands and Generics
- Tier 4 = Preferred Specialty
- Tier 5 = Non-Preferred Specialty

	FORMULARY TIERING ANALYSIS							
	Plan: State of MD -	AETNA	A - Adv	anced C	Control 1	F <mark>ormul</mark> a	nry - 2021	
Category Analysis								
Makall	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	% Preferred**
Medical / Surgical	Drug Count by Tier	966	206	794	219	188	2,373	58.6%
Surgitur	% of Drug Count per Tier	40.7%	8.7%	33.5%	9.2%	7.9%		
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	% Preferred**
Mental Health	Drug Count by Tier	119	10	38	0	6	173	74.6%
meann	% of Drug Count per Tier	68.8%	5.8%	22.0%	0.0%	3.5%		
Substance	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	% Preferred**
Use	Drug Count by Tier	9	1	7	1	1	19	57.9%
Disorder	% of Drug Count per Tier	47.4%	5.3%	36.8%	5.3%	5.3%		

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration ** Preferred Tier includes: Tier 1 preferred generics, Tier 2 preferred brands and Tier 4 preferred specialty

Comparative Analysis for formulary tier designation FOR: Advanced Control Formulary 2021 Plan - Aetna

When the factors for formulary tier designation are considered consistently across all drugs and drug classes, the outcome shows that there is a higher percentage of drugs covered at preferred formulary tiers in the MH drug category and a comparable percentage in the SUD drug category as compared to the MED/SURG drug category.

- The Medical/Surgical category has 58.6% of the drugs at a preferred formulary tier.
- The Mental Health category has 74.6% of the drugs at a preferred formulary tier.
- The Substance Use Disorder category has 57.9% of the drugs at a preferred formulary tier.

	SPECIALTY DRUG CLASSIFICATION ANALYSIS							
	Plan: State of M	D - AET	ГNA - А	dvance	d Contro	ol Formı	ılary - 2021	
	Category	Analysis						
	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Medical / Surgical	Specialty Drug Count by Tier	54	26	37	213	179	509	21.5%
Surgical	% of Specialty Drugs per Tier	10.6%	5.1%	7.3%	41.8%	35.2%		
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Mental Health	Specialty Drug Count by Tier	0	0	0	0	6	6	3.5%
пеани	% of Specialty Drugs per Tier	0.0%	0.0%	0.0%	0.0%	100.0%		
Substance	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Use	Specialty Drug Count by Tier	0	0	0	1	1	2	10.5%
Disorder	% of Specialty Drugs per Tier	0.0%	0.0%	0.0%	50.0%	50.0%		

Specialty Drug designation: Advanced Control Formulary 2021 Plan - Aetna

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

Comparative Analysis for Specialty drug designation Advanced Control Formulary 2021 Plan - Aetna

When the factors for Specialty drug designation are considered consistently across all drugs and drug classes, the outcome shows that the MH and SUD drug categories have a lower percentage of drugs designated as a Specialty drug compared to the MED/SURG drug category.

- The Medical/Surgical category has 21.5% of the drugs with a Specialty drug designation.
 - The drugs in the MED/SURG drug category with Specialty drug designation on Tier 1, Tier 2, and Tier 3 antiretroviral drugs used to treat HIV and immunosuppressive agents used with transplants, which are placed on non-specialty formulary tiers.

- The Mental Health category has 3.5% of the drugs with a Specialty drug designation.
 - The 6 drugs in the MH drug category with a Specialty drug designation include: Spravato 56mg, 84mg; Nuplazid caps/tabs; and Hetlioz caps/oral susp.
- The Substance Use Disorder category has 10.5% of the drugs with a Specialty drug designation.
 - o The 2 drugs in the SUD drug category with a Specialty drug designation include: Sublocade and Vivitrol inj

FORMULARY TIERING FOR: Standard Opt-Out Formulary 2021 Plan – Aetna

- Tier 1 = Preferred Generics
- Tier 2 = Preferred Brands
- Tier 3 = Non-Preferred Brands and Generics
- Tier 4 = Specialty
- Tier 5 = Non-Preferred Specialty

	FORMULARY TIERING ANALYSIS							
	Plan: State of MD - AE	TNA - S	Standaro	d Opt-O	ut Form	ulary w	rith ACSF - 2	021
	Category	Analysis						
Madical /	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	% Preferred**
Medical / Surgical	Drug Count by Tier	1,162	269	636	212	188	2,467	66.6%
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	% of Drug Count per Tier	47.1%	10.9%	25.8%	8.6%	7.6%		
	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Drugs	% Preferred**
Mental								
Health	Drug Count by Tier	135	17	36	0	6	194	78.4%
Health .	Drug Count by Tier % of Drug Count per Tier	135 69.6%	17 8.8%	36 18.6%	0	6 3.1%	194	78.4%
Health Substance	с <b>.</b>				Ŷ	-	194 Total Drugs	78.4% % Preferred**
	% of Drug Count per Tier	69.6%	8.8%	18.6%	0.0%	3.1%		

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration ** Preferred Tier includes: Tier 1 generics and Tier 2 preferred brands

#### Comparative Analysis for formulary tier designation for: Standard Opt-Out Formulary 2021 Plan – Aetna

When the factors for formulary tier designation are considered consistently across all drugs and drug classes, the outcome shows that the MH drug category has a higher and the SUD drug category has a comparable percentage of drugs covered at preferred formulary tiers compared to the MED/SURG drug category.

- The Medical/Surgical category has 66.6% of the drugs at a preferred formulary tier.
- The Mental Health category has 78.4% of the drugs at a preferred formulary tier.
- The Substance Use Disorder category has 66.7% of the drugs at a preferred formulary tier.

#### Specialty Drug designation: Standard Opt-Out Formulary 2021 Plan – Aetna

	SPECIALTY DRUG CLASSIFICATION ANALYSIS							
	Plan: State of MD - AETNA - Standard Opt-Out Formulary with ACSF - 2021							
	Analysis							
Medical /	Medical / Surgical	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Surgical	Specialty Drug Count by Tier	54	26	13	206	179	478	19.4%
	% of Specialty Drugs per Tier	11.3%	5.4%	2.7%	43.1%	37.4%		
Mental	Mental Health	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Health	Specialty Drug Count by Tier	0	0	0	0	6	6	3.1%
	% of Specialty Drugs per Tier	0.0%	0.0%	0.0%	0.0%	100.0%		
Substance	Substance Use Disorder	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Total Specialty Drugs	% Specialty
Use Disorder	Specialty Drug Count by Tier	0	0	0	1	1	2	11.1%
Distruct	% of Specialty Drugs per Tier	0.0%	0.0%	0.0%	50.0%	50.0%		

* Note: Drug Count was derived from: Generic Product Indicator (GPI 12) code, Brand/Generic Code, Dosage Form, Drug Name, and Route of Administration

#### Comparative Analysis for Specialty drug designation Standard Opt-Out Formulary 2021 Plan – Aetna

When the factors for Specialty drug designation are considered consistently across all drugs and drug classes, the outcome shows that the MH and SUD categories have a lower percentage of drugs designated as a Specialty drug compared to the MED/SURG category.

- The Medical/Surgical category has 19.4% of the drugs with a Specialty drug designation.
  - The drugs in the MED/SURG drug category with Specialty drug designation on Tier 1, Tier 2, and Tier 3 antiretroviral drugs used to treat HIV and immunosuppressive agents used with transplants, which are placed on non-specialty formulary tiers.
- The Mental Health category has 3.1% of the drugs with a Specialty drug designation.
  - The 6 drugs in the MH drug category with a Specialty drug designation include: Spravato 56mg, 84mg; Nuplazid caps/tabs; Hetlioz caps/oral susp.
- The Substance Use Disorder category has 11.1% of the drugs with a Specialty drug designation.
  - o The 2 drugs in the SUD drug category with a Specialty drug designation include: Sublocade and Vivitrol inj.

# **Tiering Designation**

The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used for counting drugs for a formulary analysis. Assuming that MIA is referring to the Specialty Drug Classification Analysis Table as "the Specialty tables" and to Formulary Tiering Analysis Table as the "non-Specialty tables" are not comparable because Specialty Drug Classification Designation is different from Formulary Tiering. There are drugs that are not designated specialty that are in specialty Tier 4 and 5 and counted in the Formulary Tiering Analysis Table, explaining the higher numbers found in such table. The fact that there are lower amount Specialty M/S than the total, is because there is 54 Tier 1, 26 Tier 2 and 37 Tier 3 M/S drugs designated as specialty in other tiers, and that are also added to Tier 4 and Tier 5 to get to the total, which is 54+26+37+213+179 = 509. The fact that the totals in the SUD and MH tables "correlate" is because there are no MH/SUD drugs with specialty designation placed in non-specialty tiers 1, 2, and 3, that is there are zero Tier 1, zero Tier 2, and zero Tier 3 specialty designated drugs for MH and SUD, that is 0+0+0+0+6 = 6 for MH and 0+0+0+1+1=2 for SUD. Both tables demonstrate that the formulary <u>overall</u> is not placing MH/SUD drugs in greater more restricting numbers in higher non-preferred tiers or designating drugs as specialty in greater more restricting numbers than for M/H drugs.

The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used for counting drugs for a formulary analysis. Assuming that MIA is referring to the Specialty Drug Classification Analysis Table as "the Specialty tables" and to Formulary Tiering Analysis Table as the "non-Specialty tables" are not comparable because Specialty Drug Classification Designation is different from Formulary Tiering. There are drugs that are not designated specialty that are in specialty Tier 4 and 5 and counted in the Formulary Tiering Analysis Table, explaining the higher numbers found in such table. The fact that there are lower amount Specialty M/S than the total, is because there is 54 Tier 1, 26 Tier 2 and 13 Tier 3 M/S drugs designated as specialty in other tiers, and that are also added to Tier 4 and Tier 5 to get to the total, which is 54+26+13+206+179 = 478. The fact that the totals in the SUD and MH tables "correlate" is because there are zero Tier 1, zero Tier 2, and zero Tier 3 drugs for MH and SUD, that is 0+0+0+0+6 = 6 for MH and 0+0+0+1+1=2 for SUD, that is no MH/SUD drugs with specialty designation placed in non-specialty tiers 1, 2, and 3. Both tables demonstrate that the formulary overall is not placing MH/SUD drugs in greater more restricting numbers in higher non-preferred tiers or designating drugs as specialty in greater more restricting numbers than for M/H drugs.]

AETNA	MIA analysis of	Response
response	data not	1
Advanced	discussed/explain	
Control	ed by AETNA	
Formulary –	where the data	
2021 Tiering –	appears to	
preferred tiers	indicate more	
are tier 1, 2	stringency in	
and 4 (generic,	covering branded	
branded and	M/H and SUD	
specialty	medications with	
respectively)	greater focus on	
¥ 0/	use of generics	
	for MH and SUD	
	conditions	
• The	1. Tier 2: Only	1. The MIA Instructions for Step 5 do not describe an exact required methodology that needs to be used
Medical/Surgic	5.3% of SUD and	for counting drugs for a formulary analysis. Our methodology looked at the overall drugs placed on
al category has	5.8% of MH	more accessible preferred positions and did not find a more stringent overall treatment for MH and SUD.
58.6% of the	medications versus	Tier 1 is the lowest copay tier providing the most access to members. 68.8 % of MH drugs and 47.4 % of
drugs at a	8.7% of M/S	SUD drugs are on Tier 1 which is more than the 40.7% for M/S drugs. Tier 2 has one SUD drug
preferred	medications while	Zubsolv ¹ , and 10 MH drugs: Trintellix ² , Perseris ^{,3} , Abilify Maintena Vial ⁴ , Abilify Maintena Pre-Filled
formulary tier.	Tier 1: 47.4%	Syringe ⁴ , Vraylar Caps ⁵ , Vraylar Pack ⁵ , Latuda ⁶ , Vyvanse Caps ⁷ , Vyvanse Chewable ⁷ , Mydayis Caps ⁸ ;
	SUD and 68.8% of	and 206 M/S drugs, for example Biktarvy ⁹ , Soliqua ¹⁰ and Ubrelvy ¹¹ . PBM Clinicians further analyzed
• The Mental	MH medications	the factors used to place these 11 drugs in Tier 2. Findings: all 10 MH plus one SUD drugs and the 3
Health	versus 40.7% of	M/S example drugs are brands ¹⁻¹¹ , none where designated to become available over-the-counter ¹² ,
category has	M/S medications.	relevant pipeline brand or generic drugs in 2021 showed no alternatives available ¹³ , the line of business
74.6% of the		(commercial) did not require that these drugs be placed in a particular tier ¹⁴ , the FDA drug labeling
drugs at a	2. Tier 4: Of the	information did not indicate unique drug information warranting that these drugs should be widely
preferred	medications	available in tier 1 or at higher tiers ¹⁻¹¹ , therapeutic alternative drugs were plentiful and available in tier 1
formulary tier.	considered	already ¹⁵ ; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact
	Specialty (in Tiers	on members did not indicate that these should be placed in tier 1 or other tiers as this was not indicated
• The	4 and 5), none of	in the minutes ¹⁶ . We looked at the following sources to inform each factor:
Substance Use	the 6 MH	1. DailyMed - ZUBSOLV- buprenorphine hydrochloride and naloxone hydrochloride tablet, orally
Disorder	medications was	disintegrating (nih.gov)
category has	preferred	

57.9% of the	compared to		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f5cfcfe-d52b-49e6-8fe4-
drugs at a	53.8% of the 407		550477332dd2
preferred	M/S medications	2.	DailyMed - TRINTELLIX- vortioxetine tablet, film coated (nih.gov)
formulary tier.	considered		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-
	Specialty		1ca97145e838
		3.	DailyMed - PERSERIS- risperidone kit (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4f21b1a-5691-4b14-a56d-651962d06f39
		4.	DailyMed - ABILIFY MAINTENA- aripiprazole kit (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1- ea53fe0b92b6
		5.	DailyMed - VRAYLAR- cariprazine capsule, gelatin coated VRAYLAR- cariprazine kit (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db- bc85c06ff12f
		6.	DailyMed - LATUDA- lurasidone hydrochloride tablet, film coated (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684- e8262a133af8
		7.	DailyMed - VYVANSE- lisdexamfetamine dimesylate capsule VYVANSE- lisdexamfetamine dimesylate tablet, chewable (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45- 3cfa51c1ecad
		8.	DailyMed - MYDAYIS- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate capsule, extended release (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=141a7970-3f06-44ea-9ab7-
			aeece2c085fc
		9.	DailyMed - BIKTARVY- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
			tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b- b0d9-ba3d798be309
		10.	DailyMed - SOLIQUA 100/33- insulin glargine and lixisenatide injection, solution (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f- cb711ed21bcc
		11.	DailyMed - UBRELVY- ubrogepant tablet (nih.gov)
			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab
		12.	OTC - Over The Counter (fda.gov)
			https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm

	3. CVS Health Payor Solutions. Drugs to Watch. Drug Pipeline
	https://payorsolutions.cvshealth.com/tags/drug-pipeline
	4. Per regulatory requirements federal or state as applicable.
1	5. Advanced Control Formulary – 2021 Tier 1 consistent with Clinical guidelines and standards of
	care for each disease accessible via web search or via databases that enable users to execute
	searches across multiple clinical authors. For example,
	https://www.guidelinecentral.com/guidelines/
1	6. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file
2	. The 6 MH drugs placed in the non-preferred Tier 5 are the antidepressants Spravato 56 mg and 86
n	ng, the antipsychotics Nuplazid tablets and capsules, and Hetlioz capsule and the hypnotics Hetlioz LQ
S	uspension. PBM Clinicians further analyzed the factors used to place these 6 drugs in the non-preferred
ti	ier. Findings: all 6 drugs are brands ^{1,2,3} , none where designated to become available over-the-counter ⁴ ,
	elevant pipeline brand or generic drugs in 2021 showed no alternatives available ⁵ , the line of business
	commercial) did not require that these drugs be placed in a particular tier ⁶ , the FDA drug labeling
	nformation did not indicate unique drug information warranting that these drugs should be widely
	vailable in lower tiers ^{1,2,3} , therapeutic alternative drugs were plentiful and available in lower tiers
	lready ⁷ ; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact
	on members did not indicate that these should be placed in lower tiers ⁸ . We looked at the following
	ources to inform each factor:
	. DailyMed - SPRAVATO- esketamine hydrochloride solution (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-
	Odfa3036eaed
2	2. DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet,
	coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-
	9328-46e1ee59f83b
3	5. DailyMed - HETLIOZ- tasimelteon capsule HETLIOZ LQ- tasimelteon suspension (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4a9b63-708e-49e9-8f9b-
	010625443b90
	•. OTC - Over The Counter (fda.gov)
	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm
5	5. cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf
	(cvshealth.com)cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf
	(cvshealth.com)
0	b. Per regulatory requirement (State or Federal as applicable)

7. Advanced Control Formulary – 2021 Tier 1 antidepressants, antipsychotics and hypnotic
alternatives available, and indicated by these sources to be for such treatment:
a. American Psychological Association (APA) Clinical Practice Guideline for the Treatment
of Depression Across Three Age Cohorts. https://www.apa.org/depression-guideline
b. American Psychological Association (APA) Treatment of Patients with Schizophrenia.
https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841
c. American Academy of Sleep Medicine – Pharmacologic Treatment of Chronic Insomnia in
Adults. https://jcsm.aasm.org/doi/10.5664/jcsm.6470
8. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file
PBM Clinicians further analyzed the factors used to place four example drugs of the 407 M/S
medications in Tier 4, to ascertain that the 6 MH drugs placed in the non-preferred Tier 5 are not being
placed more stringently. Examples of M/S drugs are: Ibrance ¹ , Kisqali ² , Kesimpta ³ and Sprycel ⁴ .
Findings: all 4 drugs are brands ¹⁻⁴ , none where designated to become available over-the-counter ⁵ ,
relevant pipeline brand or generic drugs in 2021 showed no alternatives available ⁶ , the line of business
(commercial) did not require that these drugs be placed in a particular tier ⁷ , the FDA drug labeling
information did not indicate unique drug information warranting that these drugs should be widely
available in lower tiers ^{1,2,3,4} , therapeutic alternative drugs were NOT plentiful and available in lower
tiers warranting that they NOT be placed int the highest formulary tier available ⁸ ; utilization trends, plan
sponsor cost, applicable manufacturer agreements and potential impact on members did not indicate that
these should be placed in lower tiers ⁹ . We looked at the following sources to inform each factor:
1. DailyMed - Search Results for ibrance (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibrance&pagesize=200&p age=1
<ol> <li>DailyMed - KISQALI- ribociclib tablet, film coated (nih.gov)</li> </ol>
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-
b181d7be2da8
3. DailyMed - KESIMPTA- of atumumab injection, solution (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a8a3f53-2062-48ff-9dbe-
b939df133ca3
4. DailyMed - SPRYCEL- dasatinib tablet (nih.gov)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-
8a03b7c521df
5. OTC - Over The Counter (fda.gov)
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm

		<ol> <li>cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)</li> <li>Per regulatory requirement (State or Federal as applicable)</li> <li>Advanced Control Formulary – 2021 Tier 1 antidepressants, antipsychotics and hypnotic alternatives consistent with guideline examples found:         <ul> <li>Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example:</li></ul></li></ol>
Standard Opt-	MIA Analysis	
Out Formulary –		
2021		
<ul> <li>The Medical/Surgic al category has 19.4% of the drugs with a Specialty drug Designation.</li> <li>The Mental Health category has 3.1% of the drugs with a Specialty drug Designation.</li> <li>The Substance Use Disorder category has 11.1% of the</li> </ul>	Tier 4: 0% of the 6 Specialty MH medications are preferred while 53.5% (206/385) of M/S Specialty Medications in Tiers 4 and 5 are preferred (in Tier 4)	<ul> <li>The 6 MH drugs placed in the non-preferred Tier 5 are the antidepressants Spravato 56 mg and 86 mg, the antipsychotics Nuplazid tablets and capsules, and Hetlioz capsule and the hypnotics Hetlioz LQ suspension. PBM Clinicians further analyzed the factors used to place these 6 drugs in the non-preferred tier. Findings: all 6 drugs are brands^{1,2,3}, none where designated to become available over-the-counter⁴, relevant pipeline brand or generic drugs in 2021 showed no alternatives available⁵, the line of business (commercial) did not require that these drugs be placed in a particular tier⁶, the FDA drug labeling information did not indicate unique drug information warranting that these drugs should be widely available in lower tiers^{1,2,3}, therapeutic alternative drugs were plentiful and available in lower tiers already⁷; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact on members did not indicate that these should be placed in lower tiers⁸. We looked at the following sources to inform each factor:</li> <li>1. DailyMed - SPRAVATO- esketamine hydrochloride solution (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed</li> <li>2. DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b</li> <li>3. DailyMed - HETLIOZ- tasimelteon capsule HETLIOZ LQ- tasimelteon suspension (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4a9b63-708e-49e9-8f9b-010625443b90</li> </ul>

drugs with a	4. OTC - Over The Counter (fda.gov)
Specialty drug	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm
Designation.	5. cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)
_	6. Per regulatory requirement state or federal as applicable
	7. Standard Opt Out – 2021 Tier 1 antidepressants, antipsychotics and hypnotic alternatives and
	indicated by these sources to be for such treatment:
	a. American Psychological Association (APA) Clinical Practice Guideline for the Treatment
	of Depression Across Three Age Cohorts. https://www.apa.org/depression-guideline
	b. American Psychological Association (APA) Treatment of Patients with Schizophrenia.
	https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841
	c. American Academy of Sleep Medicine – Pharmacologic Treatment of Chronic Insomnia in
	Adults. https://jcsm.aasm.org/doi/10.5664/jcsm.6470
	8. utilization trends, plan sponsor cost, applicable manufacturer agreements on file
	PBM Clinicians further analyzed the factors used to place some example drugs of the 206 M/S
	medications in Tier 4, to ascertain that the 6 MH drugs placed in the non-preferred Tier 5 are not being
	placed more stringently. Examples are: Ibrance ¹ , Kisqali ² , Kesimpta ³ and Sprycel ⁴ . Findings: all 4 drugs
	are brands ^{1,2,3,4} , none where designated to become available over-the-counter ⁵ , relevant pipeline brand or
	generic drugs in 2021 showed no alternatives available ⁶ , the line of business (commercial) did not
	require that these drugs be placed in a particular tier ⁷ , the FDA drug labeling information did not
	indicate unique drug information warranting that these drugs should be widely available in lower
	tiers ^{1,2,3,4} , therapeutic alternative drugs were NOT plentiful and available in lower tiers warranting that
	they NOT be placed int the highest formulary tier available ⁸ ; utilization trends, plan sponsor cost,
	applicable manufacturer agreements and potential impact on members did not indicate that these should
	be placed in lower tiers ⁹ . We looked at the following sources to inform each factor:
	1. DailyMed - Search Results for ibrance (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibrance&pagesize=20
	0&page=1
	2. DailyMed - KISQALI- ribociclib tablet, film coated (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-
	b181d7be2da8
	3. DailyMed - KESIMPTA- of a unumab injection, solution (nih.gov)
	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a8a3f53-2062-48ff-9dbe-
	b939df133ca3

	DailyMed - SPRYCEL- dasatinib tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2- 8a03b7c521df OTC - Over The Counter (fda.gov)
	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf
	(cvshealth.com)
	Per regulatory requirement state or federal as applicable
8.	consistent with guideline examples found:
	<ul> <li>Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example:</li> </ul>
	b. https://www.guidelinecentral.com/guidelines/
9.	c. National Comprehensive Cancer Network https://www.nccn.org/guidelines/category_1 utilization trends, plan sponsor cost, applicable manufacturer agreements are on file

AETNA	MIA analysis of	Responses
<b>Response in</b>	data not	
Step 5	discussed/	
Advanced	explained by	
Control	<b><u>AETNA</u></b> where	
Formulary -	the data appear	
2021	to indicate that	
	more stringency	
	in covering MH	
	medications at	
	preferred tier	
• The	1.Tier 4: 0% of	The 6 MH drugs placed in the non-preferred Tier 5 are the antidepressants Spravato 56 mg and 86 mg,
Medical/Surgica	the 6 Specialty	the antipsychotics Nuplazid tablets and capsules, and Hetlioz capsule and the hypnotics Hetlioz LQ
l category has	MH medications	suspension. PBM clinicians further analyzed the factors used to place these 6 drugs in the non-preferred
21.5% of the	are preferred	tier. Findings: all 6 drugs are brands ^{1,2,3} , none where designated to become available over-the-counter ⁴ ,

drugs with a	while 54.3%	relevant pipeline brand or generic drugs in 2021 showed no alternatives available ⁵ , the line of business
Specialty drug	(213/392) of M/S	(commercial) did not require that these drugs be placed in a particular tier ⁶ , the FDA drug labeling
Designation.	Specialty	information did not indicate unique drug information warranting that these drugs should be widely
	Medications in	available in lower tiers ^{1,2,3} , therapeutic alternative drugs were plentiful and available in lower tiers
• The Mental	Tiers 4 and 5 are	already ⁷ ; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact
Health category	preferred (in Tier	on members did not indicate that these should be placed in lower tiers ⁸ . We looked at the following
has 3.5% of the	4)	sources to inform each factor:
drugs with a		1. DailyMed - SPRAVATO- esketamine hydrochloride solution (nih.gov)
Specialty drug		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-
Designation.		0dfa3036eaed
		2. DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet,
The Substance		coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-
Use Disorder		9328-46e1ee59f83b
category has		3. DailyMed - HETLIOZ- tasimelteon capsule HETLIOZ LQ- tasimelteon suspension (nih.gov)
10.5% of the		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4a9b63-708e-49e9-8f9b-
drugs with a		010625443b90
Specialty drug		4. OTC - Over The Counter (fda.gov)
Designation.		https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm
		5. cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)
		6. Per regulatory requirement state or federal as applicable
		7. Advanced Control Formulary – 2021 Tier 1 antidepressants, antipsychotics and hypnotic
		alternatives consistent with clinical guidelines and standards of care for each disease are accessible
		via web search or via databases that enable users to execute searches across multiple clinical
		authors.
		a. American Psychological Association (APA) Clinical Practice Guideline for the
		Treatment of Depression Across Three Age Cohorts. https://www.apa.org/depression-
		guideline
		b. American Psychological Association (APA) Treatment of Patients with Schizophrenia.
		https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841
		c. American Academy of Sleep Medicine – Pharmacologic Treatment of Chronic
		Insomnia in Adults. https://jcsm.aasm.org/doi/10.5664/jcsm.6470
		8. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file

<ul> <li>PBM clinicians further analyzed the factors used to place some example drugs of the 213 M/S medications in Tier 4, to ascertain that the 6 MH drugs placed in the non-preferred Tier 5 are not being placed more stringently. Examples are: Ibrance¹, Kisqali², Kesimpta³ and Sprycel⁴. Findings: all 4 drugs are brands^{1,2,3,4}, none where designated to become available over-the-counter⁵, relevant pipeline brand or generic drugs in 2021 showed no alternatives available⁶, the line of business (commercial) did not require that these drugs be placed in a particular tier⁷, the FDA drug labeling information did not indicate unique drug information waranting that these drugs should be widely available in lower tiers^{1.4}, therapeutic alternative drugs were NOT plentiful and available in lower tiers waranting that they NOT be placed in the highest formulary tier available⁸, utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact on members did not indicate that these should be placed in lower tiers⁹. We looked at the following sources to inform each factor: <ol> <li>DailyMed - Search Results for ibrance (nih.gov)</li> <li>https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=ibrance&amp;pagesize=20 0&amp;page=1</li> </ol> </li> <li>DailyMed - KISQALL - ribociclib tablet, film coated (nih.gov)</li> <li>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaaef94-f3f5-4367-8ea2-b181d7be2da8</li> <li>DailyMed - SPRYCEL- dasatinib tablet (nih.gov)</li> <li>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df</li> <li>OTC - Over The Counter (fda.gov)</li> <li>https://www.accesdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm</li> <li>cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)</li> <li>Per regulatory requirements state or federal as applicable.</li> <li>Advanced Control Formulary – 2021 Tier 1 antidepressants, antipsychotics and hypnotic alternatives consistent wit</li></ul>
via databases that enable users to execute searches across multiple clinical authors. For example: a. https://www.guidelinecentral.com/guidelines/
b. National Comprehensive Cancer Network https://www.nccn.org/guidelines/category_1

		9. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file
Standard Opt- Out Formulary – 2021	MIA Analysis	
<ul> <li>The Medical/Surgica l category has 19.4% of the drugs with a Specialty drug Designation.</li> <li>The Mental Health category has 3.1% of the drugs with a Specialty drug Designation.</li> <li>The Substance Use Disorder category has 11.1% of the drugs with a Specialty drug Designation.</li> </ul>	Tier 4: 0% of the 6 Specialty MH medications are preferred while 53.5% (206/385) of M/S Specialty Medications in Tiers 4 and 5 are preferred (in Tier 4)	<ul> <li>The 6 MH drugs placed in the non-preferred Tier 5 are the antidepressants Spravato 56 mg and 86 mg, the antipsychotics Nuplazid tablets and capsules, and Hetlioz capsule and the hypnotics Hetlioz LQ suspension. PBM clinicians further analyzed the factors used to place these 6 drugs in the non-preferred tier. Findings: all 6 drugs are brands^{1,2,3}, none where designated to become available over-the-counter⁴, relevant pipeline brand or generic drugs in 2021 showed no alternatives available⁵, the line of business (commercial) did not require that these drugs be placed in a particular tier⁶, the FDA drug labeling information did not indicate unique drug information warranting that these drugs should be widely available in lower tiers^{1,2,3}, therapeutic alternative drugs were plentiful and available in lower tiers already⁷; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact on members did not indicate that these should be placed in lower tiers⁸. We looked at the following sources to inform each factor: <ol> <li>DailyMed - SPRAVATO- esketamine hydrochloride solution (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed</li> <li>DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b</li> <li>DailyMed - HETLIOZ- tasimelteon capsule HETLIOZ LQ- tasimelteon suspension (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=249b63-708e-49e9-8f9b-010625443b90</li> <li>OTC - Over The Counter (fda.gov) https://dcfh/cfdocs/cfivd/search.cfm</li> <li>cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)</li> <li>Per regulatory requirement state or federal as applicable</li> <li>Standard Opt Out – 2021 Tier 1 antidepressants, antipsychotics and hypnotic alternatives consistent with clinical guidelines and standards of ca</li></ol></li></ul>

<ul> <li>a. American Psychological Association (APA) Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. https://www.apa.org/depression- guideline</li> <li>b. American Psychological Association (APA) Treatment of Patients with Schizophrenia. https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841</li> <li>c. American Academy of Sleep Medicine – Pharmacologic Treatment of Chronic Insomnia in Adults. https://jcsm.aasm.org/doi/10.5664/jcsm.6470</li> <li>8. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file</li> </ul>
<ul> <li>PBM clinicians further analyzed the factors used to place some example drugs of the 206 M/S medications in Tier 4, to ascertain that the 6 MH drugs placed in the non-preferred Tier 5 are not being placed more stringently. Examples are: Ibrance¹, Kisqali², Kesimpta³ and Sprycel⁴. Findings: all 4 drugs are brands^{1,2,3,4}, none where designated to become available over-the-counter⁵, relevant pipeline brand or generic drugs in 2021 showed no alternatives available⁶, the line of business (commercial) did not require that these drugs be placed in a particular tier⁷, the FDA drug labeling information did not indicate unique drug information warranting that these drugs should be widely available in lower tiers^{1,2,3,4}, therapeutic alternative drugs were NOT plentiful and available in lower tiers warranting that they NOT be placed int the highest formulary tier available⁸; utilization trends, plan sponsor cost, applicable manufacturer agreements and potential impact on members did not indicate that these should be placed in lower tiers⁹. We looked at the following sources to inform each factor: <ul> <li>1. DailyMed - Search Results for ibrance (nih.gov)</li> <li>https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=ibrance&amp;pagesize=20 0&amp;page=1</li> </ul> </li> <li>2. DailyMed - KISQALI- ribociclib tablet, film coated (nih.gov)</li> <li>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8</li> <li>3. DailyMed - KESIMPTA- ofatumumab injection, solution (nih.gov)</li> </ul>
<ul> <li>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a8a3f53-2062-48ff-9dbe- b939df133ca3</li> <li>4. DailyMed - SPRYCEL- dasatinib tablet (nih.gov) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2- 8a03b7c521df</li> <li>5. OTC - Over The Counter (fda.gov) https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/search.cfm</li> </ul>

<ol> <li>cvs-health-payor-solutions-specialty-pipeline-drugs-to-watch-q1-to-q2-2021.pdf (cvshealth.com)</li> <li>Per regulatory requirement state or federal as applicable</li> <li>Standard Opt Out Formulary – 2021 Tier 1 antidepressants, antipsychotics and hypnotic alternatives consistent with guideline examples found: Clinical guidelines and standards of care for each disease are accessible via web search or via databases that enable users to execute searches across multiple clinical authors. For example: a. https://www.guidelinecentral.com/guidelines/</li> </ol>
<ul> <li>a. https://www.guidennecentral.com/guidennes/</li> <li>b. National Comprehensive Cancer Network https://www.nccn.org/guidelines/category_1</li> <li>9. utilization trends, plan sponsor cost, applicable manufacturer agreements are on file</li> </ul>

Findings and Conclusion of Formulary Tiering and Design: The basis for the conclusion that both as written and in operation, the processes, evidentiary standards, and factors used to impose the Formulary Tier Designation NQTL on MH/SUD drugs are comparable to and applied no more stringently than the processes, evidentiary standards, and factors used to impose the NQTL on M/S drugs, is the analysis findings as follows. As written the analyzed decisions about MH/SUD drugs do not have a different process from M/S drugs or reached more restrictive decisions. Based on minutes FRC decision was made to bring forth a business formulary recommendation to P&T Committee about adding new generic launch for SUD drug tier 1 for ACF and SOO formularies, the same decision was made for the M/S generic launch. Additionally, on minutes FRC decision was made to bring forth a business formulary recommendation to P&T Committee about adding new MH brand drug to tier 3, and the same decision was made for new M/S brand drug to tier 3. Also, the analysis of the factors and the level of evidence for the sources used to inform the factors, as written in the policies show a consistent application process arrives at the same decision. The sources of information are not explicit in the minutes but the PBM clinician analyzing the decision can find the sources and standards as described in the process and assess that the process was followed consistently. Similarly, decisions made by P&T Committee about new brand drugs were consistent, adding these new brand drugs as non-preferred when there was evidence of multiple alternative options already available in the formulary; also, the clinical comments made by physicians of comparable credentials for MH/SUD as compared to M/S drugs were evident. Although the sources were not explicit in the P&T minutes, PBM clinicians can find the sources and assess that they were used no more restrictively to make decisions about MH/SUD as compared to M/S drugs. The sources are different for each drug because the information must be drug specific. In operations the overall results and comparison showing greater percentage of drugs are preferred in each MH, SUD and M/S. Note: more drugs in preferred tiers means more options for the enrollees:

Advanced Control Formulary 2021 Plan - Aetna preferred tier

- The Medical/Surgical category has 58.6%
- The Mental Health category has 74.6%
- The Substance Use Disorder category has 57.9%

Standard Opt-Out Formulary 2021 Plan - Aetna preferred tier

- The Medical/Surgical category has 66.6% of the drugs at a preferred formulary tier.
- The Mental Health category has 78.4% of the drugs at a preferred formulary tier.
- The Substance Use Disorder category has 66.7% of the drugs at a preferred formulary tier.

Also, the analysis of the factors and the level of evidence used for the sources used to inform the factors, in operations show a consistent process. No unique process exists that is different in any way to apply the factors; sources used are different and drug/disease-specific.

- ACF Tier 2: Only 5.3% of SUD and 5.8% of MH medications versus 8.7% of M/S medications while Tier 1: 47.4% SUD and 68.8% of MH medications versus 40.7% of M/S medications
- ACF Tier 4: Of the medications considered Specialty (in Tiers 4 and 5), none of the 6 MH medications was preferred compared to 53.8% of the 407 M/S medications considered Specialty
- SOO Tier 2: Only 5.6% of SUD and 8.8% of MH medications versus 10.9% of M/S medications while Tier 1: 55.6% SUD and 69.6% of MH medications versus 47.1% of M/S medications.
- SOO Tier 4: Of the medications considered Specialty (in Tiers 4 and 5), none of the 6 MH medications was preferred compared to 53% of the 400 M/S medications considered Specialty

Further analysis as requested by MIA was added in Step 5 and did not reveal that the process is followed more stringently. The reason for the difference is that not as many available therapeutic alternative drugs exist in lower tiers for those diseases, warranting that they NOT be placed int the highest formulary tier available. The process, and evidentiary standards used to apply formulary design and tiering to mental health or substance use disorder are the same, and are applied no more stringently than the specialty drug designation decided for drugs used to treat medical or surgical disorders both as written and in operations. This analysis was done by PBM Clinicians, they are pharmacists, and they made no recommendations regarding NQTLs applied to MH/SUD and M/S drugs. No variation in the use of PBM Clinicians for MH/SUD compared to M/S NQTL analyses.

**Findings and Conclusion for non-formulary coverage requests:** PBM pharmacists looking at the data for coverage requests for drugs not covered in the formulary found that for ACF the number of MH/SUD totaling 10 requests for coverage is too small to draw conclusions of non-parity. However, a deeper dive into what types of drugs where denied (only 3 drugs) showed that the drugs all have therapeutic alternatives available in the formulary. For SOO no MH/SUD drugs had requests received.

**Findings and Conclusion for Specialty Designation:** The basis for the conclusion that both as written and in operation, the processes, evidentiary standards, and factors used to impose the Specialty Drug Designation NQTL on MH/SUD drugs are comparable to and applied no more stringently than the processes, strategies, evidentiary standards, and factors used to impose the NQTL on M/S drugs is the analysis findings as follows. The written materials and minutes analysis revealed that <u>as written</u> factors and standards used for drugs designated as a Specialty drug are the same and are not used differently or more restrictively based on a drug being for M/S or MH/SUD treatment. The review and comparison

of the decisions made for the example drugs Zyprexa Relprevv (MH) and Ozurdex (M/S) showed that the sources are different for each drug because the information must be drug specific; however, the sources are found using the same databases and evaluated using the same standards and sources are comparable and standardized regarding the information found therein. The sources of information are not explicit in the minutes but the PBM clinician analyzing the decision can find the sources and standards as described in the process and assess that the process was followed consistently. The source for Zyprexa Relprevv (MH) is the FDA labeling for that drug and its medication guide. The source for Ozurdex (M/S) is the FDA labeling for that drug and patient information resources found for that drug. No more stringent sources are used, and these sources are comparable. The MH drug Zyprexa Relprevv was designated as not specialty, and the drug Ozurdex was designated as specialty. No other MH drugs have decisions that occurred during the previous two years of minutes. No SUD drugs have decisions that occurred during the previous two years of minutes. No succe for during the previous two years of minutes. The process, and evidentiary standards used to apply specialty designation to mental health or substance use disorder are the same and are applied no more stringently than the specialty drug designation decided for drugs used to treat medical or surgical disorders. In operations an analysis of the formulary extract demonstrated that overall, there is a lower percentage of drugs designated as a Specialty drug in the MH and SUD drugs compared to the MED/SURG drugs. Overall, there are no more drugs designated as specialty in MH and SUD compared to MED/SURG drugs.

Advanced Control Formulary 2021 Plan - Aetna Specialty drug designation

- The Medical/Surgical category has 21.5%
- The Mental Health category has 3.5%
- The Substance Use Disorder category has 10.5%

Standard Opt-Out Formulary 2021 Plan – Aetna Specialty drug designation

- The Medical/Surgical category has 19.4%
- The Mental Health category has 3.1%
- The Substance Use Disorder category has 11.1%
- ACF Tier 4: 0% of the 6 Specialty MH medications are preferred while 54.3% (213/392) of M/S Specialty Medications in Tiers 4 and 5 are preferred (in Tier 4)
- SOO Tier 4: 0% of the 6 Specialty MH medications are preferred while 53.5% (206/385) of M/S Specialty Medications in Tiers 4 and 5 are preferred (in Tier 4)

By investigation of the tier placement of MH drugs in Tier 5 vs Tier 4 revealed that factors, standards are the same and sources are drug specific, and standard based on FDA labeling. Further analysis did not reveal that the process is followed more stringently. The process, factors and standards were not used more restrictively to designate more MH drugs as specialty or to place them on Tier 5 instead of Tier 4. The reason for the difference is that more drugs are available in lower tiers for MH conditions than are available to compared M/S example drugs. The process, and evidentiary standards used to apply specialty designation to mental health or substance use disorder are the same, and are applied no more stringently than the specialty drug designation decided for drugs used to treat medical or surgical disorders both as written and in operations. Aetna delegates the Specialty Drug designation to CVS Caremark, except for the purpose of applying a copay or restricting distribution at a specialty

pharmacy. This analysis was done by PBM Clinicians, they are pharmacists, and they made no recommendations regarding NQTLs applied to MH/SUD and M/S drugs. No variation in the use of PBM Clinicians for MH/SUD compared to M/S NQTL analyses.

#### 8. <u>Case Management</u>

Case Management is not an NQTL. This section is not applicable. NQTLs are treatment limitations that are not numerical in nature but otherwise may limit the scope or duration of MH/SUD benefits. Case Management is a voluntary service to our members. There are no adverse consequences to the member if a member decides not to enroll or use information provided.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

## 9. Process for Assessment of New Technologies

The process for assessment of new technologies is described in 1. Medical Necessity.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

# 10. Standards for Provider Credentialing and Contracting

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

Med/Surg Benefits	MH/SUD Benefits
Covered services: Applies to all Med/Surg and MH/SUD benefits	Covered Services: Applies to all MH/SUD benefits delivered in-
delivered in-network, except pharmacy.	network, except pharmacy.
Triggers, Timelines, and Forms: MH/SUD and M/S providers	Triggers, Timelines, and Forms: MH/SUD and M/S providers
wishing to participate in Aetna's networks submit an application using the Maryland Uniform Credentialing Form. Aetna's credentialing staff	wishing to participate in Aetna's networks submit an application using the Maryland Uniform Credentialing Form. Aetna's credentialing staff
verify the information using CMS-approved primary sources and the	verify the information using CMS-approved primary sources and the
Council for Affordable Quality Healthcare data warehouse. No	Council for Affordable Quality Healthcare data warehouse. No
provider of any type is permitted to participate in an Aetna network	provider of any type is permitted to participate in an Aetna network
without an active professional license, or if subject to OIG sanctions or	without an active professional license, or if subject to OIG sanctions or
OPM debarment, or if listed on a CMS preclusion.	OPM debarment, or if listed on a CMS preclusion report.
MH/SUD and M/S providers are re-credentialed every three years.	MH/SUD and M/S providers are re-credentialed every three years.
Aetna also monitors all providers on an ongoing basis for member	Aetna also monitors all providers on an ongoing basis for member
complaints and concerns about professional conduct and competence.	complaints and concerns about professional conduct and competence.
In 2021, the Med/Surg network was open except for 7 specialties in	The MH/SUD (Behavioral Health) network is open.
southern Maryland; as of Q42021, all panels are open. The entire	
Med/Surg network is open in northern Maryland.	Summary of Requirements: The participation criteria for providers
	and facilities are set forth in Aetna's Network Participation Criteria.
Summary of Requirements: The participation criteria for providers	Each provider must meet certain core criteria pertaining to
and facilities are set forth in Aetna's Network Participation Criteria.	qualifications, availability of services, office/facility environment,
Each provider must meet certain core criteria pertaining to	insurance and professional competence and conduct, as well as
qualifications, availability of services, office/facility environment,	additional criteria apply according to the specific type of provider. An
insurance and professional competence and conduct, as well as	Aetna Medical Director or his or her physician-designee is authorized
additional criteria apply according to the specific type of provider. An	to make exceptions to Board certification, education, DEA
Aetna Medical Director or his or her physician-designee is authorized	certification, and hospital privileges requirements. The Credentialing
to make exceptions to Board certification, education, DEA	& Performance Committee, which is comprised of participating

certification, and hospital privileges requirements. The Credentialing & Performance Committee, which is comprised of participating providers in various specialties including behavioral health, is authorized to make final determinations with respect to exceptions to unencumbered license and professional competence and conduct requirements. Detailed participation criteria are posted here: <u>https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare- professionals/documents-forms/2023-network-participation-criteria- document.pdf</u>	<ul> <li>providers in various specialties including behavioral health, is authorized to make final determinations with respect to exceptions to unencumbered license and professional competence and conduct requirements.</li> <li>Detailed participation criteria are posted here: <a href="https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/2023-network-participation-criteria-document.pdf">https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/2023-network-participation-criteria-document.pdf</a></li> <li>HI MD HCOC00170 05 page 2-8</li> </ul>
Plan language: HI MD HCOC00110 05, page 3-8 Who provides the care Network providers We have contracted with providers in the service area to provide covered services to you. These providers make up the network for your plan.	<ul> <li>Behavioral health provider</li> <li>A health professional who is properly licensed or certified to provide covered services for mental health and substance related disorders in the state where the person practices.</li> <li>Health professional</li> <li>A person who is authorized by law to provide health care services to the public; for example, physicians, nurses and physical therapists.</li> </ul>
<ul> <li>To get network benefits, you must use network providers. There are some exceptions:</li> <li>Emergency services – see the description of emergency services in the <i>Coverage and exclusions</i> section.</li> <li>Urgent care – see the description of urgent care in the <i>Coverage and exclusions</i> section.</li> <li>Clinical trials – see the description of clinical trials in the <i>Coverage and exclusions</i> section.</li> <li>Network provider not available without unreasonable delay/travel or does not have the training and expertise to treat your condition – You can get services from an out-of-network provider. You must request approval from us before you get the care. Contact us for assistance.</li> </ul>	<ul> <li>Hospital An institution licensed as a hospital by applicable law, and accredited by The Joint Commission (TJC). This is a place that offers medical care. Patients can stay overnight for care. Or they can be treated and leave the same day. All hospitals must meet set standards of care. They can offer general or acute care. They can also offer service in one area, like rehabilitation. </li> <li>Physician A health professional trained and licensed to practice and prescribe medicine under the laws of the state where they practice; specifically,</li></ul>

<ul> <li>Use of a <b>provider</b> not in the network under continuity of care <ul> <li>see the description of continuity of care in the <i>Keeping a</i> provider you go to now (continuity of care) section below.</li> </ul> </li> <li>Transplants – see the description of transplant services in the <i>Coverage and exclusions</i> section.</li> </ul>	doctors of medicine or osteopathy. Under some plans, a <b>physician</b> can also be a <b>primary care physician</b> (PCP). <b>Psychiatric hospital</b> An institution licensed or certified as a <b>psychiatric hospital</b> by applicable laws to provide a program for the diagnosis, evaluation,
HI MD HCOC00170 05 page 2	and treatment of alcoholism, drug abuse or mental disorders
Health professional	(including substance related disorders).
A person who is authorized by law to provide health care services to the public; for example, <b>physicians</b> , nurses and physical therapists.	<b>Residential treatment facility</b> An institution specifically licensed or certified as a <b>residential</b> <b>treatment facility</b> by applicable state or federal laws to provide for mental health or <b>substance related disorder</b> residential treatment programs.
<b>Hospital</b> An institution licensed as a <b>hospital</b> by applicable law, and accredited by The Joint Commission (TJC). This is a place that offers medical care. Patients can stay overnight for care. Or they can be treated and leave the same day. All <b>hospitals</b> must meet set standards of care. They can offer general or acute care. They can also offer service in one area, like rehabilitation.	
<b>Physician</b> A <b>health professional</b> trained and licensed to practice and prescribe medicine under the laws of the state where they practice; specifically, doctors of medicine or osteopathy. Under some plans, a <b>physician</b> can also be a <b>primary care physician</b> ( <b>PCP</b> ).	
<ul> <li>Skilled nursing facility</li> <li>A facility specifically licensed as a skilled nursing facility by applicable laws to provide skilled nursing care. Skilled nursing facilities also include: <ul> <li>Rehabilitation hospitals</li> <li>Portions of a rehabilitation hospital</li> <li>A hospital designated for skilled or rehabilitation services</li> </ul> </li> </ul>	

<ul> <li>Skilled nursing facility does not include institutions that provide only:</li> <li>Minimal care</li> <li>Custodial care</li> <li>Ambulatory care</li> <li>Part-time care</li> </ul>
It does not include institutions that primarily provide for the care and treatment of <b>mental disorders</b> or <b>substance related disorders</b> .

# **B.** Identify the factors used in the development of the limitation(s);

# Factors: Note: All factors are the same for medical/surgical and MH/SUD

- Participation standards and credentialing processes developed by Aetna in accordance with NCQA accreditation requirements for Health Plans and Managed Behavioral Health Organizations
- No other factors were considered and rejected. No factors were weighted more than another.

# C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

#### Sources:

#### Provider Admission (Credentialing) Standards NQTL: Outpatient group and individual providers

- NCQA standards (Aetna is NCQA Health Plan and Managed Behavioral Health Organization Accredited)
- Verification from Aetna, National Committee for Quality Assurance (NCQA) Standards and Guidelines for the Accreditation of Health Plans and CMS approved primary sources. Aetna utilizes the Council for Affordable Quality Healthcare (CAQH) data warehouse

# Provider Admission (Credentialing) Standards NQTL: Facility and Facility-Based Practitioners

• NCQA standards (Aetna is NCQA Health Plan and Managed Behavioral Health Organization Accredited)

• Facility qualifications are reviewed to ensure facility meets Aetna's established requirements for organizational credentialing, including state licensing board, operating/certificate of occupancy, accreditation entity.

# Definitions and evidentiary standards:

• Participation standards and credentialing processes developed by Aetna in accordance with NCQA accreditation requirements for Health Plans and Managed Behavioral Health Organizations. These requirements ensure efficient, accurate, and consistent credentialing, including protecting information, verifying credentials, and ongoing monitoring. Aetna's credentialing department is NCQA certified. Aetna's policies and procedures are described below.

## D. Identify the methods and analysis used in the development of the limitation(s); and

The provider admission standards and process are the same between M/S and MH/SUD providers. The variances will only be dependent upon licensing board requirements. Aetna maintains one set of credentialing policies that are equally applicable to MH/SUD and medical/surgical.

MH/SUD and M/S providers wishing to participate in Aetna's networks submit an application with the information required on the Maryland Uniform Credentialing Form. Aetna's credentialing staff verify the information using CMS-approved primary sources and the Council for Affordable Quality Healthcare data warehouse. Where Aetna has delegated credentialing to a third party, the delegate is required to use Aetna's criteria or criteria consistent with Aetna's. No provider of any type is permitted to participate in an Aetna network without an active professional license, or if subject to OIG sanctions or OPM debarment, or if listed on a CMS preclusion report.

The participation criteria for providers and facilities are set forth in Aetna's Network Participation Criteria, linked in A. Each provider must meet certain core criteria pertaining to qualifications, availability of services, office/facility environment, insurance and professional competence and conduct, as well as additional criteria apply according to the specific type of provider. An Aetna Medical Director or his or her physician-designee is authorized to make exceptions to Board certification, education, DEA certification, and hospital privileges requirements. The Credentialing & Performance Committee, which is comprised of participating providers in various specialties including behavioral health, is authorized to make final determinations with respect to exceptions to unencumbered license and professional competence and conduct requirements.

MH/SUD and M/S providers are re-credentialed every three years, as described in Policy. Aetna also monitors all providers on an ongoing basis for member complaints and concerns about professional conduct and competence.

Network participation standards for MH/SUD and M/S facilities and professional providers are in most cases identical and, where not identical, are comparable (see Network Participation Criteria). Credentialing processes for MH/SUD and M/S providers are established and monitored pursuant to written policies that are equally applicable to both MH/SUD and M/S facilities and professionals.

# E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

The same NCQA and/or state standards are used to define and monitor minimum requirements for network composition, ensure compliance with applicable state and federal regulatory standards, and to ensure compliance with applicable accreditations standards for both M/S and MH/SUD. The provider admission standards and credentialing process are the same between M/S and MH/SUD providers. The variances will only be dependent upon licensing and/or accreditation requirements per facility type.

Network participation standards and credentialing processes for MH/SUD network providers are comparable to, and not more stringent than, for M/S network providers. As detailed in the policies and discussion in the prior steps, the process is the same, including the application form used, the primary source verification, and the review process. The turnaround times and approval rates are similar across MH/SUD and M/S, especially when reviewing a larger data set, as seen in the individual practitioner TAT.

# 11. Exclusions for Failure to Complete a Course of Treatment

The plan does not exclude benefits for failure to complete a course of treatment. As such this section is not applicable.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

#### 12. Restrictions that Limit Duration or Scope of Benefits for Services

There are no restrictions on the types of facilities in which members can receive services; however, facilities must be licensed and contracted as outlined in Aetna's provider credentialing policies. This is addressed in **10**. <u>Standards for Provider Credentialing and Contracting</u>. There are no plan limits on the duration or scope of MH/SUD benefits; however, covered services must be medically necessary as addressed in **1**. <u>Medical Necessity</u>. Medically necessary care is "clinically appropriate, in terms of type, frequency, extent, site and duration, and considered effective for the patient's illness, injury or disease."

The HMO product requires members to stay in-network, which is a service area where the HMO is licensed to operate. Geographic limitations inherent in an HMO product are not NQTLs imposed by the health plan. Rather, they are limitations set by the HMO's certificate of authority as dictated by applicable law (see, e.g., MD Health Gen. §§ 19-708(b)(9), 19-710(c)).

For most services, the Plan restricts the geographic location in which services can be received to the service area. The Plan defines a service area as the geographic area where network providers for the Plan are located. There are some exceptions, such as for emergency services, urgent care, provider availability, and transplants. Enrollees are covered for urgent care obtained from a facility outside of the service area if the health care service cannot be delayed until the enrollee returns to the service area.

Network providers agree to provide timely access to care, however if a network provider is not reasonably available, upon approval, the enrollee can get services from an out-of-network provider.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

## 13. <u>Restrictions for Provider Specialty</u>

No, other than credentialing requirements for network providers (such NQTL analysis provided above), the plan does not impose restrictions on provider types for covered services. As such this section is not applicable.

There are no restrictions based on the licensure or certification of a health care provider that limit the scope or duration of benefits for services provided under the plan or coverage. Providers must be duly licensed, as verified through the credentialing process, and practicing within the scope of their license. For example, the plan will cover charges for anesthesia only when billed by provider types qualified to administer anesthesia safely to patients. As noted, the comparative analysis related to that type of restriction is included in the NQTL report for provider credentialing. There are no other restrictions.

- A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;
- **B.** Identify the factors used in the development of the limitation(s);
- C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;
- D. Identify the methods and analysis used in the development of the limitation(s); and
- E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

# 14. <u>Reimbursement for INN Providers, OON Providers, INN Facilities, OON Facilities (separately)</u>

A. Provide the specific plan language for each NQTL in the above defined category and identify the medical/surgical and mental health and/or substance use disorder benefits to which it applies;

Med/Surg Benefits	MH/SUD Benefits
Participating Provider and Facility Reimbursement	Participating Provider and Facility Reimbursement
Covered services: Applies to all Med/Surg and MH/SUD non-	Covered services: Applies to all Med/Surg and MH/SUD non-
prescription benefits delivered in-network	prescription benefits delivered in-network
Plan language: ➤ Section # 110 / Form # HI COC00110 05 / Page # 7-8 When we say "expense" in this general rule, we mean the negotiated charge for a network provider.	Plan language: ➤ Section # 110 / Form # HI COC00110 05 / Page # 7-8 When we say "expense" in this general rule, we mean the <b>negotiated</b> charge for a <b>network provider</b> .
Negotiated charge	Negotiated charge
For health coverage:	For health coverage:
This is the amount a <b>network provider</b> has agreed to accept or that	This is the amount a <b>network provider</b> has agreed to accept or that
we have agreed to pay them or a third party vendor (including any	we have agreed to pay them or a third party vendor (including any
administrative fee in the amount paid).	administrative fee in the amount paid).
We may enter into arrangements with <b>network providers</b> or others related to:	We may enter into arrangements with <b>network providers</b> or others related to:
The coordination of care for members	The coordination of care for members
Improving clinical outcomes and efficiencies	<ul> <li>Improving clinical outcomes and efficiencies</li> </ul>
Some of these arrangements are called:	Some of these arrangements are called:
Value-based contracting	Value-based contracting
Risk sharing	Risk sharing
Accountable care arrangements	Accountable care arrangements
These arrangements will not change the <b>negotiated charge</b> under this plan.	These arrangements will not change the <b>negotiated charge</b> under this plan.

Section # 10 / Form # HI HSOB 08 / Page # 2	Section # 10 / Form # HI HSOB 08 / Page # 2
<ul> <li>How your cost share works</li> <li>The deductibles, copayments and coinsurance, if any, listed in the schedule below are the amounts that you pay for covered services. These amounts are based on the negotiated charge for in-network and allowable amount for out-of-network services. See the <i>How your plan works</i> section of the certificate for more information.</li> </ul>	<ul> <li>How your cost share works</li> <li>The deductibles, copayments and coinsurance, if any, listed in the schedule below are the amounts that you pay for covered services. These amounts are based on the negotiated charge for in-network and allowable amount for out-of-network services. See the <i>How your plan works</i> section of the certificate for more information.</li> </ul>
<b>Non-Participating Provider and Facility Reimbursement</b> <b>Covered services:</b> Emergency care and care unavailable in-network as described in the plan language below	<b>Non-Participating Provider and Facility Reimbursement</b> <b>Covered services:</b> Emergency care and care unavailable in-network as described in the plan language below
Aetna complies with MD Code, Health-General §§ 19-710(e) and 19-710.1), which requires payment of specified rates to non-participating hospitals, trauma physicians for trauma care rendered to a trauma patient in a trauma center, and any other health care provider for E&M and other services.	Aetna complies with MD Code, Health-General §§ 19-710(e) and 19-710.1), which requires payment of specified rates to non-participating hospitals, trauma physicians for trauma care rendered to a trauma patient in a trauma center, and any other health care provider for E&M and other services.
Plan language: HI MD COC 00110 05 page 3 Who provides the care Network providers We have contracted with providers in the service area to provide covered services to you. These providers make up the network for your plan.	Plan language: HI MD COC 00110 05 page 3 Who provides the care Network providers We have contracted with providers in the service area to provide covered services to you. These providers make up the network for your plan.
To get network benefits, you must use <b>network providers</b> . There are some exceptions:	To get network benefits, you must use <b>network providers</b> . There are some exceptions:

- Emergency services see the description of emergency services in the *Coverage and exclusions* section.
- Urgent care see the description of urgent care in the *Coverage and exclusions* section.
- Clinical trials see the description of clinical trials in the *Coverage and exclusions* section.
- Network provider not available without unreasonable delay/travel or does not have the training and expertise to treat your condition – You can get services from an out-ofnetwork provider. You must request approval from us before you get the care. Contact us for assistance.
- Use of a **provider** not in the network under continuity of care – see the description of continuity of care in the *Keeping a provider you go to now (continuity of care)* section below.
- Transplants see the description of transplant services in the *Coverage and exclusions* section.

- Emergency services see the description of emergency services in the *Coverage and exclusions* section.
- Urgent care see the description of urgent care in the *Coverage and exclusions* section.
- Clinical trials see the description of clinical trials in the *Coverage and exclusions* section.
- Network provider not available without unreasonable delay/travel or does not have the training and expertise to treat your condition – You can get services from an out-ofnetwork provider. You must request approval from us before you get the care. Contact us for assistance.
- Use of a **provider** not in the network under continuity of care – see the description of continuity of care in the *Keeping a provider you go to now (continuity of care)* section below.
- Transplants see the description of transplant services in the *Coverage and exclusions* section.

# **B.** Identify the factors used in the development of the limitation(s);

#### Participating Provider Reimbursement

Factors: Note: All factors are the same for medical/surgical and MH/SUD

- 1. Index Rates (e.g. Medicare reimbursement rates)
- 2. Market dynamics (e.g. supply and demand)
- 3. Provider type (e.g. MD, NP)
- 4. Service type (e.g. counseling, initial assessment)

# Participating Facility Reimbursement

Factors: Note: All factors are the same for medical/surgical and MH/SUD

- 1. Provider type
- 2. Scope and complexity of services
- 3. Service type
- 4. Index rates
- 5. Competitive data

6. Market dynamics

# Non-Participating Provider and Facility Reimbursement

Factors: Note: All factors are the same for medical/surgical and MH/SUD

• State and federal law: State and federal laws prescribe how plans must reimburse OON providers for emergency services or when the member did not voluntarily use OON benefits

No other factors were considered and rejected. No factors were weighted more than another.

# C. Identify the sources (including any processes, strategies, or evidentiary standards) used to evaluate the factors identified above;

## Participating Provider Reimbursement

**Sources and Processes:** 

- 1. For Index Rates: CMS RBRVS rates: Aetna's Medical Economics Unit (MEU) identifies the CMS RBRVS rates for the service codes and proposes the AMFS rates as a percentage of the CMS rates. MEU communicates the preliminary rates to network management.
- 2. For Market Dynamics: Network analysis of market dynamics:
- 3. For Provider Type: For both MH/SUD and M/S providers, rates are tiered based on provider type/level of training, consistent with CMS methodology.
- 4. For Service Type: Service types are identified by CPT and HCPC codes.

When contracting with a given provider, additional factors may enter into consideration:

Unit Co	ost				
				-	

<u>Provider leverage</u>: AKA bargaining power. This is generally a function of the relative scarcity of the provider's specialty or area of focus, member needs for that specialty/focus, whether the provider group is a large system or practice group that includes numerous specialties, plan sponsor demand, the provider's participation with other payors, and any other factors that dictate a provider's ability to negotiate a rate higher **sector**, as well as the number of members the carrier is able to drive to the provider.

No other sources were considered and rejected.

# Participating Facility Reimbursement

# Sources and Processes:


- 1. For Provider Type: Type of facility (inpatient hospital, ambulatory surgery center, etc.)
- 2. For Scope and Complexity of Services: Range of practice specialties, levels of care and settings offered by the facility
- 3. For Service Type: Service types are identified by CPT and HCPC codes. For facility-based providers, type of service also refers to inpatient or outpatient.
- 4. For Index Rates: Medicare DRGs and Medicare RVRBS rates
- 5. For Competitive Data: To the extent that can be determined from information publicly available through state and federal All Payor Claims Databases. Also includes consultants' analyses of Aetna's discount position in the market compared to other carriers, and what Aetna pays other facilities.
- 6. For Market Dynamics: The local networks

When contracting with a given provider, additional factors may enter into consideration:

Unit Cost				
	-	_		

<u>Provider leverage</u>: AKA bargaining power. This is generally a function of the relative scarcity of the provider's specialty or area of focus, member needs for that specialty/focus, whether the provider group is a large system or practice group that includes numerous specialties, plan sponsor demand, the provider's participation with other payors, and any other factors that dictate a provider's ability to negotiate a rate higher **a set of the set** 

No other sources were considered and rejected.



#### Non-Participating Provider Reimbursement

State and federal law: State and federal laws prescribe how plans must reimburse OON providers for emergency services or when the member did not voluntarily use OON benefits. Actna complies with MD Code, Health-General §§ 19-710(e) and 19-710.1, which requires payment of

specified rates to trauma physicians for trauma care rendered to a trauma patient in a trauma center and any other health care provider for E&M and other services. No sources were weighted more than another. No other sources were considered and rejected.

Evidentiary Standards: CMS Medicare rates; average rates from HMO paid claims

#### Non-Participating Facility Reimbursement

State and federal law: State and federal laws prescribe how plans must reimburse OON providers for emergency services or when the member did not voluntarily use OON benefits. The factor is the source. The HMO will pay a claim submitted by a facility at the rate approved by the Health Services Cost Review Commission (HSCRC). These rates are loaded for Aetna's claim processing system to access. Other than those hospital services regulated by the HSCRC, the source is the FAIR Health database or CMS Medicare rates. No other sources were considered and rejected.

Evidentiary Standards: Rates approved by the Health Services Cost Review Commission; FAIR Health database of charges made by providers in the geographic area; CMS Medicare rates

## D. Identify the methods and analysis used in the development of the limitation(s); and

#### Participating Provider Reimbursement

There are two main steps for setting network provider reimbursement, which are the same for MH/SUD and M/S services: (1) developing and refreshing the rates **and the set of the** 

(1) In developing and refreshing the rates, the Plan uses comparable factors, strategies, processes and evidentiary standards for MH/SUD and M/S services, both as written and in operation.

(2) In contracting with providers, the Plan also uses comparable factors, strategies, processes and evidentiary standards for MH/SUD providers and M/S providers, both as written and in operation.

Participating Facility Reimbursement

The factors, strategy, processes and evidentiary standards for determining reimbursement for MH/SUD facility-based providers are comparable to M/S facility-based providers

Non-Participating Provider and Facility Reimbursement

Non-participating providers and facilities are reimbursed for eligible services for HMO members in accordance with the methodologies set forth in state law regarding non-participating provider and facility reimbursement.

E. Provide any evidence and documentation to establish that the limitation(s) is applied no more stringently, as written and in operation, to mental health and substance use disorder benefits than to medical and surgical benefits.

Aetna maintains one policy on rate development,	
	https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-
center/face/aca part 45 ndf	

# MHPAEA Data Report for Calendar Year Ending December 31, 2021 (§15–144(f))

 Health Plan
 Aetna Health Inc.

 HMO
 HMO

Benefit	Classification	# of Authorization Requests Received	# of Authorization Requests Approved	# of Authorization Requests Denied	% Approved	% Denied
Mental Health Benefits	INN-Inpatient	4	4	0	100%	0%
	OON-Inpatient	0	0	0	#DIV/0!	#DIV/0!
	Emergency Services	0	0	0	#DIV/0!	#DIV/0!
	RX	36	31	5	86%	14%
	INN-Outpatient- Office	4	4	0	100%	0%
	OON-Outpatient- Office	8	8	0	100%	0%
	INN-Outpatient- AllOther	8	8	0	100%	0%
	OON-Outpatient- AllOther	0	0	0	#DIV/0!	#DIV/0!
Substance Use Disorder	INN-Inpatient					
Benefits		6	6	0	100%	0%
	OON-Inpatient	0	0	0	#DIV/0!	#DIV/0!
	Emergency Services	0	0	0	#DIV/0!	#DIV/0!
	RX	0	0	0	#DIV/0!	#DIV/0!
	INN-Outpatient- Office	0	0	0	#DIV/0!	#DIV/0!
	OON-Outpatient- Office	0	0	0	#DIV/0!	#DIV/0!

Medical /Surgical BenefitsINN-InpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInpatientInp
OON-Inpatient0000Emergency Services0000#DIV/0!#DI
Emergency Services 0 0 0 #DIV/0! #DI
<b>RX</b> 23 19 4 83%
INN-Outpatient- Office 0 0 0 #DIV/0! #DI OON-Outpatient-
Office 0 0 0 #DIV/0! #DI
INN-Outpatient- AllOther 435 323 102 74% OON-Outpatient- AllOther 0 0 0 0 #DIV/0! #DI

MHPAEA Data Report for Calendar Year Ending December 31, 2021 (§15–144(f))

Health Plan	Aetna Health Inc. HMO	
-------------	--------------------------	--

Benefit	Classification	# of Claims Submitted	# of Claims Approved	# of Claims Denied	% Approved	% Denied
Mental Health	INN-Inpatient					
Benefits		78	63	15	81%	19%
	<b>OON-Inpatient</b>	1	0	1	0%	100%
	Emergency					
	Services	64	63	1	98%	2%
	RX	2544	1753	791	68%	32%
	INN-					
	Outpatient-					
	Office	1335	1236	99	93%	7%
	OON-					
	Outpatient-	10	0	10	00/	4000/
	Office INN-	40	0	40	0%	100%
	Outpatient-					
	AllOther	1434	1395	39	97%	3%
	OON-		1000	00	0170	070
	Outpatient-					
	AllOther	13	0	13	0%	100%
Substance						
Use Disorder	INN-Inpatient					
Benefits		34	29	5	85%	15%
	<b>OON-Inpatient</b>	0	0	0	#DIV/0!	#DIV/0!
	Emergency Services	48	47	1	98%	2%

	51/			10	=00/	= (
	RX	93	44	49	50%	50%
	INN-					
	Outpatient-					
	Office	150	125	25	83%	17%
	OON-					
	Outpatient-					
	Office	14	0	14	0%	100%
	INN-	<u></u>	<b>u</b>		0,0	10070
	Outpatient-					
	AllOther	245	207	38	84%	16%
		245	207	30	04 %	10%
	OON-					
	Outpatient-					
	AllOther	13	0	13	0%	100%
Medical						
/Surgical	INN-Inpatient					
Benefits	•	1271	1050	221	83%	17%
	<b>OON-Inpatient</b>	4	0	4	0%	100%
	=	4	0	4	0 /0	10070
	Emergency					
	Services	1242	1155	87	93%	7%
	RX	14326	10168	4158	71%	29%
	INN-					
	Outpatient-					
	Office	13703	12886	817	94%	6%
	OON-					
	Outpatient-					
	Office	119	0	119	0%	100%
	INN-	110	<u> </u>	110	070	10070
	Outpatient-					
	AllOther	18849	18087	762	96%	4%
		18849	10007	702	90%	470
	OON-					
	Outpatient-				0.01	1000
	AllOther	240	0	240	0%	100%